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Abstract 
Canine primary glaucoma is a painful and blinding disease associated with 
pathologically high intraocular pressure. The two main recognised forms are primary 
closed angle glaucoma (PCAG) and primary open angle glaucoma (POAG). Pectinate 
ligament dysplasia (PLD), an abnormality of the iridocorneal angle, is a consistent risk 
factor for canine PCAG. PCAG and PLD have been shown previously to be highly 
heritable although inheritance is considered complex. Gonioscopy was performed in > 
1100 dogs of seven breeds to provide current estimates of PLD prevalence between 
September 2013 and March 2016. PLD was associated with age (P < 0.01) and there 
was inter-examiner variability in performing PLD grading (P = 0.05). These results 
have influenced the policy making of the United Kingdom’s canine hereditary eye 
disease scheme. Genome-wide association studies (GWAS) were performed to identify 
regions of the genome associated with PCAG in four dog breeds. Two loci 
(chr24:17,381,226-18,739,902 and chr37:24,747,131-24,958,250) were associated with 
PCAG in the Basset Hound, the former being syntenic with a region previously reported 
to be associated with primary glaucoma in humans. Meta-analysis of summary data 
from the Welsh Springer Spaniel and Dandie Dinmont Terrier GWAS analyses revealed 
an additional (shared) PCAG locus (chr28:18,835,904-19,358,417). Whole genome 
sequencing was used to interrogate PCAG loci for candidate causal variants and RNA 
sequencing was used to investigate candidate genes for PCAG in the Basset Hound. For 
POAG, a candidate gene approach was used to screen ADAMTS17 for causal mutations 
in three different dog breeds. POAG was shown to be an autosomal recessive trait 
associated with a different ADAMTS17 mutation in each breed (c.193_211del in Basset 
Hound, c.1552G>A in Basset Fauve de Bretagne and c.3070_3075del in Shar Pei). 
DNA tests have been developed to enable a reduction in the incidence of POAG in these 
breeds and a controlled elimination of each mutation over time. 
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this breed. The PLD data have also influenced the stance of the United Kingdom’s 
canine hereditary eye disease scheme, with regard to recommendations regarding the 
necessity to perform gonioscopy in certain breeds, the frequency of gonioscopy testing 
and how PLD can be better graded than the existing system.  
In the longer term, publication of the PCAG loci identified in multiple dog breeds will 
provide a springboard to facilitate identification of candidate genes and variants through 
further work both by the AHT and by other groups. The significant findings regarding 
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the genetics of PCAG, a complex disease, will lead to an improved understanding of the 
underlying genetic architecture of this disease in dogs, offering the potential for 
improved prevention and/or treatment strategies across species. 
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1 Introduction 
 Anatomy and physiology of the canine aqueous humour outflow pathways 1.1
 Aqueous humour and intraocular pressure 1.1.1
Aqueous humour (AH) is the fluid that fills the anterior and posterior chambers of the 
eye and is secreted by the epithelium of the ciliary processes of the ciliary body which 
are located in the posterior chamber. AH functions to deliver nutrients to and remove 
metabolic waste from the intraocular tissues and it is the constant balance between AH 
production and drainage that maintains intraocular pressure (IOP) within a physiological 
range which, in the dog, is generally considered to be 10 - 25 mmHg
1-3
. IOP values may 
vary in relation to time of day, breed and age. Canine IOP follows a similar circadian 
phase as humans, with highest IOP values occurring in the morning and lowest in the 
evening
2,3
. Advancing age is associated with a decrease in IOP in the dog
1
. The reason 
for this is unknown but most likely relates to a reduction in AH production as AH 
outflow is thought to reduce with age
4
. 
 Aqueous humour outflow pathways 1.1.2
AH may leave the eye via two main routes: 
 The conventional outflow pathway 
 The unconventional outflow pathway 
Conventional outflow occurs down a pressure gradient and is pressure-dependent
5
. This 
form of outflow accounts for approximately 85 % of total AH outflow from the normal 
canine eye
6
. Unconventional outflow is passive and largely independent of IOP being 
regulated mostly by osmotic gradients
7
. This form of outflow accounts for 
approximately 15 % of AH outflow from the normal canine eye
6
. Compromise of AH 
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outflow leads to increased IOP which is considered a constant risk factor in canine 
glaucoma and a major risk factor in human glaucoma. In simple terms, elevated IOP in 
the anterior segment is transmitted to the posterior segment leading to death of retinal 
ganglion cells and their axons (Figure 1.1). 
 
Figure 1.1. Schematic of the eye. 
Sub-image A demonstrates the elevated intraocular pressure transmitted to the posterior 
segment of the globe in the glaucomatous eye where retinal ganglion cells and their 
axons reside. Sub-image B reflects the aqueous humour outflow pathways (modified 
from Danford et al.
8
). 
1.1.2.1 The conventional outflow pathway 
The majority of AH drains peripherally from the anterior chamber via the iridocorneal 
angle (ICA) into the sieve-like trabecular meshwork of the ciliary cleft before entering a 
plexus of channels which drains into the eye’s venous system. The histological 
appearance of the normal canine ICA is depicted in Figure 1.2. The ICA is bordered 
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anteriorly by the peripheral cornea and perilimbal sclera and posteriorly by the iris base 
and anterior ciliary body musculature. The normal canine ICA is spanned by numerous, 
fine, branching stands of iris tissue which connect the anterior iris base to the posterior 
cornea. These ‘fibres’ are collectively termed the pectinate ligament (PL). A single PL 
fibre is composed of a collagen core which is completely encased in cells (melanocytes 
and fibroblasts) which are confluent with the iris surface
9
. The PL fibres branch 
frequently and anastomose with the trabecular beams within the anterior ciliary cleft. 
The ciliary cleft is the peripheral circumferential region posterior to the ICA and 
contains the trabecular meshwork through which AH drains via bulk flow down a 
pressure gradient
5
. The trabecular meshwork is composed of the anterior uveal and the 
posterior corneoscleral meshworks. The trabeculae, like the PL fibres, also have a 
collagen core, but this is interspersed with modified elastin and other extracellular 
matrix (ECM) proteins including laminin and fibronectin
10
. The trabeculae are lined by 
cells (trabeculocytes) which are thought to play an important role in regulating outflow 
and therefore IOP. Trabeculocytes have phagocytic properties allowing them to digest 
trapped particles and they also have the ability to increase ECM turnover in response to 
mechanical strain
11
. Trabeculocytes also produce several non-structural proteins that 
regulate ECM turnover and remodelling including transforming growth factor beta-2 
(TGFβ-2), myocillin, stromelysin, secreted protein acidic and rich in cysteine (SPARC), 
thrombospondin -1 and -2, bone morphogenetic protein-7, tenascin C and matrix 
metalloproteinases and their inhibitors
12-19
. From interior to exterior, the trabeculae 
become smaller and more closely approximated to each other allowing the trabecular 
meshwork to act like a sieve, reducing the particle size within the AH as it filters from 
the uveal to the corneoscleral trabecular meshworks. 
From the corneosceral trabecular meshwork, AH must then traverse the juxtacanalicular 
tissue before entering the vascular network that is the angular aqueous plexus (similar to 
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the Schlemm’s canal of primates). The juxtacanalicular tissue is a thin layer (5 - 20 m 
thick) containing fibroblast-like cells within an ECM of proteoglycans (including 
versican and perlecan) and their associated glycosaminoglycans (including dermatan 
sulphate, chondroitin sulphate and hyaluronic acid). Structural and functional proteins 
present include fibrillar and non-fibrillar collagen, elastin, fibronectin and laminin
20
. 
This ECM is thought to be critically important in providing resistance to AH outflow 
and therefore IOP regulation
21
. Evidence for this comes from experimental treatment 
with hyaluronidase which resulted in reduction of IOP
22
. It is thought that the 
glycosaminoglycans of the ECM assist in IOP regulation by altering the state of their 
polymerisation which controls their capacity for hydration.  
AH must then move from the juxtacanalicular tissue across the endothelium (inner wall) 
of the angular aqueous plexus before subsequent drainage into the distal outflow 
vessels. AH makes the transition into the plexus via the formation of endothelial 
vacuoles and intercellular and intracellular pores. The plexus interconnects with radial 
collector vessels which, in turn, drain into the anterior ciliary veins or the scleral venous 
plexus. Longitudinal ciliary muscle fibres insert on the elastic fibre system (composed 
of an elastin core with surrounding microfibrils composed of fibrillin-1 and 
microfibrillar-associated proteins -1 and -2) of the trabecular meshwork and 
juxtacanalicular tissue. Furthermore, myofibroblastic cells have been observed within 
the inner, posterior region of the corneoscleral and outer, posterior region of the uveal 
trabecular meshworks. These findings suggest that these cells and the smooth muscle 
cells of the ciliary body along the same plane of orientation function to facilitate the 
removal of AH by maintaining opening of the spaces of the angular aqueous plexus
23
. 
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Figure 1.2. Histological appearance of the normal canine ICA (H&E x 20).  
PL = pectinate ligament fibres. SVP = scleral venous plexus. Photograph courtesy of 
Emma Scurrell, CytoPath Ltd. 
1.1.2.2 The unconventional outflow pathway 
In the unconventional route, AH still traverses the trabecular meshwork but, instead of 
moving anteriorly across the juxtacanalicular tissue and into the angular aqueous plexus, 
it is directed posteriorly through ciliary body. AH passes through the connective tissue 
between the longitudinal muscle fibres of the ciliary body (which attach to the ICA 
trabeculae) before collecting in the potential uveoscleral space. From here, AH enters 
the suprachoroidal space before entering choroidal and scleral blood vessels. AH flow 
via this pathway is thought to be relatively independent of IOP being instead driven by a 
difference in osmotic pressure created between the colloids within the choroidal and 
scleral blood vessels and the ciliary body tissue
24
. 
1.1.2.3 Embryology of the ICA and pectinate ligament dysplasia 
Development of the ICA occurs in three sequential steps: 
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1. Separation of anterior mesenchyme into corneoscleral and uveal regions 
followed by differentiation of ciliary muscle and folding of neuroectoderm into 
the ciliary processes. 
2. Enlargement of corneal trabeculae and development of spaces within the 
trabecular meshwork, accompanied by regression of the corneal endothelium 
that covers the opening to the ICA. 
3. Postnatal remodeling of the ICA aided by cellular necrosis and macrophage-
mediated phagocytosis. This results in further opening of the spaces within the 
trabecular meshwork and the outflow pathways. 
 
In the dog, a species born with fused eyelids, the peripheral iris and cornea are in 
contact at birth. As in other species, differential growth occurs with posterior movement 
of the iris and ciliary body relative to the cornea revealing the trabecular meshwork and 
outflow pathways as the ICA deepens
25
. Early studies in the Beagle have described 
maturation of the ICA in dogs reporting its morphology to be complete by eight weeks 
after birth
26,27
. Specifically, the fibres which collectively form the PL are thought to 
form by a process of rarefaction of an initial sheet of mesenchymal tissue spanning the 
ICA
27,28
. Pectinate ligament dysplasia (PLD) describes the broad sheets of tissue which 
span the ICA (extending from the base of the anterior surface of the iris to the periphery 
of the posterior cornea) thought to result from a lack of this rarefaction during this time 
frame (Figure 1.3). PLD is thus a form of goniodysgenesis, which is defined as 
abnormal development of the ICA, and is considered a risk factor for the development 
of canine primary closed angle glaucoma (PCAG) based on the finding that severe PLD 
is associated with PCAG in affected eyes in numerous breeds
29-33
.  
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Figure 1.3. Histological appearance of PLD in a dog without PCAG (H&E x 40).  
Beams of the trabecular meshwork can be seen within the extremely narrowed ciliary 
cleft. Photograph courtesy of Emma Scurrell, CytoPath Ltd. 
1.1.2.4 The effect of aging on the aqueous humour outflow pathways 
Numerous changes associated with advancing age have been documented to occur 
within the outflow pathways most of which confer increased resistance to AH outflow. 
Age-related narrowing of the canine ICA has been documented in more than one breed 
with progressive reduction in the width of the ciliary cleft being associated with an 
increasingly shallow anterior chamber
29,34
. Progression of PLD in individual dogs over 
time has also recently been demonstrated, which challenged the original theory that this 
anomaly is always a congenital one. In a study of 96 Flatcoated Retrievers (FCR), 39 
(40.6 %) demonstrated progression of PLD 1.92 - 12.58 years later (mean 6 years, 
median 5.75 years) with 12 (12.5 %) demonstrating progression to severe PLD and 
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being considered at risk of glaucoma development
35
. PLD progression over time in 
other breeds had not yet been reported. 
It is known that the beams of the trabecular meshwork become thicker with age in dogs 
but other changes are not well described in this species
22,36
. In primates, several changes 
within the trabecular meshwork and juxtacanalicular tissue have been documented. 
There is age-related trabeculocyte loss which appears to occur at a higher rate in 
primates with primary open angle glaucoma (POAG) than in age-matched controls
37,38
. 
As trabeculocytes have phagocytic properties, such loss may result in an accumulation 
of debris within the trabecular meshwork leading to an increased resistance to outflow. 
It is known that fibronectin, a major component of the trabecular meshwork, 
accumulates with age although the significance of this is not fully understood
39
. There is 
also increased cross-linking of the fibres of the trabecular meshwork’s elastin system 
which leads to reduced compliance of the tissue and potential capacity for modulation 
of outflow
40
. This increased stiffness of the ECM is likely to be most important in the 
juxtacanalicular tissue – a region thought to be pivotal in IOP determination. 
 Classification and pathophysiology of canine primary glaucoma 1.2
The glaucomas constitute a heterogeneous group of diseases characterised by retinal 
ganglion cell apoptosis and optic neuropathy (Figure 1.4 and Figure 1.5). Primary 
glaucoma in dogs refers to those glaucomas which are thought to occur as a result of 
inherent defects in the AH outflow pathways which lead to IOP dysregulation. Primary 
glaucoma is generally considered to be a bilateral condition and occurs in the absence of 
any other identifiable intraocular disease such as haemorrhage, inflammation, neoplasia 
and lens luxation
41
. Canine primary glaucoma is relatively poorly characterised which 
likely relates in part to the late presentation of affected dogs. Affected eyes usually have 
very advanced disease associated with markedly elevated IOP, blindness and pain. 
Painless forms are not recognised. Canine primary glaucomas are traditionally divided 
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into two categories based on the appearance of the ICA as seen on gonioscopy. These 
are PCAG and POAG. Exact diagnostic criteria for canine PCAG and POAG are not 
published. For the purposes of this study, the following diagnostic criteria were 
employed: 
PCAG 
 Closed ICAs on gonioscopy 
 Elevated IOP > 50mmHg 
 The absence of any possible cause of secondary glaucoma 
 The finding of severe PLD (>90 % of the ICA affected) in the contralateral eye 
POAG 
 Open ICAs on gonioscopy 
 Elevated IOP > 25mmHg 
 The absence of any possible cause of secondary glaucoma 
 The absence of PLD in the contralateral eye 
 Buphthalmos 
 Lens subluxation 
 
Figure 1.4. Histological appearance of the retina in a dog with PCAG (H&E x 100).  
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There is atrophy of the inner retinal layers. NFL = nerve fibre layer, GCL = ganglion 
cell layer, INL = inner nuclear layer. Photograph courtesy of Emma Scurrell, CytoPath 
Ltd. 
 
Figure 1.5. Histological appearances of the optic nerve head (ONH) (H&E x 40). 
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A) The appearance of a normal ONH in a normotensive canine eye. B) The ONH in a 
canine eye with PCAG. The ONH is posteriorly displaced (‘cupped’) as a result of 
chronic IOP elevation. Courtesy of Emma Scurrell, CytoPath Ltd. 
 
 Gonioscopy 1.2.1
Gonioscopy describes the examination of the anterior ICA and ciliary cleft, and normal 
gonioscopic findings in the dog are presented in Figure 1.6
42
. Like many species, the 
canine ICA cannot be directly visualised as it is obscured by the scleral shelf. If 
examination at an oblique angle is attempted, the ICA cannot be visualised owing to the 
phenomenon of total internal reflection of light rays which occurs when light rays pass 
from a medium of higher refractive index (1.376 for the cornea) to one of lower 
refractive index (1.00 for air). The application of a contact lens (goniolens) removes the 
cornea-air interface creating a new contact lens-air interface and overcomes this 
phenomenon. Goniolenses may be direct or indirect. In dogs, direct goniolenses are 
most commonly employed and overcome the phenomenon of total internal reflection by 
virtue of their relative convexity. The Koeppe lens is an example of a commonly used 
direct goniolens
43
. Following topical anaesthesia of the cornea and application of a 
coupling gel to the concave side of the lens, it is placed onto the surface of the cornea in 
the conscious dog (Figure 1.7). The lens is held in place by a combination of vacuum 
forces and a small flange which surrounds the lens and sits in the conjunctival fornices 
under the eyelids. The ICA is then examined with the aid of a light source and, usually, 
magnification. A portable slit-lamp biomicroscope is most practical for these combined 
purposes in the dog. The entire ICA and ciliary cleft opening are then systematically 
evaluated giving attention to PL conformation and ICA width. As described above, the 
normal PL consists of fine strands of iris tissue which extend from the iris base to the 
corneal endothelium. The line of insertion is referred to as the deep pigmented line
44
. A 
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more superficial and less densely pigmented zone represents the pigmentation of the 
corneoscleral limbus and is known as the superficial pigmented line. The presence and 
thickness of these two lines varies from dog to dog (being correlated with coat colour) 
and also even between different quadrants of the same eye
42
. The appearance of the PL 
itself is variable, particularly between breeds
42
. Dogs with darkly pigmented irides 
usually have darkly pigmented and obvious PL fibres, whereas in dogs with pale or blue 
irides, the PL fibres may be extremely fine and difficult to visualise. Fibrae latae 
describe the presence of broad PL fibres and a small percentage of these within a given 
ICA is deemed normal variation which is in contrast to the sheets of tissue which 
represent PLD (Figure 1.8).  
 
Figure 1.6. The gonioscopic view of a normal ICA as viewed through a Koeppe 
goniolens.  
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1 = corneoscleral limbus (superficial pigmented line), 2 = site of insertion of pectinate 
ligament (PL) fibres (deep pigmented line), 3 = PL fibres and 4 = iris. The double-
headed white arrow delineates the opening of the ICA. 
 
 
Figure 1.7. Application of a Koeppe goniolens to the cornea of a dog. 
Following application of topical anaesthetic to the ocular surface and coupling gel to the 
lens, the Koeppe lens has been directly applied to the corneal surface being held in place 
by a flange and vacuum forces. In the photograph, the ventral ICA can be visualised. 
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Figure 1.8. The gonioscopic view of a canine ICA demonstrating PLD as seen 
through a Koeppe goniolens. 
1-2 = corneoscleral limbus (no distinction between superficial and deep pigmented 
lines), 3 = PLD and 4 = iris. The double-headed white arrow delineates the opening of 
the ICA which is spanned by broad sheets of tissue (PLD). No pectinate ligament fibres 
are discerned but ‘flow holes’ are present (white stars). 
The United Kingdom’s BVA/KC/ISDS Eye Scheme is based on eye examination and is 
a means of identifying inherited and non-inherited ocular conditions in dogs. Under the 
Eye Scheme, predisposition to PCAG is assessed by gonioscopy by a certified 
veterinary ophthalmologist. The ophthalmologist is required to estimate the proportion 
(or percentage) of PLD that affects the entire circumference of the ICA along with a 
subjective interpretation of ICA width (BVA unpublished data). Interpreting the width 
is especially challenging and can vary significantly even within regions of an individual 
eye and between the eyes of normal dogs and thus it is common for investigators not to 
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consider width assessment when evaluating goniodysgenesis in scientific 
studies
31,35,45,46
. Dispute also occurs as to what constitutes a ‘normal’ level of PLD with 
different investigators suggesting that figures of between 6.25 % and 25 % may 
constitute normal, or at least, acceptable levels of variation
31,35,47,48
. Before the 
publication of the studies reported in this thesis, the BVA/KC/ISDS Eye Scheme 
considered a dog to be either ‘unaffected’ or ‘affected’ by PLD (referring to the 
condition as goniodysgenesis or primary glaucoma) but did not employ any further 
grading beyond this binary classification. A dog was deemed ‘unaffected’ if both eyes 
exhibited < 20 % PLD for the entire circumference of the ICA and ‘affected’ if either or 
both eyes exhibited ≥ 20 % PLD35.  Anecdotally, however, estimation of the percentage 
of PLD is thought to be open to a high degree of subjectivity with the potential for 
individual examiners to judge the same ICA very differently. This anecdotal suspicion 
has led to the application of ‘gonioscopy grading schemes’ in research as an attempt to 
reduce the influence of subjectivity on examination findings
31,35,47,48
. All of the above 
referenced schemes involve initial estimation of the percentage of ICA circumference 
affected by PLD before assignment to one of four - eight different ordinal grades 
depending on the scheme employed as summarised in Table 1.1. At the time of project 
outset, the scheme by Pearl et al. was the most recently published (in online format) and 
was adopted in estimating PLD prevalence and progression in the dog breeds 
investigated. This scheme was employed in the studies enclosed in this thesis because it 
is composed of four relatively broad grades making it more likely to be able to 
categorise different eyes similarly than schemes with larger numbers of narrow grades. 
In this scheme, the boundaries between the different grades are unequally divided. The 
proposed benefit of this scheme is that it allows the identification of PLD at both ends 
of the spectrum i.e. those eyes which had absolutely no evidence of PLD and those with 
> 90 % PLD and being considered at risk of PCAG
31,35
. 
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Table 1.1. Details of four previously published gonioscopy grading schemes. 
Gonioscopy only allows examination of the entrance of the ICA and visualisation of the 
ciliary cleft (abnormalities of which are likely to be important in the pathogenesis of 
PCAG) is not possible at all if PLD is extensive
50
. Additional techniques such as high-
resolution ultrasound and ultrasound biomicroscopy are currently being evaluated and 
may, to some extent, eventually replace gonioscopy
51,52
. 
 Primary closed angle glaucoma 1.2.2
PCAG is by far the most common form of primary glaucoma in the dog affecting over 
40 breeds worldwide
28,53
. In contrast to POAG, but similar to human primary angle 
closure glaucoma (PACG)
54-56
, female dogs of certain breeds are more likely to be 
affected by PCAG than male dogs
29,53,57-59
. Female American Cocker Spaniels, Cocker 
Spaniels, Basset Hounds (BH), Welsh Springer Spaniels (WSS) and Samoyeds have 
been reported to be affected more frequently with PCAG than males
53,60
. A sex 
Ordinal 
grade 
Read et al. 
 (1998)
31
 
Ekesten & 
Narfström 
(1992)
49
 
Pearl et al. 
 (2015)
35
 
Fricker et al. 
(2015)
48
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difference has also been described for PLD in the American Cocker Spaniel but not in 
the English Springer Spaniel, FCR or Samoyed
29,34,61
. The reason for the sex 
predisposition for PCAG is unknown but may relate to gender differences in anterior 
chamber morphology as female dogs and humans tend to have shorter axial globe 
lengths and narrower ICA openings
62,63
. In humans, females are affected by PCAG 
more frequently than males
54-56
.  
As mentioned previously, PLD is known to be a risk factor, and a prerequisite, for 
PCAG in dogs and has been shown to have high heritability
29-32,64
. This, together with a 
relatively high prevalence of PLD and PCAG in a number of purebred dog breeds is 
suggestive of a genetic aetiology. The BVA/KC/ISDS Eye Scheme lists the following 
dog breeds to be either certifiable or under investigation for PLD 
(http://www.bva.co.uk/Canine-Health-Schemes/Eye-scheme): 
 American Cocker Spaniel  
 BH 
 Border Collie (BC) 
 Cocker Spaniel 
 Dandie Dinmont Terrier (DDT) 
 English Springer Spaniel 
 FCR 
 Golden Retriever (GR) 
 Great Dane 
 Hungarian Vizsla (HV) 
 Leonberger 
 Japanese Shiba Inu 
 Siberian Husky 
 Spanish Water Dog 
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 WSS 
 Welsh Terrier 
In predisposed breeds, risk of PCAG disease is associated with the percentage of ICA 
affected by PLD with only eyes with a very high percentage (> 90 %) PLD being at 
risk
29,31,65
. The vast majority of dogs with PLD, however, do not go on to develop 
PCAG and thus, PLD alone, is insufficient for PCAG
41
. It has been suggested that PLD 
may be a marker for other inherent defects of the AH outflow pathways, but these are 
yet to be characterised
31
.  
The degree of PLD present does not appear to be correlated with IOP in normotensive 
dogs
30,31,48
. PCAG presents as an acute onset disease with clinical signs of markedly 
elevated IOP (typically > 50 mmHg), pain, corneal oedema, mydriasis and 
blindness
28,66
. A diagnosis is usually made when these characteristic signs are present in 
the affected eye with no evidence of other intraocular disease and where gonioscopic 
abnormalities of the contralateral unaffected eye are present
41
. 
Other than PLD being a prerequisite for PCAG, the pathogenesis of this form of 
glaucoma is poorly understood. Collapse of the ciliary cleft is the most obvious 
histological finding (Figure 1.9), but whether this occurs secondary to increased IOP 
being generated elsewhere (for example in the juxtacanalicular tissue) or is a 
progressive narrowing primarily generated within the ciliary cleft itself is unknown
41
. A 
histological diagnosis of PLD is challenging in the face of chronic glaucoma owing to 
the collapse of the ciliary cleft emphasising the importance of gonioscopic evaluation of 
the contralateral eye
67
. 
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Figure 1.9. The ICA of a dog with PCAG (H&E X 40). 
The ciliary cleft (boxed in red) is collapsed. Photograph courtesy of Emma Scurrell, 
CytoPath Ltd. 
 Primary open angle glaucoma  1.2.3
POAG is less common than PCAG in the dog and, at the time of project outset, had only 
been reported in two breeds - the Beagle and the Norwegian Elkhound
68-70
. In both of 
these, POAG is an autosomal recessive trait.  
In POAG, the ICA appears normal on gonioscopy in the very early stages of disease but 
becomes progressively narrow, and eventually closes, in association with chronic IOP 
elevation
41,71
. POAG has a relatively insidious onset in dogs and typical clinical signs 
include buphthalmos, mydriasis, lens subluxation, corneal oedema and vascularisation, 
visual deficits and elevated IOP (> 25 mmHg)
28,66,72,73
. Age of onset varies but clinical 
signs may occur as early as 6 months in Beagles – the breed in which this form of 
glaucoma has been most extensively studied
73
. Owing to the insidious and slowly 
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progressive nature of POAG, however, clinical diagnosis is usually made only in very 
advanced cases
41
. The exact pathogenesis of canine POAG is unknown. Excluding the 
studies reported in this thesis, all reported forms of canine POAG have been linked to 
mutations in ADAMTS10 or ADAMTS17
68-70,74,75
. These mutations are thought to result 
in altered processing of the ECM and/or defects in microfibril structure which lead to 
decreased AH outflow and increased IOP. 
Before commencing this project, POAG had been diagnosed by myself in several Shar 
Pei (SP) and anecdotally by other veterinary ophthalmologists. Although POAG in the 
SP had not been published, there was a publication describing primary lens luxation 
(PLL) in this breed, although the description of the phenotype of some of the affected 
dogs was more consistent with a diagnosis of POAG rather than PLL
76
. Differential 
diagnosis between POAG and PLL can be difficult owing to the coexistence of 
increased IOP, lens subluxation and an apparently normal globe size in some dogs at 
initial clinical presentation
77
.  PLL almost exclusively affects terriers in which the 
disease is caused by another mutation in ADAMTS17. In terriers with PLL, the lens is 
usually acutely displaced into the anterior chamber causing glaucoma through 
obstruction of the pupil and/or ICA
77
. In the SP, however, the most common clinical 
sign of PLL has been reported to be iridodonesis with some dogs presenting with 
buphthalmos. This is not consistent with the classic presentation of PLL and is more 
consistent with POAG
76
. For this project, genetic investigation of POAG in three breeds 
was performed: BH, Basset Fauve de Bretagne (BFdB) and SP. 
 Genetics of canine primary glaucoma 1.3
Where primary glaucoma occurs with an increased prevalence in a certain canine breed, 
a genetic component is suspected
78
. Several techniques are available to further 
investigate the genetic basis of inherited disease, including glaucoma, which will be 
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briefly discussed before an appraisal of the previous investigations into canine primary 
glaucoma.  
 Techniques used to investigate the genetics of primary glaucoma 1.3.1
1.3.1.1 Pedigree analysis 
Compilation of a pedigree is particularly useful in determining the mode of inheritance 
when the disease results from a mutation in a single gene leading to a simple Mendelian 
trait. The disease should be seen to segregate within the family and, if the disease is well 
phenotyped (in particular with reference to age of onset), it is usually relatively 
straightforward to identify whether inheritance is autosomal dominant, autosomal 
recessive or sex-linked. This is the case for POAG in the Beagle, which was first 
established to be an autosomal recessive condition by test matings and pedigree analysis 
in 1981
79
. Pedigree analysis has also been employed to study the mode of inheritance of 
canine PCAG. Originally, autosomal dominant and autosomal recessive mechanisms of 
inheritance of PCAG were reported in the WSS and Siberian Husky respectively 
although it is now generally accepted that canine PCAG is inherited as a complex trait, 
where the disease results from the effects of multiple genetic and possibly 
environmental factors
60,78
. PLD and narrowing of the ICA are forms of goniodysgenesis 
and are considered risk factors for PCAG in multiple breeds
29-31,33,48,60,65,80,81
. In the 
Bouvier des Flandres, pedigree analysis has suggested PLD to be inherited as a 
recessive trait and, in the FCR, English Springer Spaniel, Samoyed and Great Dane, 
PLD and ICA narrowing increase in severity with degree of kinship
29,30,32,33,65
. 
Molecular techniques are, however, required to identify the genetic cause of disease.  
1.3.1.2 Molecular genetic markers 
A molecular genetic marker is a region of DNA with a known location on a 
chromosome that varies between individuals and populations. Microsatellites and single 
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nucleotide polymorphisms (SNPs) are examples of molecular genetic markers that are, 
in combination, commonly used in molecular applications ranging from forensic 
identification, parentage testing, creation of genetic maps and disease mapping. Regions 
of DNA that are in close proximity tend to be inherited together, and genetic markers 
are therefore commonly used to investigate the relationship between an inherited 
disease and the genetic mutations that cause it.  
 Microsatellites 1.3.1.2.1
A microsatellite is a tract of repetitive DNA in which certain DNA motifs (ranging in 
length from 2 – 5 base pairs) are repeated, typically 5 - 50 times. Microsatellites occur 
at thousands of locations in the canine genome and are notable for their high mutation 
rate and diversity in the canine population. Diversity of each microsatellite arises from 
the number of DNA motif repeats, allowing for multiple alleles to exist within a given 
population.  
A few considerations are required for suitable microsatellite selection. Microsatellites 
composed of dinucleotide repeats occur more frequently than longer motifs and are 
more stable than tetranucleotides and are, therefore, preferred
82
. Microsatellites 
composed of the dinucleotides CA or GT are also preferable as they tend to be more 
mutatable (polymorphic). The microsatellite should be as long as possible with the 
dinucleotide being found to repeat at least 12 times in the reference sequence. In 
candidate gene studies (described below), to maximise the likelihood that the 
microsatellite, and by implication the gene and any disease-causing mutations, will be in 
linkage disequilibrium (LD) with one another, the microsatellite should be located as 
close to the gene in question as possible. LD varies from breed to breed but averages 
around 2 Mb in the dog and thus microsatellites occurring within 500 kb of the 
candidate gene should be selected where possible
82-84
. Two microsatellites should be 
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selected to closely flank the gene and, once selected, a pair of primers must be designed 
with which to amplify each microsatellite (section 2.2.5). 
 Single nucleotide polymorphisms 1.3.1.2.2
A single nucleotide polymorphism (SNP) represents a change at a specific genomic 
position from one nucleotide to another. SNPs are generally bi-allelic and tend to be less 
informative than microsatellites. However, SNPs occur at a much higher density across 
the canine genome occurring, on average, every 1 kb
85
. This high density makes them 
very useful for whole genome mapping strategies. 
1.3.1.3 The candidate gene approach 
A candidate gene approach is particularly useful when the disease is inherited as a 
simple Mendelian trait. This approach identifies specific genes that are considered good 
candidates to harbour mutations causing the disease in question, and assesses the 
association of markers within those genes with the disease in a set of affected and 
unaffected individuals.  
 Selection of candidate genes 1.3.1.3.1
Candidate genes are often selected on the basis of previous association with a 
phenotypically identical or similar disease in other species or breeds or from knowledge 
of their function. Novel candidate genes may also be selected on the basis of their 
presence in genomic loci identified to be associated with the disease in question. Such 
genes become of particular interest when their known function or activity in affected 
tissues implicates their involvement further
82
. 
A list of candidate genes is often formed by an appraisal of the scientific literature 
surrounding the condition, for example by the use of online tools such as PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) or online databases such as OMIM 
(https://www.omim.org/). Once a list has been established, the chromosomal location of 
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the gene, or its canine orthologue, must be established within the canine genome. This is 
usually performed by using a publicly available genome database such as Ensembl 
(http://www.ensembl.org).  
 Association analysis of candidate genes 1.3.1.3.2
Once the chromosomal location of a candidate gene is known, polymorphic markers 
(e.g. microsatellites) within close proximity of or within the candidate gene can be 
identified. These markers are then genotyped in both affected animals (cases) and 
unaffected animals (controls). Following genotyping, statistical association analyses are 
performed to test for association between the markers and the disease in question. If the 
candidate gene contains a pathogenic mutation, there should be significant association 
of the investigated markers with disease and the candidate gene may then be 
investigated in more detail. On the other hand, if the markers show no association with 
disease, the candidate gene is unlikely to contribute to disease and is usually excluded 
from further investigation
82
. 
Such an approach was used to identify mutations in HSF4 in three different dog breeds 
by screening 20 candidate genes known to be associated with inherited cataract in 
humans
86
. Prior to the studies described in this thesis, the candidate gene approach had 
been less successful in identifying causal mutations for cases of canine primary 
glaucoma. In humans, mutations in the myocillin gene (MYOC) have been associated 
with multiple primary glaucoma phenotypes in particular POAG
87-91
. Using a candidate 
gene approach, POAG in the Beagle was shown not to be associated with mutations in 
MYOC and, indeed, no mutations in this gene have been associated with any form of 
canine primary glaucoma to date
92,93
. A candidate gene approach did reveal associations 
between mutations in SRBD1 and PCAG in Shiba Inu and Shih Tzu dogs, however, 
although the exact causative mutations remain elusive
94
. 
  
Chapter 1 Introduction 
44 
 
1.3.1.5 Whole-genome locus mapping 
For inherited diseases which do not share a close phenotypic description with a disease 
in another breed or species which has already been molecularly characterised and/or for 
which inheritance is thought to be complex, or where the list of candidate genes is 
prohibitively long, more sophisticated molecular techniques are required. Whole 
genome approaches have the advantage of not being limited to a list of proposed 
candidate genes and do not require prior knowledge of a target locus.  
DNA sequences (i.e. genetic markers and mutations) that are located close to one 
another on a chromosome are likely to be inherited together during meiosis. The further 
apart they are the more likely it is that recombination will occur between them, and they 
will not be inherited together. Genotyping of markers across the entire genome in cases 
and controls, and comparison of marker allele segregation with the disease in question 
can identify the likely loci harbouring the disease causal mutation. These studies can be 
conducted using a family-based approach (linkage analysis) or using ‘unrelated’ cases 
and controls in an association-based analysis – i.e. genome-wide association study. 
 Linkage analysis 1.3.1.5.1
Linkage analysis can be performed in many different ways but traditionally has 
involved the evaluation of genetic markers (microsatellites or SNPs) across a pedigree 
(or family) in which the disease has been shown to segregate
95
. The power to detect 
linkage is proportional to the number of individuals affected within families and the 
total number of families. Once linkage to a specific chromosomal locus is identified, 
analysis of genes contained within the region is conducted. Traditional linkage analysis 
has been widely and successfully used to identify genetic variants with Mendelian 
inheritance, including primary glaucoma in humans. Linkage studies have led to the 
identification of MYOC and OPTN as genes implicated in Mendelian POAG in humans 
and were used to identify the POAG locus in the Beagle
69,96,97
. Canine linkage analysis 
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tends to work very well in experimental colonies but presents more of a challenge ‘in 
the field’ as it is more difficult to collect cases and controls and information is often 
incomplete which reduces study power. Since the establishment and availability of a 
canine reference genome and the development of newer technologies such as SNP 
genotyping arrays, traditional linkage analysis is less commonly used in the molecular 
investigation of canine inherited disease. Furthermore, linkage analyses have proven 
less successful in the investigation of complex traits, of which canine PCAG is thought 
to be an example. 
 Genome-wide association studies 1.3.1.5.2
Genome-wide association studies (GWAS) involve the use of a SNP genotyping array - 
a dense array of genetic markers which capture a substantial proportion of common 
variation in the genome sequence
98
. The aim of GWAS is to map susceptibility loci 
through the detection of associations between genotype and phenotype using cases and 
controls. Over the last decade, GWAS has improved the understanding of the genetic 
basis of numerous complex traits by revealing susceptibility loci and providing insights 
into the allelic architecture of multifactorial traits
99,100
. 
A number of canine SNP arrays have been developed and used over the years, 
containing SNP markers based on the 7.8X canine reference sequence derived from a 
Boxer dog
85
. The CanineHD BeadChip (Illumina) containing 172,115 SNPs has been 
most widely used to date, although this has recently been updated to a denser array 
containing 220,853 SNPs
101,102
. Furthermore, ThermoFisher has recently launched a 
canine genotyping array containing over 670,000 SNPs. In the CanineHD BeadChip, 
each chip contains millions of 3 micron beads which are covalently bound to hundreds 
of thousands of copies of a single locus-specific 50-mer oligonucleotide. Single base, 
allele-specific extension of the oligonucleotide with subsequent fluorescent staining of 
the extension product enables identification of the allele at that locus. Once allele 
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identification has been performed at each SNP locus for each sample, the genotype of 
that sample can be determined. Analysis software packages are then used to test the data 
for associations between SNPs and the trait in question once filtering has been 
conducted to exclude poorly performing individuals and markers. Significant 
association of a SNP or SNPs allows identification of a locus for further investigation. 
A positional candidate approach may then be performed with or without fine-mapping 
to refine the associated locus. 
The number of samples required for GWAS to be informative in locus identification 
depends on the inheritance pattern of the investigated trait. For simple Mendelian 
recessive traits, as few as 20 cases and 20 controls, and perhaps even less,  may be 
required
103
. For complex traits, in which more than one gene or mutation may be 
involved, a larger number of samples is required. For example, in dogs, it has been 
predicted that a fivefold risk allele can be detected with 100 cases and 100 controls but a 
twofold risk allele would require approximately 500 cases and 500 controls to be 
identified. This is in distinct contrast to human studies, in which as many as 6,000 
samples may be needed to detect a twofold risk allele as a result of the relatively short 
LD in this species
104
. The dog has a unique pattern of LD, extending over several 
megabases (Mb) within breeds (10 – 100 X further than in humans), but only tens of 
kilobases (kb) between breeds
85
. LD patterns can vary greatly between breeds, with a 
general trend of greater LD in breeds that have experienced significant population 
bottlenecks
105
. 
GWAS have previously been used to investigate the genetic basis of glaucoma in dogs. 
In their investigation of POAG (an autosomal recessive trait) in the Norwegian 
Elkhound, Ahonen et al. performed GWAS in 9 cases and 8 controls (using the 172,115 
SNP CanineHD array) to map the glaucoma gene to a 750 kb region on canine 
chromosome 20
70
. This region was found to contain ADAMTS10, which had previously 
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been reported to be associated with POAG in another breed, and thus was an excellent 
candidate gene for further investigation. Ahonen et al. also performed GWAS in the 
DDT to investigate PCAG, which is thought to be a complex trait, using the Illumina 
Canine SNP20 BeadChip array (Illumina)
106
. There was an association between PCAG 
and a 9.5 Mb locus on canine chromosome 8 although no SNPs reached Bonferroni 
significance. 
1.3.1.6 Sequencing 
Sequencing strategies may be employed in mutation mapping, fine-mapping and 
identification of disease-causing mutations. 
 Sanger sequencing 1.3.1.6.1
Sanger sequencing, also known as the chain termination method, is a technique for 
DNA sequencing based upon the selective incorporation of chain-terminating 
dideoxynucleotides (ddNTPs) by DNA polymerase during in vitro DNA replication. It 
was developed by Frederick Sanger and colleagues in 1977. It was the most widely used 
sequencing method for approximately 25 years before it was replaced by next-
generation sequencing (NGS) methods. However, the Sanger method remains in wide 
use, for smaller-scale projects, validation of NGS results and for obtaining especially 
long contiguous DNA sequence reads (> 500 nucleotides). The classical chain-
termination method requires a single-stranded DNA template, a DNA primer, DNA 
polymerase, dNTPs and modified fluorescently labelled ddNTPs. The ddNTPs lack a 3'-
OH group which is necessary for the formation of a phosphodiester bond between two 
nucleotides. Thus, incorporation of a ddNTP instead of a dNTP, causes DNA elongation 
to terminate. 
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 Next-generation sequencing 1.3.1.6.2
NGS is based on massively-parallel, high throughput sequencing of millions of short 
nucleotide sequences. Targeted NGS may be used to sequence a genomic locus 
identified by a previous whole-genome scan or to sequence the exons of a gene, for 
example in a candidate gene analysis. NGS may also be used in a non-targeted fashion 
in whole-genome and RNA sequencing.  
NGS has already been used in the investigation of canine POAG and PCAG but has 
only successfully led to the identification of mutations associated with POAG thus 
far
69,107
. 
 Previous studies of the genetics of human and canine glaucoma 1.3.2
The high prevalence of PCAG in certain dog breeds implies a genetic link. Despite this, 
the genetics of the disease have received relatively little scientific attention. This, 
however, is changing as molecular techniques to investigate genetic disease, in 
particular GWAS and whole-genome sequencing, become increasingly available and 
affordable. The genetics of human primary glaucoma have been extensively studied, 
however, serving as a useful learning resource for those researching the canine disease 
equivalents. 
In humans, glaucoma is the most common cause of irreversible blindness worldwide
59
. 
POAG is by far the most common form of primary glaucoma followed by PACG (the 
human equivalent of canine PCAG) and genetic studies of these diseases are most 
relevant to the investigation of canine primary glaucoma and this project
108,109
. Primary 
congenital glaucoma, exfoliative glaucoma and pigment dispersion glaucoma have all 
been, and continue to be, investigated but are less relevant to the canine situation. 
Most forms of human primary glaucoma appear to be genetically complex – likely 
involving a large number of grouped or independently inherited genes along with 
environmental factors
8,110,111
. However, Mendelian forms of POAG have been reported 
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in humans in association with mutations in MYOC, OPTN, CYP1B, TBK1 and 
WDR36
112-115
. Of these genes, MYOC has gained most interest from researchers 
investigating canine primary glaucoma. MYOC protein has been found to be elevated in 
the AH of dogs with POAG and PCAG but, to date, no MYOC mutations have been 
discovered in dogs with primary glaucoma
92,93,116,117
.  Numerous other genes have been 
implicated in human POAG with GWAS helping to elucidate genes involved in the 
more complex forms. A large GWAS of 3,853 POAG patients and 33,480 matched 
control subjects revealed associations for three novel susceptibility loci for POAG: 
TXNRD2, FOXC1 and ATXN2
118
. The functions of these genes suggest that studies of 
ocular development (FOXC1), neurodegeneration (ATXN2) and mitochondrial 
dysfunction (TXNRD2) may help define the biological pathways that contribute to 
POAG
118
. Another study reported seven novel POAG susceptibility loci (FNDC3B, 
ANKRD55-MAP3K1, LMX1B, LHPP, HMGA2, MEIS2 and LOXL1) and GWAS have 
also been used to identify loci associated with IOP, improving risk prediction for 
primary glaucoma
119-121
. Recently, a bioinformatics study resulted in the compilation of 
542 genes with confirmed associations with POAG and its related phenotypes (normal 
tension glaucoma, ocular hypertension, juvenile open-angle glaucoma, and primary 
congenital glaucoma)
8
. In this study, functional annotation and pathway analyses of 
these genes were performed which revealed that no single molecular pathway 
encompasses the pathophysiology of POAG and suggested that inflammation and 
senescence may play pivotal roles in POAG with the TGF-β signaling pathway being 
repeatedly implicated. 
All cases of canine POAG investigated to date are Mendelian, showing simple 
autosomal recessive inheritance, and have been associated with mutations in 
ADAMTS10 or ADAMTS17
68-70,74
. Interestingly, mutations in ADAMTS10 and 
ADAMTS17 have also been associated with reduced scleral rigidity and PLL (equivalent 
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to ectopia lentis in humans) respectively in certain dog breeds, further highlighting the 
importance of these genes in connective tissue biology in the mammalian eye
122-124
. 
Secondary, but not primary, glaucoma has been reported in humans with Weill-
Marchesani, Weill-Marchesani-like and Marfan syndromes as a result of mutations in 
ADAMTS10, ADAMTS17 and FBN-1 (fibrillin-1)
125-131
, and autosomal-recessive ectopia 
lentis caused by a homozygous mutation in ADAMTSL4
132
. These genes, all expressed 
within the trabecular meshwork, are involved in microfibril formation and maintenance, 
and diseases as a result of mutations in these genes are often referred to as 
microfibrillopathies
133-135
. In these human microfibrillopathies, glaucoma occurs in 
conjunction with other ocular phenotypes such as spherophakia and ectopia lentis and 
systemic phenotypes relating to connective tissue disorders including brachydactyly and 
heart defects
125,136-139
. The pathogenesis of canine POAG as a result of mutations in 
ADAMTS10 and ADAMTS17 is unknown. Microfibrils are components of elastic fibres 
which are important structural units within the trabecular meshwork and are likely to be 
involved in assisting AH movement into the distal outflow pathways as previously 
discussed
137
. Furthermore, microfibrils are involved in ECM metabolism, for example 
through the binding and storage of TGF-β which is known to contribute to increased 
trabecular outflow resistance
21,133,134,137,140,141
. Increased resistance to AH outflow may 
also be caused by the accumulation of various products within the trabecular 
meshwork
9
. Evidence for this comes from the identification of plaque-formation in the 
trabecular meshwork of humans and Beagles with POAG
19,20,142,143
. Furthermore, 
ADAMTS4 has been shown to be important in AH outflow in human and porcine 
eyes
144
. These studies suggest that the ADAMTS and ADAMTSL gene families play an 
important role in intraocular physiology and demonstrate how mutations within the 
same gene can cause multiple ocular phenotypes. 
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Human PACG is characterised by a shallow anterior chamber, increased lens thickness, 
complete or partial ICA closure, short axial globe length, hyperopia and optic nerve 
injury
58,145,146
.  Reduced anterior chamber depth and narrowing of the ICA are important 
risk factors for PACG and correlate with age, sex and ethnicity
146-148
. Risk for PACG 
increases with age, and females are at higher risk than males
54,58
. Furthermore, PACG is 
more prevalent in Chinese, Malay, Asian Indian and Eskimo populations
149-152
. Human 
GWAS, typically involving thousands of cases and controls, have helped identify 
numerous genetic loci associated with PACG including the PCMTD1-ST18, COL11A1 
and PLEKHA7 loci
153-155
. Although many genes underlying PACG remain 
undiscovered, several have been proposed. These include MMP-9 (matrix 
metalloproteinase-9) which is involved in ECM metabolism
154,156,157
. PACG has also 
been associated with genes involved in regulation of axial globe length and connective 
tissue remodeling such as MFRP (membrane type frizzled related protein), MTHFR 
(methylenetetrahydrofolate reductase) and CHX10 (retinal homeobox)
158-160
. Other 
genes implicated in PACG pathogenesis include eNOS (endothelial nitric oxide 
synthase), HSP70 (heat-shock protein 70), HGF (hepatocyte growth factor), GSTT1 
(glutathione S-transferase T1), GSTM1 (glutathione S-transferase M1), CALCR 
(calcitonin receptor-like receptor), APOE (apolipoprotein E), TNFA (tumour necrosis 
factor A), TNFR1 (tumor necrosis factor-α receptor 1) and SPARC158,159,161-168. SPARC 
protein is found within the trabecular meshwork and is involved in ECM remodelling 
making it an attractive candidate gene for PACG. The list of genes associated with 
human PACG is being added to all the time, further highlighting the complexity of the 
disease. Recently, a large multi-ethnic GWAS meta-analysis involving 10,503 PACG 
cases and 29,567 controls drawn from 24 countries revealed five new genetic loci: 
EPDR1, CHAT, FLIS3, FERMT2, and DPM2-FAM102A
169
. 
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Genetic studies of canine PCAG have been far more limited, nevertheless susceptibility 
loci have been identified and some candidate genes postulated. PCAG genetics have 
been studied in most detail in the BH owing to the establishment of an affected breeding 
colony. In this breed three genetic loci have been identified leading to the proposal of 
the three positional candidate genes COL1A2, NEB and RAB22A, which are all 
expressed in the anterior segment of the eye
170,171
. Based on their function, COL1A2 and 
NEB appear to be promising candidate genes. COL1A2 encodes for the pro-alpha2 chain 
of collagen type 1 – an important component of the trabecular meshwork. NEB encodes 
the muscle contractility regulating protein, nebulin, which is expressed in the ciliary 
body musculature, and the belief that muscle-related mechanisms are involved in the 
AH humour outflow pathways makes NEB a feasible candidate. RAB22A, is known to 
be an oncogene, and thus its potential role in primary glaucoma is more difficult to 
explain. 
SRBD1 (S1 RNA-binding domain 1) has been associated with primary glaucoma in 
humans and has also been identified as a PCAG risk gene in the Shih Tzu and Shiba 
Inu
94
. In a study reporting findings of GWAS of PCAG in the DDT, although an 
association was found between PCAG and a region on canine chromosome 8, no 
candidate gene or causal mutations have been identified
106
. 
 Aims and objectives 1.4
This study was conceived with three main aims: 
1. To provide robust and current PLD prevalence data for seven dog breeds known 
to be affected by PLD and PCAG: FCR, BH, DDT, WSS, GR, BC and HV.  
2. To investigate the genetic basis of PLD and PCAG in four dog breeds: BH, 
FCR, DDT and WSS. 
3. To investigate the genetic basis of POAG in three dog breeds: BH, BFdB and 
SP. 
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2 Materials and methods 
 Determination of pectinate ligament dysplasia prevalence 2.1
 Animals used 2.1.1
Canine breeds at risk of PCAG were identified on the basis of scientific publications 
and/or inclusion on the BVA/KC/ISDS Eye Scheme (1.2.2). Health representatives from 
relevant breed clubs were contacted, informed of the study and their clubs invited to 
participate. Participation involved setting up gonioscopy screening sessions for each 
breed to identify dogs affected with PLD (cases) and unaffected dogs (controls). The 
breeds investigated were the FCR, BH, DDT, WSS, BC, HV and GR. These seven 
breeds of dog were enrolled in gonioscopy screening sessions at different locations 
across the United Kingdom between September 2013 and March 2016 between the 
hours of 10:00 and 16:00 GMT. The sessions were promoted by a variety of different 
mechanisms, including correspondence from the KC to the owners of KC registered 
dogs of each breed, via breed club websites and via social media.  All dogs that were 
volunteered for screening were accepted, regardless of their age, ancestry or KC 
registration status. 
 Examination procedure 2.1.2
All experiments were conducted in accordance with the ARVO statement for the Use of 
Animals in Ophthalmic and Vision Research and approved by the AHT’s Research and 
Ethical Approval Committee. All dogs were pets and ophthalmological examination 
was only performed after informed and written owner consent. All examinations were 
performed by myself, a board-certified veterinary ophthalmologist of the European 
College of Veterinary Ophthalmologists (ECVO). 
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IOP was estimated using rebound tonometry with a TonoVet Tonometer (TonoVet, 
Kruuse). Tonometry was performed immediately prior to topical anaesthesia and 
gonioscopy. This tonometer takes six consecutive measurements, discards the highest 
and lowest readings and averages the remaining four. Only readings with a maximum 
standard deviation of 5 % were recorded. Three averaged readings were taken for each 
eye and the average of these three readings was then calculated and used for subsequent 
analyses. 
Gonioscopy was performed bilaterally in conscious dogs following topical anaesthesia 
achieved by application of 0.5 % proxymetacaine (Bausch & Lomb, Chauvin 
Pharmaceuticals Ltd.) using a 17 or 19 mm Koeppe goniolens (Ocular Instruments) 
filled with 2 mg/g carbomer gel (Viscotears; Alcon) before placing onto the cornea.  
The entire 360
o
 of the ICA was then examined using a handheld slit-lamp 
biomicroscope (Keeler PSL Classic; Keeler) for the presence of PLD which was 
quantified according to the percentage of the ICA circumference affected, estimating 
this to the nearest 5 %. Regions of ICA were judged to be affected by PLD where they 
exhibited abnormally broad PL fibres or solid sheets of tissue as previously described in 
section 1.2.1
31
. No attempt to measure ICA width was made as this was considered too 
subjective in line with previous publications
31,35,48
.  
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Figure 2.1. A series of gonioscopy photographs to illustrate the PLD grading 
system used.  
The grading system has been applied assuming the photographs are representative of the 
entire 360
o
 of ICA in each case. (a) Normal appearance of the ICA and PL. Unaffected 
(grade 0).  (b) Approximately 15 % of the ICA is affected by abnormally thickened PL 
fibres. Mildly affected (grade 1). (c) Approximately 25 % of the ICA is affected by PL 
‘sheeting’. Moderately affected (grade 2). (d) Approximately 75 % of the ICA is 
affected by PL ‘sheeting’. Moderately affected (grade 2). (e) Over 90 % of the ICA is 
affected by ‘sheeting’. Severely affected (grade 3). 
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 Analyses pectinate ligament dysplasia data 2.1.4
2.1.4.1 Pectinate ligament dysplasia: prevalence, progression and associations with 
age, sex and intraocular pressure 
For each dog examined, data were collected on breed, sex, age at time of examination 
and, for each eye, percentage ICA affected by PLD and IOP. The mean percentage of 
ICA affected by PLD and mean IOP for the left and right eyes were averaged for each 
dog. To reduce the influence of subjectivity on estimation of PLD (percentage of ICA 
circumference affected to the nearest 5 %), PLD results were assigned to one of four 
ordinal scale grades, based on the percentage of ICA circumference affected (Table 2.1) 
as previously described
35
. Eyes were classified as ‘unaffected’ if 0 % of the ICA was 
affected by PLD (ordinal grade 0), ‘mildly affected’ if < 20 % was affected (grade 1), 
‘moderately affected’ if 20 - 90 % was affected (grade 2) and ‘severely affected’ if > 90 
% was affected (grade 3) (Table 2.1). The continuous variables age and IOP were not 
normally distributed and so were converted into ordinal variables with four ranks based 
on quartile values. The following statistical analyses were performed: 
 The variables IOP and age were examined for normal distribution using the 
Shapiro-Wilk test, and the overall pattern of the data and deviations from the 
pattern were examined using scatterplots. 
 For each breed, the prevalence of PLD was determined by calculating 
proportions of dogs graded as 0, 1, 2, and 3.  
 The linear relationships between the ordinal variable PLD grade and age, and 
PLD grade and IOP were evaluated using Spearman’s correlation coefficient 
(rho).  
 The proportions of male and female dogs affected with PLD were compared 
using the Chi-square test of independence.  
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 The variables IOP and age were not normally distributed for the three breeds, 
and therefore the linear relationship between IOP and age was assessed using 
Spearman’s correlation coefficient.  
 The difference in average IOP between male and female dogs was assessed 
using the Mann-Whitney U test.  
 The variables age and IOP were compared between breeds using the Kruskal-
Wallis test.  
 The proportions of male and female dogs in the three breeds were compared 
using the Chi-square test of independence.  
Table 2.1. Degree of PLD estimated by gonioscopy as percentage of total ICA 
circumference affected and equivalent ordinal grade as published by Pearl et al.
35
. 
2.1.4.2 Pectinate ligament dysplasia: progression 
In the WSS, PLD progression in individual dogs was investigated. This was not 
performed in the other breeds owing to insufficient historic data. In the WSS, following 
examination as part of the cross-sectional study above, Eye Scheme certificates of any 
previous gonioscopic examination were sought and obtained where available for each 
dog. Only dogs with certificates that clearly documented the degree of PLD at this 
Percentage of ICA 
affected by PLD 
Definition Ordinal grade 
0 % Unaffected 0 
5 - 15 % Mildly affected 1 
20 – 90 % Moderately affected 2 
> 90 % Severely affected 3 
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earlier examination and dogs that were previously examined by a single examiner 
(Beverley Cottrell) were included in this study (n = 65). This allowed comparison of 
gonioscopy results over time. As only two examiners (Beverley Cottrell and myself) 
were involved, it was thought that subjectivity would be reduced whilst ensuring the 
second examiner was masked as to the result of the first examiner.  
 
For the analyses described in 2.1.4.1 and 2.1.4.2, a P value of < 0.05 was considered 
statistically significant, and all analyses were performed by Dr Abel Ekiri using IBM 
SPSS statistical software (version 22).  
2.1.4.3 Gonioscopy in the dog: inter-examiner variability and the search for a 
grading scheme (section 3.2) 
Both eyes of 49 Welsh springer spaniel dogs (98 eyes) were examined by two panellists 
of the BVA/KC/ISDS Eye Scheme on the same day (Beverley Cottrell and myself). The 
two examiners had never worked together and were trained at different institutions 
under different mentors. Each examiner was masked to the findings of the other 
examiner and to those of any previous examinations. Gonioscopy was performed as 
detailed in 2.1.2. For the purpose of this study, left and right eyes were classified 
independently. Data were first analysed for individual examiners to provide descriptive 
statistics of percentage of PLD assigned to examined eyes. Kernel density plots were 
then created to allow visualisation of the distribution of data for each examiner. The 
relationship between the results of the two examiners was assessed with a scatterplot 
and simple linear regression with degree of association between the two examiners’ 
results being assessed using Pearson’s product moment correlation coefficient. The non-
parametric Wilcoxon signed rank test was used to test the null hypothesis that there was 
no difference between the percentages of PLD assigned to each eye by the two 
examiners with a P < 0.05 considered statistically significant and allowing rejection of 
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the null hypothesis. The signed rank test was applied to both the full set of 98 paired 
observations and to the subset of eyes for which both examiners considered PLD to be 
present. A Bland-Altman plot was created to further characterise any inter-examiner 
discrepancy of PLD percentage scores. Following assignment of percentage scores of 
PL to the four different ordinal grading schemes, quantification of agreement beyond 
that expected by chance alone between the two examiners for each scheme was assessed 
using the Cohen’s kappa statistic. The level of agreement based on the kappa statistic 
was interpreted as follows: ≤ 0.20 = ‘poor’, ˃ 0.20 - ≤ 0.40 = ‘fair’, ˃ 0.41 – ≤ 0.60 = 
‘moderate’, ˃ 0.60 – ≤ 0.80 = ‘good’ and  ˃ 0.80 – 1.00 = ‘very good’172. For the 
purposes of this study, only grading schemes which resulted in a ‘good’ or ‘very good’ 
level of agreement were considered acceptable. All of these analyses were performed by 
myself using the internet-based software GraphPad (https://www.graphpad.com/). 
 Mutation mapping and identification 2.2
 DNA collection and extraction 2.2.1
DNA samples were collected from all dogs examined as part of the PLD prevalence 
study and also from clinical cases of PCAG and POAG. All DNA samples were 
collected from privately owned pet dogs following fully informed and written owner 
consent. Samples were collected in the form of five buccal mucosal swabs from each 
dog, which were air dried and then stored at -20 
o
C until DNA extraction. DNA samples 
received from collaborators were either received as buccal mucosal swabs, blood 
samples collected in EDTA or as DNA in solution. All samples were stored at -20 
o
C.  
DNA was extracted from buccal mucosal swabs using a QIAamp® DNA Blood Midi 
Kit (Qiagen) following a modified protocol. Briefly, buccal cells were lysed by 
incubation of four of the five swabs in a solution of 1,600 L phosphate buffered saline 
(PBS), 1,600 L Lysis Buffer (Qiagen) and 80 L Proteinase K (Qiagen) in a 15 mL 
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conical tube (Falcon) at 56 
o
C for 20 minutes. After 10 minutes of incubation, each 
sample was mixed by vortexing for 10 seconds. Following incubation, DNA was 
precipitated by the addition of 1,600 L absolute ethanol and mixed by vortexing. 
Precipitated DNA was collected via passage of the solution through supplied filter 
columns (Qiagen) by centrifugation at 1,620 x g for 3 minutes (5804/5804 R, 
Eppendorf). DNA collected on the filter was then purified with two separate wash steps 
using 2 mL of each of the supplied two wash buffers AW1 and AW2, followed by 
centrifugation at 4,500 x g for 1 minute and 15 minutes respectively. DNA was eluted 
by addition of 150 L AE elution buffer followed by centrifugation at 4,500 x g for 1 
minute. The elution step was performed a total of three times to result in a DNA 
solution approaching 450 L in volume.  
DNA was extracted from whole blood stored in EDTA using a protocol based on the 
Nucleon BACC2 Genomic DNA Extraction Kit (Tepnel Life Sciences). Briefly, up to 5 
mL of blood was added to a 50 mL polypropylene tube (Falcon). Nucleon Reagent A 
(stored at 4 
o
C) was then added to make up a total volume of 25 mL and the tube 
inverted 10 times to lyse red blood cells. White blood cells were collected by 
centrifugation of the sample at 4,500 x g for 10 minutes followed by removal of the 
supernatant. To lyse the white blood cells in the pellet, 10 mL of Nucleon Reagent B 
was then added and the pellet broken up by shaking, followed by overnight incubation 
at 37 
o
C. The lysis mix was then transferred to a 15 mL polypropylene tube (Falcon), 
and 800 L of 5M sodium perchlorate added, followed by mixing by inversion to 
achieve protein precipitation. Two millilitres of chloroform was then added and the 
sample mixed by inversion for 4 minutes before centrifugation at 4,500 x g for 5 
minutes. This step resulted in the formation of three distinct layers within the sample: a 
bottom layer of chloroform; a middle layer of precipitated protein; and a top layer of 
DNA-containing aqueous solution. The DNA-containing layer was transferred using a 
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sterile pastette to a new 15 mL tube. The protein precipitation stage was then repeated 
(addition of chloroform and centrifugation) followed by removal of the DNA-containing 
aqueous phase. Finally, 5 mL ice cold absolute ethanol was added and the DNA-
containing solution gently inverted until the precipitated DNA could be observed. The 
DNA spool was captured using a sealed glass hook and air-dried before transfer to a 
microcentrifuge tube containing 300 L 1X TE buffer (Appendix I). 
 DNA normalisation and concentration 2.2.2
DNA concentration and purity were determined using a spectrophotometer 
(NanoDrop
TM
 1000 Spectrophotometer, Thermo Scientific) and fluorometer (Qubit
TM
 
Fluorometer used in conjunction with the Qubit
TM
 dsDNA BR Assay Kit, Invitrogen). 
Samples for genome-wide association mapping were normalised in ultrapure water 
(MQ; Ultra Clear UV Plus Water System, SG) to a final concentration of 20 ng/L and 
a final volume of 25 L. Samples for pre-NGS QC were normalised in MQ to a final 
concentration of 30 - 80 ng/L and a final volume of 50 L. Samples used for 
microsatellite genotyping and Sanger sequencing were normalised with MQ to 
concentrations of 20 ng/L. For samples in need of concentration, DNA was 
precipitated using MultiScreenHTS PCR filter plates (Millipore) before resuspension in a 
smaller volume of MQ. 
  
Chapter 2 Materials and methods 
62 
 
 Polymerase chain reaction  2.2.4
The polymerase chain reaction (PCR) is used to amplify a specific region of DNA. A 
standard PCR mix comprises: DNA template; two primers complimentary to the 3’ end 
of the sense and antisense DNA fragments to be amplified; deoxynucleotide 
triphosphates (dNTPs); a heat stable DNA polymerase (e.g. Taq polymerase); and 
buffer solution. A standard PCR protocol requires cycling through a series of thermally 
controlled steps, comprising an initiation phase, 30 - 45 cycles of three sequential steps 
(denaturation, annealing and elongation/extension), followed by a final elongation phase 
and an infinite holding step:  
1. Initiation step: Required to activate Hot Start polymerases at 94 - 98 oC for 5 - 
10 minutes. 
2. Denaturation: The reaction is first heated to 95 oC for 30 seconds to denature 
the double-stranded DNA template. This step disrupts the hydrogen bonds 
between the strands and yields single-stranded DNA. 
3. Annealing: The reaction is cooled to 50 - 60 oC for approximately 30 seconds to 
allow the primers to hybridise to the complementary single stranded DNA. The 
annealing temperature varies according the melting temperature (Tm) of the 
primers but is typically 3 - 5 
o
C below the primer Tm. If annealing temperature 
is too low then non-specific binding may occur. DNA polymerase then binds to 
the DNA-primer hybrid so that elongation may begin. 
4. Elongation: DNA polymerase synthesises a new strand of DNA complementary 
to the strand to which the primer has bound using the dNTPs in the reaction mix. 
Extension occurs in the 5’ to 3’ direction by condensing the 5’-phosphate group 
of the complimentary dNTP onto the 3’-hydroxyl group of the nascent DNA 
strand. The temperature used varies according to the optimum temperature of the 
DNA polymerase. For Taq polymerase, a temperature of 72 
o
C is typically 
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selected. Under optimal conditions, target DNA amplification occurs in an 
exponential fashion. Steps 2 - 4 are repeated 30 - 45 times. 
5. Final elongation: This step is performed to ensure that any remaining single-
stranded DNA is fully extended. It is performed at the same temperature as the 
elongation phase (typically 72 
o
C) and for 5 - 30 minutes. 
6. Final hold. This step is performed for an indefinite amount of time to safely 
store the final PCR reaction for a short period. A temperature of 7 - 12 
o
C is 
usually employed. 
The thermal cycling reactions and parameters used varied from experiment to 
experiment and are presented in Appendix II and III. For allelic discrimination assays, 
an additional step was incorporated to measure fluorescent emissions (allelic reads) in 
the reaction. PCR amplification for microsatellite genotyping consisted of two three-
step cycles. The first was used to amplify from the tailed forward primer and reverse 
primer and another, at a lower annealing temperature, for annealing of the tailed primer 
and the tailed fluorescent primer. Unless stated otherwise, HotStarTaq Plus DNA 
Polymerase (Qiagen) was used for all PCR reactions. For DNA templates with high GC 
content, an additive, Q solution (Qiagen) was added to facilitate double-stranded DNA 
denaturation. For each PCR experiment, a non-template control was included as a 
quality control measure. Thermal cycling for PCR and microsatellite genotyping was 
carried out on a T100
TM
 thermal cycler (Bio-Rad) and for allelic discrimination on a 
StepOnePlus
TM
 Real-Time PCR System (Applied Biosystems). 
 Primer design 2.2.5
All primers for microsatellite genotyping, Sanger sequencing and mutation detection by 
allelic discrimination assays were designed using Primer3 (http://bioinfo.ut.ee/primer3-
0.4.0/primer3/) and details can be found in Appendix IV
173-175
. All primers were 
designed to meet the following criteria: 
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 Primer length: 16 - 24 bp with an optimum length of 21 bp. 
 Primer melting temperature (Tm): 57 - 63 oC with an optimum of 60 oC. 
 Maximum Tm difference: 2 oC between each primer of a pair in order that both 
primers will anneal with similar efficiency at the experimental temperature. 
 Guanine-cytosine (GC) content: Minimum 40 % and maximum 60 %. High 
GC content leads to stable imperfect hybrids and low GC depresses the Tm of 
perfect hybrids. In GC-rich regions, this parameter was relaxed to a minimum of 
20 % and maximum of 80 %. 
 Maximum allowable length of a mononucleotide repeat (Max Poly-X): 3 - 
increasing this reduces the specificity of the primer. 
 Consecutive guanine and cytosine bases at primer 3’ end (CG clamp): 2 - 
increasing this provides tighter primer binding but at the expense of reducing 
suitable primers. 
Each primer pair was ‘blasted’ (BLAST = Basic Local Alignment Search Tool) against 
the canine reference assembly (CanFam3.1) using the Ensembl genome browser 
(http://www.ensembl.org/index.html), to ensure that primers were specific to the 
targeted DNA fragment. Primers with more than 100 alignments were discarded and 
new ones designed. For primer pairs designed for microsatellite genotyping, an 18 bp 
tail (TGACCGGCAGCAAAATTG) was added to the 5’-end of the forward primer as 
previously reported
176
. A third primer with sequence complementary to the tail was 
labelled with a fluorescent molecule, FAM (with blue fluorescence), to allow detection 
of fragments on an ABI 3130xl genetic analyser (Applied Biosystems).  
For allelic discrimination assays (SNP genotyping), a pair of primers was designed 
along with two allele-specific probes. One probe was labelled with 6-FAM and the other 
with HEX reporters and both were labelled with a Black Hole Quencher®. The design 
criteria for the probes were as follows: 
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 The targeted nucleotide should be within the middle third of the probes 
 Tm 4 – 5 oC > than Tm of primers 
 Product size as small as possible 
 The 5’ nucleotide should not be guanine 
All primers and probes were purchased from Integrated DNA Technologies (IDT, 
Belgium). 
 Agarose gel electrophoresis 2.2.6
Following PCR amplification of the initial DNA templates (and a non-template control), 
an aliquot of the product was run on an agarose gel to ensure the presence of expected 
PCR product. Molecular grade agarose (Bioline) was used to make a 1.5 % gel (1.5 g 
agarose in 100 mL 1X TAE buffer (National Diagnostics)). The agarose was dissolved 
by heating and 3 L of 0.625 mg/mL ethidium bromide was added prior to casting. 
Once set, the gel was completely submerged in 1X TAE buffer in an electrophoresis 
tank (PerfectBlue
TM
 Gel System Mini L, PeqLab). An aliquot (2 L) of each PCR 
product was mixed with 5 L STOP loading dye before loading into lanes of the gel. A 
2-Log DNA Ladder (10 µL; New England Biolabs) was loaded as a size control. 
Electrophoresis was performed at 120 V for 45 minutes. The gels were analysed under 
ultraviolet light using a fluorochemistry imager (FluorChem
TM
 5500 Imager, Alpha 
Innotech). Samples for which a single band of the expected size was visible, and when 
the band was absent from the non-template control lane, were considered suitable for 
microsatellite genotyping or sequencing (following purification). 
 Microsatellite genotyping 2.2.7
Microsatellite genotyping was used to investigate associations between candidate genes 
and PLD and PCAG. Microsatellites were identified and selected as described in 
1.3.1.2.1 and primers were designed as described above with resulting products between 
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200 and 400 bp in size. After amplification with the third fluorescent primer, PCR 
products were separated by size on an ABI 3130xl Genetic Analyzer using the 
GeneScan 400HD Rox size standard (Applied Biosystems). Data were analysed and 
alleles assigned to each sample using GeneMapper v4.0 software (Life Technologies 
Ltd.). 
 Sanger sequencing 2.2.8
2.2.8.1 Purification of PCR products 
Following initial PCR and successful amplification, as assessed by agarose gel 
electrophoresis, PCR product purification was performed to remove excess primers and 
PCR reagents. PCR products were purified using 96-well MultiScreenHTS PCR filter 
plates (Millipore), according to the manufacturer’s instructions.  Briefly, 100 µL MQ 
was added to each well containing PCR product. Following this, each sample was 
transferred into the corresponding well on the filter plate. The filter plate was then 
assembled onto a vacuum manifold and a vacuum of 15 inches Hg was applied for 10 - 
20 minutes until each well appeared empty. The filter plate was then removed from the 
manifold, 20 µL MQ was added to each well and the DNA was resuspended by gentle 
agitation for 20 minutes on a rocking table (Luckham Ltd.). The purified products were 
then transferred to a 96-well PCR plate for storage and further use. 
2.2.8.2 Sequencing reaction 
The same primers used for initial PCR amplification were also used for Sanger 
sequencing. Sequencing was performed in both the forward and reverse directions (by 
performing reactions with forward and reverse primers separately). Sanger sequencing 
was performed using Bigdye v3.1 chemistry (Life Technologies Ltd). The reaction and 
cycling parameters used are presented in Table 2.2 and Table 2.3. 
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Table 2.2. Recipe for Sanger sequencing. 
Reaction component Volume/reaction (L) Final concentration 
Template (PCR product) 2  
2.5 X Bigdye Ready Reaction Mix 0.5 0.2 X 
10 X SBDD Buffer 1 1.7 X 
Primer (1.6 M) 1 0.27 M 
Ultrapure water (MQ) 1.5  
 
Table 2.3. Thermal cycling parameters for Sanger sequencing.  
Step Temperature Duration Cycles 
Initial denaturation 96 
o
C 30 s  
Denaturation 92 
o
C 4 s  
X44 
Annealing 55 
o
C 4 s 
Extension 60 
o
C 110 s 
 
Following sequencing, excess reagents were removed by isopropanol precipitation. 
Briefly, 60 µL of 80 % isopropanol was added to each reaction in the 96-well PCR plate 
to precipitate the DNA. The plate was then centrifuged at 2,254 x g for 30 minutes to 
collect the DNA at the bottom of each well. The supernatant was discarded by tipping 
the plate upside-down, and blotting the inverted plate on tissue to prevent cross-
contamination. Further purification was performed by the addition of 100 µL of 60 % 
isopropanol followed by centrifugation at 2,254 x g for 10 minutes to collect the DNA 
at the bottom of each well. The supernatant was discarded as above, and excess 
isopropanol was removed by placing the plate upside-down on tissue, followed by 
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centrifugation at 141 x g for 1 minute. To ensure all isopropanol was removed and the 
DNA pellet was as pure as possible, the plate was dried in a 37 
o
C oven for 10 minutes. 
Finally, precipitated DNA was resuspended in 10 µL Hi-Di Formamide (Applied 
Biosystems). The sequencing products were then separated on an ABI 3130xl genetic 
analyser and data analysed using the Staden software package 
(http://staden.sourceforge.net/)
177
. The raw sequencing data were first processed using 
Pregap4 to determine if sequence quality was sufficient for alignment, to convert data 
from ABI to ZTR format and to create experiment files. Gap4 was then used to 
assemble and compare sequence reads, align and compare them to a reference sequence 
and view the sequence traces. 
 Genome-wide association studies 2.2.9
GWAS were used to investigate the genetics of PLD and PCAG in four dog breeds: BH, 
FCR, DDT and WSS. DNA samples were used from dogs with the following 
phenotypes: 
1. Dogs with normal appearing ICAs aged five years and above (controls). 
2. Dogs with PLD affecting at least 50 % of the ICA of each eye as assessed by 
gonioscopy (PLD cases). 
3. Dogs with PCAG (PCAG cases). Criteria for a diagnosis of PCAG included 
elevated IOP > 50 mmHg, the absence of any possible cause of secondary 
glaucoma and the finding of severe PLD (> 90 % of the ICA affected) in the 
contralateral eye. 
Dogs were designated as controls or PLD cases based on the results of gonioscopy 
performed by myself. Dogs were classified as PCAG cases following examination by 
board-certified veterinary ophthalmologists and included many samples from both 
national and international collaborators. 
Chapter 2 Materials and methods 
69 
 
All DNA was extracted and normalised in house before submitting to an external 
laboratory for genotyping (Neogen). Cases and controls were randomly intercalated at 
the normalisation stage and, where possible, also at the DNA extraction stage. This was 
to preserve data quality and avoid any impact of between-chip variability in processing. 
GWAS were all performed using the CanineHD BeadChip (Illumina) which contains 
172,115 SNPs (based on the CanFam2.0 reference sequence)
101
. Samples were 
submitted for genotyping in three batches over two years (corresponding with sample 
collection). New genotyping data were merged with previous data and reclustered in 
GenomeStudio (Illumina) to preserve data quality before analysis. Any SNPs that were 
found to be associated with disease were also checked for expected clustering in 
GenomeStudio. GWAS data were analysed using the freely available software package 
PLINK (http://zzz.bwh.harvard.edu/plink/)
178
. Data were filtered for quality control 
parameters including sample call rate, SNP call rate and minor allele frequency (MAF).  
SNPs were excluded from analysis if they were not polymorphic, had a MAF < 0.05 or 
had a call rate of < 97 %. Individuals were excluded if > 10 % SNP genotypes were 
missing.  
SNPs were not excluded on the basis of Hardy-Weinberg equilibrium due to the inbred 
nature of purebred dogs, the small sample size of the studies, and the non-population-
based sampling methods, making it more likely that truly associated SNPs could be 
filtered out using Hardy-Weinberg. Clustering/assay performance of associated SNPs 
were checked in GenomeStudio. GWAS analyses were conducted using a standard 
unadjusted allelic chi-squared test for association (1 degree of freedom (df)). Genome-
wide Manhattan plots were created to display the GWAS findings with respect to their 
genomic positions to highlight any signals of potential interest. Manhattan plots 
represent the P-values of the entire GWAS on a genomic scale. The P-values are 
represented in genomic order by chromosome and position on the chromosome (x-axis). 
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The value on the y-axis represents the −log10 of the P-value. Because of local 
correlation of the genetic variants, arising from infrequent genetic recombination/LD, 
groups of significant P-values tend to rise up high on the Manhattan plot, making the 
graph look like a Manhattan skyline.  
For each individual breed, the following analyses were performed: 
1. PCAG cases and controls 
2. PCAG and PLD cases combined and controls 
3. PLD cases and controls 
4. PCAG cases and PLD cases 
5. PCAG cases and PLD cases and controls combined 
2.2.9.1 Assessment and correction of population stratification 
As part of all GWAS conducted, quantile-quantile (Q-Q) and multi-dimensional scaling 
(MDS) plots of cases and controls were created using PLINK (Appendix VI). MDS is a 
means of visualising the level of similarity (homogeneity) between the cases and 
controls and refers to a set of related ordination techniques to display the information 
from the GWAS genotypes in a distance matrix. Cases and controls should be 
intercalated in the plot with little evidence of separate clustering. The MDS plot allows 
visualisation of potential outlier samples, for example if an incorrect breed was included 
in the analysis, which would then be excluded from subsequent analyses. 
Q-Q plots were created in Excel using summary association statistics (χ2 values from 
unadjusted PLINK analysis and χ2 values converted from P-values of score test in 
GEMMA (Genome-wide Efficient Mixed-Model Association, 
www.xzlab.org/software.html)
179
. The Q-Q plot is used to assess the number and 
magnitude of observed associations between genotyped SNPs and the disease compared 
to the association statistics expected by chance because of the large number of statistical 
tests performed. Observed association statistics are ranked from smallest to largest on 
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the y-axis against the null hypothesis of no association on the x-axis. General deviations 
from the null line suggest that there is bias in the study set, such as population 
stratification. Deviation of observed associations from the end of the null line is 
suggestive of true association of genotype with phenotype. Inflation of observed 
statistics due to relatedness or population substructure can be estimated by genomic 
control (λ). Genomic control is defined as the median χ2 (1 df) association statistic 
across SNPs divided by its theoretical median under the null distribution and is 
proportional to sample size
180. A value of λ ≈ 1 indicates no stratification, whereas λ > 1 
indicates stratification or other confounders such as family structure of cryptic 
relatedness, or differential bias. λ < 1.05 is generally considered benign. 
Data were subsequently corrected for population stratification using the mixed model 
GEMMA.  A mixed model is a class of statistical model in which phenotypes are 
modelled using both fixed effects such as GWAS SNPs and fixed covariates and 
random effects (the genotypic covariate matrix).  GEMMA takes into account the 
familial and pedigree structure of the case-control sample set by calculating kinship 
matrices directly from the genome-wide SNP data and its application results in a 
reduction in the λ which becomes visually evident on the Q-Q plot as the observed 
statistics more closely approximate to the null line.  
2.2.9.2 Statistical association of variants with disease 
P-values derived from GEMMA were used to create a Manhattan plot for each analysis. 
A P-value of 0.05 after correction for multiple testing using the Bonferroni correction 
(0.05/number of tests) was the threshold for significant statistical association in all 
studies (typically –log10P = 6.3) and prompted further investigation of associated SNPs.  
Associations between GWAS SNPs and candidate variants and disease were assessed 
using the Fisher’s exact test and logistic regression using an additive model to compute 
an odds ratio and confidence interval for the association of SNPs with disease.  Logistic 
Chapter 2 Materials and methods 
72 
 
regression and log-likelihood ratio tests were used to assess the shape of the association 
between variants and disease by comparing a general inheritance model with a linear 
per allele model.  The variance in disease risk explained by one or more SNPs was 
obtained from the pseudo R
2
 value from the regression model. 
Logistic regression and log-likelihood ratio tests were also used to examine the 
independence of SNPs statistically associated with disease risk.  This was done by 
comparing the log likelihood of a nested model (2 df) with that of a full model (3 df) by 
adding the other SNP (coded in a linear 1 df) into a model containing the strongest 
associated SNP (coded as a general inheritance 2 df form).  This analysis was also 
repeated reciprocally. 
2.2.9.3 Meta-analysis studies 
In the meta-analysis studies, summary estimates (beta coefficients and standard errors) 
from each individual breed association analysis (using GEMMA) were combined using 
meta-analysis for SNPs that were informative in all breeds and that had passed 
individual-breed QC filters (MAF and call rate) in all breeds.  Effect allele designation 
was harmonised amongst studies prior to analysis by beta coefficient flipping where 
required. A fixed effects model and inverse-variance weighted averages of beta 
coefficients to obtain a combined estimate of the overall association between SNPs and 
disease was used.  Heterogeneity was assessed using the Q statistic.  An inflation factor 
(λ) was calculated for the meta-analysis which was estimated from the median of the 
chi-squared tests generated on all SNPs that were tested. The above statistical analyses 
described in 2.2.9.2 and 2.2.9.3 were conducted using STATA 10.0 (College Station, 
TX, USA) and were performed by Dr Sally Ricketts. 
2.2.9.4 Genome-wide haplotype analysis 
In addition to standard GWAS, multi-SNP haplotype analysis methods for association 
analysis were performed using unadjusted association data in PLINK. The disadvantage 
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of this approach was that the data had not been corrected for population stratification. 
The potential advantage of this approach is that it might reveal certain associations not 
detected by single SNP analysis because haplotypes may capture a causal variant more 
effectively than any single measured SNP. Genome-wide sliding windows of 1 – 8 
SNPs were selected and Manhattan plots of association of these SNP windows with 
phenotype were created. The threshold for genome-wide significance for haplotype 
analysis was also set using Bonferroni correction. Haplotype permutation analyses were 
also performed in PLINK using 100,000 permutations. Permutation procedures provide 
a computationally intensive approach to generating significance levels empirically. Such 
values have desirable properties: for example, relaxing assumptions about normality of 
continuous phenotypes and Hardy-Weinberg equilibrium, dealing with rare alleles and 
small sample sizes, providing a framework for correction for multiple testing, and 
controlling for identified substructure or familial relationships by permuting only within 
cluster.  
The threshold for significance for haplotype permutation association analysis was set at 
log100.05 (1.3). Haplotype association and permutation plots are presented in Appendix 
VII rather than in the main text as they did not reveal any additional significant 
associations of SNPs with disease that were not detected by standard GWAS.  
 Next-generation sequencing of DNA 2.2.10
All NGS was performed on the Illumina sequencing platforms. Whole-genome 
sequencing (WGS) of all samples was outsourced to the High Throughput Genomics 
(HTG) group at the Welcome Trust Centre for Human Genetics (WTCHG, University 
of Oxford), Cambridge Genomic Services (CGS, University of Cambridge) or 
Edinburgh Genomics (University of Edinburgh). The amount of DNA, library 
preparation, read length and depth, and sequencing platforms used varied, particularly 
for early samples (Table 2.4). 
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Targeted NGS was performed in-house on a MiSeq platform. The NGS process is made 
up of three parts that are broadly similar for WGS and targeted sequencing: library 
preparation, cluster generation and sequencing. The description that follows applies 
specifically to targeted sequencing as it was performed in-house.    
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Table 2.4. Summarised details of DNA amount, library preparation, sequencing laboratory, read length and coverage and sequencing 
platform for samples submitted for WGS. 
Sample ID Mass, volume of DNA sent Library preparation Sequencing laboratory Read length, coverage Platform 
WSS_24604 4nM, 18uL (pooled) In-house, TruSseq LT PCR free CGS 150 bp PE, 20x NextSeq 
WSS_25078 4nM, 18uL (pooled) In-house, TruSeq LT PCR free CGS 150 bp PE, 20x NextSeq 
FCR_25382 1000 ng, 60 uL WTCHG, PCR FREE WTCHG 100 bp PE, 20x HiSeq4000 
FCR_25384 1000 ng, 60 uL WTCHG, PCR FREE WTCHG 100 bp PE, 20x HiSeq4000 
BaH_28502 2500 ng, 55 uL Edinburgh Genomics, TruSeq Nano Edinburgh Genomics 150 bp PE, 30x HiSeqX 
BaH_29716 2500 ng, 55 uL Edinburgh Genomics, TruSeq Nano Edinburgh Genomics 150 bp PE, 30x HiSeqX 
BaH_31929 2500 ng, 55 uL Edinburgh Genomics, TruSeq Nano Edinburgh Genomics 150 bp PE, 30x HiSeqX 
DD_26698 2500 ng, 55 uL Edinburgh Genomics, TruSeq Nano Edinburgh Genomics 150 bp PE, 30x HiSeqX 
DD_27784 2500 ng, 55 uL Edinburgh Genomics, TruSeq Nano Edinburgh Genomics 150 bp PE, 30x HiSeqX 
WSS_25165 2500 ng, 55 uL Edinburgh Genomics, TruSeq Nano Edinburgh Genomics 150 bp PE, 30x HiSeqX 
WSS_7617 2500 ng, 55 uL Edinburgh Genomics, TruSeq Nano Edinburgh Genomics 150 bp PE, 30x HiSeqX 
DD_14598 764 ng, 40 uL Edinburgh Genomics, TruSeq Nano Edinburgh Genomics 150 bp PE, 30x HiSeqX 
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2.2.10.1 Library preparation  
DNA libraries were prepared using the Nextera XT DNA Library Preparation Kit 
(Illumina). The Nextera DNA Sample Preparation Kit uses an engineered transposome 
to simultaneously fragment and tag ("tagment") input DNA, adding unique adapter 
sequences in the process (Figure 2.2). A limited-cycle PCR uses these adapter 
sequences to amplify the insert DNA. The PCR also adds index sequences on both ends 
of the DNA, thus enabling dual-indexed sequencing of pooled libraries.  
 
Figure 2.2. Nextera XT library preparation.  
A - Nextera XT transposome with adapters is combined with template DNA. B - 
Tagmentation to fragment and add adapters. C - limited cycle PCR to add sequencing 
primer sequences and indicies. (http://support.illumina.com). 
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Library preparation was performed according to the manufacturer’s recommendations, 
with some modifications. Briefly, 5 L of 0.2 ng/L input DNA was combined with 10 
L supplied Tagment DNA Buffer and 5 L of Amplicon Tagment Mix, and the 
solution was mixed by pulsing. The tagmentation solution was incubated at 55 
o
C for 5 
minutes, followed by the addition of 5 L of Buffer NT and mixing. Tagmented DNA 
was then purified using AMPure XP (Beckman Coulter Life Sciences) beads and the 
purified tagmented DNA eluted in MQ. PCR was then performed by combining 5 L of 
index primer 1, 5 L of index primer 2, 15 L purified tagmented DNA and 25 L 
KAPA HIFI HS RM to individual wells of a PCR plate and thermal cycling performed 
according to the conditions in Table 2.5. 
Table 2.5. Thermal cycling parameters for Nextera XT library preparation. 
Purification with AMPure XP beads was repeated and the purified DNA library was 
resuspended in 25 µL MQ. Eluted libraries were quantified by quantitative PCR 
(qPCR), using the KAPA Library Quantification Kit for the Illumina Genome Analyser 
Platform (KAPA Biosystems), on an Eco Real-Time PCR System (Illumina). Briefly, a 
10 L reaction volume was used, made up of 6 L 2X KAPA SYBR FAST qPCR 
Step Temperature Duration Cycles 
Initiation 72 
o
C 3 m  
Initial denaturation 98 
o
C 30 s  
Denaturation 98 
o
C 10 s  
X12 
Annealing 63 
o
C 30 s 
Extension 72 
o
C 3 m 
Hold 10 
o
C ∞  
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Master Mix containing primer premix, 2 L MQ and 2 L Library DNA (diluted 
1:1,000 with Library Dilution Buffer) or 2 L DNA standard or 2 L MQ (non-template 
control). Thermal cycling was then performed as below (Table 2.6). Experimental DNA 
library reactions were performed in triplicate whereas those of DNA standards and non-
template controls were performed in duplicate. 
Table 2.6. Quantitative PCR cycling conditions. 
Average concentrations determined by qPCR were then adjusted to account for 
differences in the average length of the DNA library and the length of the DNA 
standards (452 bp). The following formula was used:  C = A x 
452
S
x D, where C = 
concentration to be determined (pM) , A = average concentration (pM) determined by 
qPCR, S is the size of the fragments (bp) as determined by Bioanalyser analysis 
(outsourced to CGS, University of Cambridge) and D is the dilution factor (1,000) used 
in the qPCR reaction. Finally, all captured libraries were diluted to 3,000 pM (3 nM) 
and pooled in equimolar amounts for multiplexed sequencing.  
2.2.10.2 Cluster generation 
Cluster generation is performed by the sequencing platform (e.g. Miseq) prior to 
sequencing. The pooled library is first immobilised on the surface of a flow-cell; the 
single-stranded DNA library fragments first randomly bind to oligonucleotides on the 
Step Temperature  Duration Cycles 
Initial denaturation 95 
o
C 5 m  
Denaturation 95 
o
C 30 s  
Annealing, extension and 
data acquisition  
60 
o
C 45 s X 35 
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surface of the flow-cell, via the complimentary adapters added during library 
preparation. Unlabelled nucleotides and enzyme are then added and the bound 
fragments are then extended to form double-stranded DNA and the adapter on the 
unattached end also binds covalently to the flow-cell surface to form a bridge. Through 
a series of expansions, bridge amplification and denaturation, each library fragment is 
clonally amplified to create millions of unique clusters. The reverse strands are removed 
to leave single-stranded DNA molecules attached at one end to the flow-cell. The free 
ends are then blocked and sequencing primers hybridise to the DNA templates. 
2.2.10.3 Sequencing 
The Illumina systems use sequencing by synthesis (SBS) technology in which DNA 
templates are sequenced in parallel, base by base. Four fluorescently-labelled 
nucleotides compete to bind to millions of templates simultaneously. The labelled 
nucleotides are reversibly terminated so that the templates only extend by a single base 
in each round of synthesis. After each round of synthesis, a laser is applied to excite the 
clusters with the resultant colour of fluorescence denoting the identity of the newly 
bound base. After this, cleavage of the terminator molecule and fluorescent label occurs, 
allowing the commencement of the next round of base addition to the DNA template.  
Targeted NGS was performed in-house on the MiSeq platform, and the first 100 bases 
of each fragment were sequenced from one end only, resulting in 100 bp single end 
reads. Initial data quality control was performed by the MiSeq, generating the raw 
sequencing data in FASTQ format. For WGS (outsourced to commercial sequencing 
laboratories), the first 100 or 150 bases of each fragment were sequenced from both 
ends of the fragment to result in 100 bp or 150 bp paired-end reads. Initial quality 
control was conducted by the commercial laboratories to include the Illumina base-
calling pipeline and Illumina tag identification.  
2.2.10.4 Data analysis 
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Raw sequencing data were received as FASTQ files containing millions of sequence 
reads 100 or 150 bp in length. The FASTQ files were run through the AHT pipeline 
which was designed by Dr Mike Boursnell. This pipeline is made up of a number of 
analytical tools. The BWA (Burrows-Wheeler-Alignment) tool aligns short sequences to 
the reference sequence (CanFam3.1) by assigning chromosomal coordinates to each 
read, creating a read file in SAM (Sequence Alignment/Map) format
181
. Picard was used 
to manipulate SAM files to create BAM (Binary Alignment/Map) files in which the 
reads were sorted according to chromosomal coordinates. The BAM files could be 
directly analysed at this stage using the Integrated Genomics Viewer (IGV) if desired 
(for example if a strong candidate gene had already been identified)
182,183
.  
SAMtools was used to manipulate both SAM and BAM files, removing PCR duplicate 
reads and retaining only read pairs of the highest quality. SAMtools was also used to 
index the reference FASTA files and read BAM files. GATK (Genome Analysis 
Toolkit) provides a Java programming framework for writing tools for the analysis of 
NGS data
184
. The pipeline included various built-in tools including base quality score 
recalibration, identification of indels and SNPs and depth coverage calculations. 
Variants were filtered by effect of variant using the Ensembl Variant Effect Predictor 
(VEP) to provide an ‘effect score’ for variants giving rise to new annotated files 
(VCF_VEP) before conversion into Excel files
185,186
. The effect score is a scoring 
system (graded 1 to 5) developed by the AHT to rank the variants by their anticipated 
effect on proteins. For example, coding deletions, coding insertions and nonsense 
variants were assigned the highest effect score of 5, whereas intergenic variants were 
assigned the lowest effect score of 1. To further aid in variant filtration, segregation 
scores were also assigned by comparing WGS data between affected and unaffected 
dogs. The higher the score, the better the variant segregated with disease status, with the 
highest possible score equal to the number of individuals used in the analysis. 
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Depending on the nature of the disorder being investigated, effect scores and 
segregation scores are used to filter out variants unlikely to be pathogenic, thereby 
reducing the number of candidate variants to a practical and manageable level for 
further investigation.  
 Identification of candidate variants 2.2.11
A next-generation WGS approach was used to identify variants that segregated with 
PCAG in loci determined by GWAS. Associated loci were defined based on pair wise 
linkage disequilibrium estimates (R
2
 ≥ 0.5) of the SNPs using the Tagger program 
embedded in Haploview
187,188
. A list of SNPs in LD with the top GWAS SNP was 
generated which could denote a region tagged by the GWAS association signal.   SNPs 
were excluded from analysis if they had a minor allele frequency < 0.05 or had a call 
rate of < 97 %. but were not excluded on the basis of Hardy-Weinberg equilibrium. As 
canine PCAG is thought to be a complex disease, possibly involving a combination of 
risk alleles, effect score was set at the minimum. However, to reduce the number of 
variants to a practical level, the highest possible segregation score was selected. In 
section 4.2, candidate variants were searched within susceptibility loci in breed-specific 
analyses using a single WGS from one PCAG case and 97 controls of other breeds 
without PCAG and belonging to breeds not thought to be predisposed to PLD or PCAG. 
Identified variants were further explored using WGS from 465 canids, held by the Dog 
Biomedical Variant Database (DBVD) consortium to which the AHT belongs. Only 
variants that were private to the breed in question were further investigated. 
 Variant screening 2.2.12
The method used to screen samples for candidate variants varied, depending on the 
nature of the variant and number of samples being screened and all raw genotyping 
results are presented in Appendix VIII. Insertion or deletion (indel) mutations result in 
a change in PCR amplicon size which was generally assessed by amplified fragment 
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length polymorphism (AFLP) analysis. This was achieved using capillary 
electrophoresis of 5’ 6FAM-labelled PCR products on an ABI 3130xl genetic analyser 
and data were analysed with GeneMapper v4.0 (Life Technologies Ltd.). Sanger 
sequencing (as described in section 2.2.8) was employed to screen small sample cohorts 
for indel or SNP variants. Allelic discrimination was used to identify SNP variants in 
larger sample cohorts. This method makes use of allele-specific fluorescently labelled 
probes, with each probe labelled with a unique fluorescent reporter (6-FAM or HEX) on 
the 5’-end and a quencher on the 3’-end. As long as the reporter and quencher are in 
close proximity to each other, as they are when not hybridised to the mutation, the 
quencher absorbs the fluorescence emitted by the reporter dye. During PCR, however, 
the probe hybridises to the target SNP and is cleaved by the 5’- to 3’-exonuclease 
activity of polymerase. This results in spatial separation of the reporter and quencher 
increasing the fluorescence of the reporter dye. By determining which reporter dye is 
fluorescing, the allele-specific primer that is hybridising with the DNA template, and 
therefore allele, can be identified. 
 Gene expression studies 2.3
 Tissue collection and RNA extraction 2.3.1
Most dogs with primary glaucoma require eye removal (enucleation) on welfare 
grounds when the eyes are irreversibly blind, painful and there is no response to 
therapy. When possible, and following informed written owner consent, tissue samples 
were collected and stored immediately following enucleation. Following enucleation, 
each globe was transected along the sagittal plane into two equal halves. Each half 
globe was immersed in 15 mL RNAlater solution (Ambion) before storing at -80 
o
C 
until later use as previously described
189,190
. RNA was extracted from selected tissue 
samples using the Qiagen RNeasy Midi Kit (Qiagen). Following thawing of each half 
globe, a section of ICA was dissected under an operating microscope with microsurgical 
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instrumentation aiming for approximately 200 - 250 mg tissue. The posterior boundary 
of the dissected tissue was the posterior pars plana and the anterior boundary was the 
corneoscleral limbus. No lens tissue was included in the dissection but the sclera was 
included. Adherent conjunctiva and episcleral tissues were removed. The resultant 
tissue section was weighed on an electronic balance to ensure a final weight of 150 - 
250 mg tissue. The tissue was placed in a 15 mL centrifuge tube (Falcon) and 80 µL 2M 
DDT (dithiothreitol) and 4 mL RLT buffer before homogenisation using a motorised 
rotor-stator homogeniser (Omni International). The lysate was then centrifuged for 10 
minutes at 4,500 x g to remove debris and prevent subsequent filter clogging. The 
supernatant (3 - 4 mL) was then transferred by pipetting into a clean 15 mL tube. To the 
supernatant was added one volume of 70 % ethanol before mixing by vigorous shaking, 
followed by the addition of 4 mL of sample to an RNeasy Midi column on a supplied 15 
ml centrifuge tube and centrifugation for 5 minutes at 4,500 x g. The flow-through was 
discarded and the step was repeated with any remaining sample, followed by the 
addition of 4 mL Buffer RW1 to the spin column and centrifugation for 5 minutes at 
4,500 x g, discarding the flow-through. In order to eliminate any contaminating DNA, 
20 µL DNAase was added to 140 µL RDD and gently mixed before pipetting gently 
onto the spin column filter and left to stand at room temperature for 15 minutes. 
Biomolecules such as carbohydrates and proteins were removed by the addition of 2 mL 
Buffer RW1 to the column, which was left to stand for 5 minutes and then centrifuged 
for 5 minutes at 4,500 x g. The flow-through was discarded and traces of salts were 
removed by the addition of 2.5 mL Buffer RPE to the column before centrifugation for 
2 minutes at 4,500 x g. The flow-through was discarded and a further 2.5 ml Buffer 
RPE was added before centrifugation for 5 minutes at 5,000 rpm. The spin column was 
then transferred to a new 15 mL centrifuge tube and 250 µL RNase free water was 
added to elute, left to stand for 1 minute then centrifuged for 3 minutes at 4,500 x g. 
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This step was then repeated and the eluted RNA transferred to a 1.5 mL eppendorf tube. 
RNA concentration and purity was assessed by Nanodrop with a target final 
concentration of 20 – 80 ng/µL. RNA integrity was initially assessed by agarose gel 
electrophoresis (section 2.2.6). Intact total RNA run on an ethidium bromide denaturing 
gel has clear 28S and 18S rRNA bands. The 28S rRNA band should be approximately 
twice as intense as the 18S band. Partially degraded RNA has a smeared appearance. 
RNA was stored at -20 
o
C for up to 2 weeks or at -80
o
C for long-term storage. 
 Quantitative reverse transcriptase PCR   2.3.2
Quantitative reverse transcriptase PCR (qRT-PCR) was used to compare gene 
expression between normal and affected tissues. Two step qRT-PCR was performed 
using complementary DNA (cDNA) synthesised by the reverse transcription of tissue-
extracted RNA. 
2.3.2.1 Reverse transcription of RNA 
Reverse transcription was performed using the QuantiTect Reverse Transcription Kit 
(Qiagen) according to the manufacturer’s instructions. Template RNA was thawed on 
ice and the supplied gDNA Wipeout Buffer, Quantiscript Reverse Transcriptase, 
Quanitiscript RT Buffer, RT Primer Mix and RNase-free water were thawed at room 
temperature. Each solution was mixed by gentle flicking and brief centrifugation before 
keeping on ice. Before reverse transcription, a genomic DNA elimination reaction was 
performed using 2 µL 7x gDNA Wipeout Buffer and 12 µL template RNA (up to 1 µg). 
The reaction was performed with incubation for 2 minutes at 42 
o
C before placing on 
ice. A reverse-transcription reaction was performed for each sample, which included 1 
µL Quantiscript Reverse Transcriptase, 4 µL 5x Quantiscript RT Buffer, 1 µL RT 
Primer Mix and the entire genomic DNA elimination reaction (14 µL). The reaction was 
mixed, stored on ice and then incubated for 15 minutes at 42 
o
C. Incubation was then 
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performed at 95 
o
C to inactivate Quantiscript Reverse Transcriptase. The reaction 
(cDNA) was stored at -20 
o
C until subsequent use for sequencing or qPCR. 
2.3.2.2 Quantitative PCR  
Forward primer, reverse primer and assay probe were designed using the IDT 
PrimerQuest design tool (https://eu.idtdna.com/Primerquest/Home/Index). To avoid 
amplification of any contaminating genomic DNA, primers were designed so that one 
primer hybridises to the 3’ end of one exon and the other to the 5’ end of the adjacent 
exon, thereby flanking the exon splice sites. Such primers ensure that only cDNA 
synthesised from spliced mRNAs is amplified, but genomic DNA is not. Desired 
amplicon parameters were adjusted as follows: minimum amplicons size = 60, 
maximum amplicon size = 120, optimum amplicon size = 90. A sequence specific 
fluorescently labelled probe (5’FAM), complimentary to sequence between the two 
primers, was incorporated in each assay. In addition to the qPCR assay, PrimeTime® 
Gene Expression Master Mix (IDT) and template cDNA were required. The 
PrimeTime® Gene Expression Master Mix is a ready-to-use 2X concentrated master 
mix designed for use in probe-based, real-time quantitative PCR. It contains an 
antibody-mediated, Hot Start DNA polymerase, dNTPs, MgCl2, enhancers and 
stabilisers and a reference dye. The template cDNA samples generated by reverse 
transcriptase were normalised to 20 ng/µL (as assessed by Nanodrop). qPCRs were 
performed in 10 µl reactions using a StepOnePlus
TM
 Real-Time PCR System  (Applied 
Biosystems) as detailed in Table 2.7 and Table 2.8. 
Table 2.7. Thermal cycling recipe for qPCR. 
Reaction component Volume/reaction (L) Final concentration  
cDNA template (20 ng/µl) 4 8 ng/µl 
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Table 2.8. Thermal cycling parameters for qPCR. 
cDNA derived from normal and affected tissues were used in each experiment with 
reactions performed in triplicate and with a no template control. To enable relative 
quantification of real-time PCR products, the ratio between the amounts of target gene 
and a house-keeping gene was determined using the ΔΔCT method191. Unless otherwise 
stated, the house-keeping gene used for the reference assay was TATA box binding 
protein (TBP).  
The methodology behind this technique is as follows: during the annealing stage of the 
PCR both probe and primers anneal to the DNA target. Polymerisation of a new DNA 
strand is initiated from the primers, and once the polymerase reaches the probe, its 5'-3'-
exonuclease degrades the probe, physically separating the fluorescent reporter from the 
quencher, resulting in an increase in fluorescence. Fluorescence is detected and 
measured in the real-time PCR machine, and its geometric increase corresponding to 
exponential increase of the product is used to determine the threshold cycle (CT – the 
precise cycle at which the level of fluorescence exceeds a desired threshold) in each 
PrimeTime® Gene Expression 
Master Mix (2 X) 
5 1 X 
PrimeTime® qPCR assay (10 X) 1 1 X 
Step Temperature Duration Cycles 
Polymerase activation 95 
o
C 3 m  
Denaturation 92 
o
C 15 s  
X 40 
Annealing/extension 60 
o
C 1 m 
Hold 4 
o
C Up to 24 h 
Chapter 2 Materials and methods 
87 
 
reaction. CT values were averaged for each sample/probe triplicate for both the target 
gene and house-keeping gene and the difference between the two was calculated (ΔCT). 
The difference between the average ΔCT value of the sample of interest (cDNA from 
affected tissue) and the average ΔCT of the reference sample (cDNA from unaffected 
tissue) was then calculated (ΔΔCT). An unpaired t-test was performed and the gene was 
defined as differentially expressed where a statistically significant change in expression 
level, measured as fold change (FC), was observed and where FC was ≥ 2 or ≤ -2.  
 Next-generation RNA sequencing 2.3.3
The integrity and purity of total RNA were assessed using an Agilent Bioanalyzer 2100 
at CGS (University of Cambridge), and OD260/280 using Nanodrop. Total RNA (20ng 
- 1µg per sample, at a concentration of ≥ 20ng/uL with RIN ≥ 8.0 and OD260/280 ≥ 
1.8) was submitted to Otogenetics Corporation for library preparation and sequencing: 1 
- 2 μg of cDNA was generated using Clontech Smart cDNA kit (Clontech Laboratories) 
from 100ng of total RNA. cDNA was fragmented using Covaris (Covaris) and profiled 
using an Agilent Bioanalyzer 2100. Libraries were prepared using NEBNext reagents 
(New England Biolabs, Catalog No. 634925): mRNAs were purified using Poly(A) 
selection from the total RNA sample, and then fragmented. cDNA was then synthesised 
using random priming, followed by end repair, phosphorylation, A-tailing, adapter 
ligation and finally PCR amplification. The quality, quantity and size distribution of the 
Illumina libraries were determined using an Agilent Bioanalyzer 2100. The libraries 
were then loaded on an Illumina HiSeq2500 for clustering and sequencing according to 
the standard operation. Paired-end 90-100 nucleotide reads were generated and data 
quality was assessed using FASTQC (Babraham Institute, Cambridge, UK). After 
achieving optimum QC results, samples were analysed. The bioinformatics workflow 
for RNA-Seq, was performed by Otogenetics, and is summarised as follows: 
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 Sequence reads trimmed to remove adapters and low quality bases at the ends. 
After trimming, sequence reads shorter than 30 nucleotides were discarded. 
 FASTQC quality control of Fastq file per sample. 
 Sequence reads mapped to CanFam3.1 reference genome. 
 Calculation of read count values of gene expression (FPKM – Fragments Per 
Kilobase Million). 
 Differential gene expression analysis with unique read counts among samples. 
2.3.3.1 Statistical analysis of transcriptome data  
Sufficient samples were collected from five BH PCAG cases and four non-BH controls 
to allow for differential gene expression studies between these two groups in the loci 
identified in 4.2.2.1.6. Differential expression of FPKM (read counts) between PCAG 
cases and controls was calculated as the base 2 log of fold change of controls/PCAG 
cases (log2 (FPKM of PCAG cases/FPKM of controls)). Differential gene expression 
could not be performed for genes with insufficient alignments or insufficient read depth. 
The test statistic was used to compute significance of the observed change in FPKM. 
The P-value represents the uncorrected P-value of the test statistic and the Q-value 
represents the False Discovery Rate-adjusted P-value of the test statistic. Significance of 
differential gene expression (‘yes’ or ‘no’) was based on whether the P-value was 
statistically greater than the Q-value. 
2.3.3.2 Assessment of gene function and candidacy 
For genes shown to be differentially expressed, their functions and associated 
phenotypes (for potential candidacy for canine PCAG) were assessed using VarElect 
GeneCards® (http://varelect.genecards.org). GeneCards is a searchable, integrative 
database that provides comprehensive information on all annotated and predicted human 
genes. It automatically integrates gene-centric data from approximately 125 web 
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sources, including genomic, transcriptomic, proteomic, genetic, clinical and functional 
information.  .
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3 Pectinate ligament dysplasia: prevalence and a study of inter-
examiner variability in performing pectinate ligament dysplasia grading 
 Pectinate ligament dysplasia: prevalence, progression and associations with 3.1
age, sex and intraocular pressure  
 Introduction  3.1.1
Gonioscopy is performed to identify PLD, which is advised in predisposed breeds prior 
to breeding.  At the time of project outset, the BVA/KC/ISDS Eye Scheme 
recommended gonioscopy to be performed as a ‘once in a lifetime test’ as PLD was 
considered a congenital and static abnormality. There was, however, emerging evidence 
that this might not be the case with a single report of PLD progression over time in 
individual FCR
35
. 
The aims of the following studies were to:  
1. Estimate the prevalence of PLD in BH, FCR, DDT, WSS, BC, GR and HV.  
2. Investigate possible associations between IOP and sex, age and PLD in BH, 
FCR, DDT and WSS.  
3. Investigate possible associations between PLD and sex and age in BH, FCR, 
DDT, WSS, BC, GR and HV.  
4. Investigate PLD progression in individual WSS.  
 Results 3.1.2
In total, gonioscopy was performed in 198 BH, 170 FCR, 95 DDT, 227 WSS, 102 BC, 
112 HV and 230 GR by myself. For each dog, data were collected on PLD, sex and age 
at time of examination. In the BH, FCR, DDT and WSS, IOP measurements were also 
recorded. 
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3.1.2.1 BH, FCR & DDT 
These three breeds were examined as part of a single study. Investigations into PLD 
prevalence and possible associations of PLD with age and sex and associations between 
IOP and sex and age were conducted. Of the dogs examined gonioscopically, IOP was 
estimated using rebound tonometry in 198 BH, 137 FCR and 95 DDT. This study has 
since been published
46
. 
 BH 3.1.2.1.1
Of the 198 BH examined, 72 (36.4 %) were male and 126 (63.6 %) were female. The 
median age at examination was 43.1 months (minimum = 4.0 months, maximum = 
152.9 months). One hundred and forty-five of 198 (73.2 %) of BH were affected by 
PLD (ordinal grades 1 - 3): 69 (34.8 %) were mildly affected (grade 1), 72 (36.4 %) 
were moderately affected (grade 2), and 4 (2 %) were severely affected (grade 3) (Table 
3.1). A significant positive correlation was observed between PLD and age (rho = 0.26, 
P < 0.01). No correlation was observed between PLD and IOP (rho = 0.14, P = 0.06). 
The proportion of female dogs affected by PLD (grades 1 - 3) was higher compared to 
male dogs (P = 0.004). The normality test revealed that the variables IOP (P < 0.001) 
and age (P < 0.001) were not normally distributed and as such, the relationship between 
IOP and age was examined using Spearman’s correlation coefficient. No correlation 
was observed between IOP and age (rho = 0.043, P = 0.55). Average IOP was not 
significantly different between male and female dogs (P = 0.53).  
 FCR 3.1.2.1.2
Of the 170 FCR examined, 67 (39 %) were male and 103 (61 %) were female. The 
median age at examination was 48.3 months (minimum = 7.5 months, maximum = 
147.6 months). One hundred and six of 170 (62.4 %) FCR were affected by PLD 
(ordinal grades 1 - 3): 70 (41.2 %) were mildly affected (grade 1), 36 (21.2 %) were 
moderately affected (grade 2) and 0 were severely affected (grade 3) (Table 3.1). A 
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significant positive correlation was observed between PLD and age (rho = 0.34, P < 
0.01). No correlation was observed between PLD and IOP (rho = -0.02, P = 0.85). The 
proportion of dogs affected by PLD (grades 1 - 3) was not significantly different 
between male and female dogs (P = 0.34). The variables IOP and age were not normally 
distributed (P < 0.001 for both) and as such, the relationship between IOP and age was 
examined using Spearman’s correlation coefficient. No correlation was observed 
between IOP and age (rho = -0.14, P = 0.095). Average IOP was not significantly 
different between male and female dogs (P = 0.34). 
 DDT 3.1.2.1.3
Of the 95 DDT examined, 35 (36.8 %) were male and 60 (63.2 %) were female. The 
median age at examination was 47.5 months (minimum = 4.9 months, maximum = 
165.3 months). Fifty-two of 95 (54.7 %) DDT were affected by PLD: 31 (32.6 %) were 
mildly affected (grade 1), 20 (21.1 %) were moderately affected (grade 2) and 1 (1.1 %) 
was severely affected (grade 3) (Table 3.1). A positive linear relationship was observed 
between PLD and age (rho = 0.57, P < 0.001). A significant negative correlation was 
observed between PLD and IOP (rho = -0.35, P = 0.001). The proportion of dogs 
affected by PLD (grades 1 - 3) was not significantly different between male and female 
dogs (P = 0.86). The variables IOP and age were not normally distributed (P = 0.01 and 
P < 0.001 respectively) and as such, the relationship between IOP and age was 
examined using Spearman’s correlation coefficient. A moderately strong and significant 
negative correlation was observed between IOP and age in DDT dogs (rho = - 0.578, P 
< 0.0001).  
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Table 3.1. Frequency of PLD in BH, FCR and DDT. 
PLD 
grade 
BH FCR DDT 
No. % 95% CI No. % 95% CI No. % 95% CI 
0 53 26.8 20.6, 32.9 64 37.6 30.4, 44.9 43 45.3 35.3, 55.3 
1 69 34.8 28.2, 41.5 70 41.2 33.8, 48.6 31 32.6 23.2, 42.1 
2 72 36.4 29.7, 43.1 36 21.2 15.0, 27.3 20 21.1 12.9, 29.3 
3 4 2.0 0.1, 3.9 0 0  1 1.1 0.0, 3.1 
Total 198 170 95 
No. = number of dogs, CI = confidence interval 
 Interbreed comparison 3.1.2.1.4
The prevalence of PLD was significantly higher in BH (145/198) compared to FCR 
(106/170, P = 0.025) or DDT (52/95, P = 0.002). No significant difference was observed 
in the distribution of age and sex among the three dog breeds (Table 3.2). However, 
average IOP among the three dog breeds was significantly different (P < 0.001). 
Average IOP in DDT was significantly higher compared to BH (P = 0.039) or FCR (P < 
0.001).  
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Table 3.2. Comparison of distribution of mean age, sex, and mean IOP in BH, FCR 
and DDT. 
3.1.2.2 WSS 
In the WSS, PLD prevalence and potential associations of PLD with sex, age and IOP 
and of IOP with sex and age were investigated. In addition, the progression of PLD over 
time in individual dogs was investigated. The results of this study have since been 
published
45
. 
 Prevalence and associations of PLD 3.1.2.2.1
Of the 227 dogs examined by gonioscopy, 79 (34.8 %) were male and 148 (65.2 %) 
female. The median age (± SD) was 48.6 months ± 41.7 (minimum = 5.8 months, 
maximum = 170.8 months). One hundred and thirty-nine dogs (61.2 %) were affected 
with PLD (grades 1 - 3): 57 (25.1 %) were mildly affected (grade 1), 78 (34.4 %) were 
moderately affected (grade 2) and 4 (1.8 %) were severely affected (grade 3) (Table 
3.3). A weak but statistically significant positive correlation was observed between PLD 
and age (rho = 0.22, P = 0.002). No correlation was observed between PLD and IOP 
Variable Breed  
P-value 
BH FCR DDT 
Age at examination 
Median (months) 
 
43.1 
 
48.3 
 
47.5 
 
0.20 
Sex 
Male 
Female 
 
72 (36.4%) 
126 (63.6%) 
 
67 (39%) 
103 (61%) 
 
35 (36.8%) 
60 (63.2%) 
 
0.82 
IOP 
Median (mmHg) 
 
13.50 
 
12.50 
 
14.17 
 
<0.001 
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(rho = -0.03, P = 0.68). The proportion of dogs affected by PLD (of any grade) was not 
significantly different between male and female dogs (P = 0.49).  During examination of 
the relationship between IOP and age, the normality test revealed that IOP was normally 
distributed (P = 0.166) but age was right skewed (P < 0.0001). As such, the relationship 
between IOP and age was examined using Spearman’s correlation coefficient. No 
correlation was observed between IOP and age (rho = -0.092, P = 0.19). 
Table 3.3. Frequency of PLD in WSS. 
PLD grade WSS 
No. % 95% CI 
0 88 38.8 32.4, 45.1 
1 57 25.1 19.5, 30.8 
2 78 34.4 28.2, 40.5 
3 4 1.8 1.0, 3.5 
Total 227 
No. = number of dogs, CI = confidence interval 
 Progression of PLD 3.1.2.2.2
Gonioscopy had been performed prior to this study in 65/227 dogs comprising 17 males 
and 48 females. All 65 dogs (100 %) were classified as unaffected under the Eye 
Scheme at first examination with clear documentation that no PLD was present (0 % 
ICA affected by PLD, grade 0) and had all been examined by a single examiner 
(Beverley Cottrell). These same 65 dogs were examined by myself at a later time point.  
The median age at first examination was 11.2 months (range = 64.7 months, minimum = 
4.2 months, maximum = 68.9 months), while the median age at second examination was 
76 months (range = 140.2 months, minimum = 21.9 months, maximum = 162.1 
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months). At second examination, 35/65 dogs (53.8 %) were classified as affected 
(grades 1 - 3): 10 (15.4 %) dogs progressed to become mildly affected (grade 1), 24 
(36.9 %) dogs became moderately affected (grade 2), and 1 (1.5 %) dog became 
severely affected (grade 3) (Figure 3.1). The proportion of dogs affected by PLD was 
significantly different (P < 0.0001) at first examination (0/65) compared to second 
examination (35/65). The proportion of dogs affected by PLD (of any grade) was not 
significantly different between male (7/17) and female (28/48) dogs (P = 0.22). 
 
 
Figure 3.1. Comparison between number of dogs with PLD at first and second 
gonioscopy examinations. 
 
3.1.2.3 BC, HV & GR 
Before publication of these studies, these three breeds were listed as ‘under 
investigation’ for PLD under the BVA/KC/ISDS Eye Scheme. Thus, an estimation of 
PLD prevalence in these breeds was considered important as the result may influence 
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the Eye Scheme’s future policy making decisions. The results of this study have since 
been published
192
. 
 BC 3.1.2.3.1
Of the 102 BC examined, 49 (48 %) were male and 53 (52 %) were female. The median 
age ± SD of BC was 43.7 months ± 46.4 (minimum = 2.0 months, maximum = 172.8 
months). Eighteen of 102 (17.6 %) BC were PLD affected (ordinal grades 1 - 3): 7 (6.9 
%) were mildly affected (grade 1), 7 (6.9 %) were moderately affected (grade 2), and 4 
(3.9 %) were severely affected (grade 3) (Table 3.4). No significant correlation was 
observed between PLD and age (rho = -0.015, P = 0.879). The proportion of male and 
female dogs affected by PLD (grades 1 - 3) was not significantly different (P = 0.169).  
 HV 3.1.2.3.2
Of the 112 HV examined, 35 (31.3 %) were male and 77 (68.8 %) were female. The 
median age ± SD of HV dogs examined was 44.5 months ± 37.7 (minimum = 3.1 
months, maximum = 145.2 months). Thirty eight of 112 (33.9 %) HV were affected by 
PLD (ordinal grades 1 - 3): 22 (19.6 %) were mildly affected (grade 1), 14 (12.5 %) 
were moderately affected (grade 2) and 2 (1.8 %) were severely affected (grade 3) 
(Table 3.4). A weak but significant positive correlation was observed between PLD and 
age (rho = 0.366, P < 0.01). The proportion of dogs affected by PLD (grades 1 - 3) was 
not significantly different between male and female dogs (P = 0.957).  
 GR 3.1.2.3.3
Of the 230 GR examined, 93 (40.4 %) were male and 137 (59.6 %) were female. The 
median age ± SD of GR examined was 41.4 months ± 38.6 (minimum = 4.8 months, 
maximum = 173.8 months). One hundred and eleven of 230 (48.3 %) GR were affected 
by PLD: 51 (22.2 %) were mildly affected (grade 1), 51 (22.2 %) were moderately 
affected (grade 2) and 9 (3.9 %) were severely affected (grade 3) (Table 3.4). A weak 
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but significant positive linear relationship was observed between PLD and age (rho = 
0.173, P = 0.009). The proportion of dogs affected by PLD (grades 1 - 3) was not 
significantly different between male and female dogs (P = 0.114). 
Table 3.4. Frequency of PLD in BC, HV and GR. 
PLD  
grade 
BC HV GR 
 
No. % 95% CI No. % 95% CI No. % 95% CI 
0 84 82.4 74.5, 89.2 74 66.1 57.1, 75.0 119 51.7 45.2, 58.3 
1 7 6.9 2.9, 11.8 22 19.6 12.5, 26.8 51 22.2 17, 27.4 
2 7 6.9 2.0, 11.8 14 12.5 6.3, 18.8 51 22.2 17, 27.8 
3 4 3.9 1.0, 7.8 2 1.8 0.0, 4.5 9 3.9 1.7, 6.5 
Total 102   112   230   
No. = number of dogs, CI = confidence interval 
 Interbreed comparison  3.1.2.3.4
The prevalence of PLD (grades 1 - 3) was significantly higher in HV (38/112, 33.9 %) 
and GR (111/230, 48.3 %) compared to BC (18/102, 17.6 %, P = 0.007 and P < 0.001 
respectively), and higher in GR (111/230, 48.3 %) compared to HV (38/112, 33.9 %, P 
= 0.011).  Age distribution among the three breeds was not significantly different (P = 
0.494, Table 3.5). Distribution of male and female dogs among the three breeds was 
significantly different (P = 0.042). The proportion of males and females was 
significantly different between BC and HV dogs: the proportion of males was higher in 
BC (49/102, 48 %) compared to HV (35/112, 31 %; P = 0.012). The proportion of males 
and females was not significantly between BC and GR dogs (P = 0.196), or HV and GR 
dogs (P = 0.100). 
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Table 3.5. Comparison of distribution of mean age and sex in BC, HV and GR. 
 Discussion 3.1.3
3.1.3.1 Prevalence 
These studies provide current prevalence data for PLD in United Kingdom populations 
of BH, FCR, DDT, WSS, BC, HV and GR. Under the BVA/KC/ISDS Eye Scheme, and 
at the time these studies were performed, dogs were considered to be ‘affected’ if 20 % 
or more of the entire ICA circumference was affected by PLD
35
. Thus, those dogs 
classified as ordinal grades 2 or 3 (‘moderately’ or ‘severely’ affected, respectively) 
would be classified as ‘affected’ under the Eye Scheme (Table 2.1). Previous PLD 
prevalence data for six of the breeds are lacking, but Read et al. reported 34.7 % FCR to 
be moderately or severely affected by PLD
31
. This is much higher than the 21.2 % 
reported here; the most likely explanation for the reduction in prevalence of PLD in this 
breed is increased awareness of the anomaly amongst FCR breeders since the initial 
report and subsequent increased uptake in gonioscopic screening of dogs before 
breeding with exclusion of affected individuals from the breeding population. Another 
possible explanation for the different prevalence rates is a possible difference in age 
between the two groups. PLD has been shown to be progressive in this breed and Wood 
Variable Breed 
BC HV GR P-value 
Age at examination 
  Median ± SD (months) 
 
43.7 ± 46.4 
 
44.5 ± 37.7 
 
41.4 ± 38.6 
 
0.494 
Sex 
  Male 
  Female 
 
49 (48 %) 
53 (52 %) 
 
35 (31.3%) 
77 (68.8%) 
 
93 (40.4 %) 
137 (59.6 %) 
 
0.042 
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et al. also found a significant positive association between PLD and age
32,35
. This seems 
an unlikely explanation, however, as, although Wood et al. did not report mean age of 
the population they investigated, 77.6 % of the dogs studied were < 60 months when 
examined whereas the mean age of the population reported here was 58.7 months.   
PLD was particularly prevalent in the BH and WSS with 38.4 % and 36.2 % affected by 
moderate or severe PLD respectively. This is most likely due to a higher frequency of 
the genetic factor(s) responsible for PLD in these breeds, which could in turn be a result 
of the use of popular sires that carry these factors and/or a reduced uptake of 
gonioscopic screening within these breeds. PLD prevalence in the DDT, FCR, GR was 
similar to that previously reported in the English Springer Spaniel (25.5 %) and FCR 
(34.7 %) and is much higher than the 6 % prevalence reported by Read et al. in a control 
sample of 100 dogs of other breeds
29,31
. PLD prevalence in the BC (17.6 %) was 
significantly lower than in the other breeds studied potentially owing to a reduced 
frequency of the genetic risk factors for PLD in this breed in the United Kingdom. 
PLD prevalence was 26.1 % in GR in these studies. A previous study reported a much 
higher PLD prevalence in GR in Switzerland with 56.5 % dogs affected; these dogs 
would have to be excluded from a breeding program according to the guidelines of the 
ECVO
193
. Although PLD prevalence may be genuinely higher in Swiss than in United 
Kingdom GR, it is important to note, however, that the ECVO scheme differs from the 
BVA/KC/ISDS Eye Scheme and so direct comparison of the results of the two studies is 
not possible. At the time the Swiss study was performed, and under the ECVO scheme, 
an eye with any degree of pectinate ligament ‘sheeting’ (also known as laminae) would 
be classed as affected rather than only eyes with ≥ 20 % which might, in part, explain 
the greater apparent PLD prevalence in Swiss GR. 
Before publication of the aforementioned studies, four of the breeds investigated (DDT, 
BC, HV and GR) were ‘under investigation’ for PLD by the BVA/KC/ISDS Eye 
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Scheme. The results of these studies have been informative to the Eye Scheme and the 
DDT is now listed as breed which should be certified for PLD status before breeding. 
These studies support the BC and HV to continue to be ‘under investigation’ but that the 
GR should also be certified for PLD under the Eye Scheme. Any decision to make PLD 
certifiable should be as evidence-based as possible and should be guided by knowledge 
of PLD prevalence in the wider canine population. In their study in FCR, Wood et al. 
(1998) estimated the degree of PLD in 100 dogs of 30 different breeds as a control 
samples. In this study, 11 % of dogs were classified as ‘affected’ and this figure may 
serve as a useful bench mark in making such decisions. 
3.1.3.2 Associations between PLD and sex and IOP 
There was no association between IOP and degree of PLD in the absence of glaucoma 
in the WSS which is in line with previous studies in other breeds
29,32
. These findings are 
in consensus with the general clinical observation that dogs with severe PLD appear to 
maintain normal IOP until the acute onset of PCAG, rather than demonstrating a 
progressive increase in IOP. However, dynamic changes in IOP over an extended period 
in dogs with and without PLD have not been investigated to date and are required to 
fully demonstrate a lack of association between IOP and PLD. There was also no 
association between IOP and sex which was unsurprising and in line with previous 
studies in other breeds
29,32
. 
This study showed that female BH were more likely to have PLD than male BH, but the 
same was not true of any of the other six breeds. A sex predisposition for 
goniodysgenesis/PLD has previously been reported in the American Cocker Spaniel, but 
not in the English Springer Spaniel, FCR or Samoyed
29,31,47,61
.  This suggests that 
genetic risk factors for PLD might well vary between breeds. In humans, females are 
affected by PACG more frequently than males
54-56
. This is likely due to differences in 
anterior chamber morphology between the sexes. A shallow anterior chamber is the 
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major risk factor for development of PACG in humans, and women have shallower 
anterior chambers than men
58,147,148
. The effect of sex on PCAG in dogs seems to vary 
with breed. A sex predisposition has been reported in American Cocker Spaniels, 
Cocker Spaniels, BH, WSS and Samoyeds
53,60
. Currently, there is no clear explanation 
for a predisposition to PCAG in female dogs which is consistent between breeds. In 
Beagles, a breed not typically considered to be affected by PCAG, females have been 
shown to have differences in anterior chamber morphology compared to males
63
. The 
ICA width was significantly smaller for female dogs than male dogs
63
. However, in the 
Samoyed and English Springer Spaniel, breeds known to be affected by PCAG, there 
was no difference in ICA width between female and male dogs
29,49
. A previous study 
reported female WSS to be affected by PCAG more frequently than males at a ratio of 
2.4:1
60
. If such a sex predisposition were true, then it would have been a reasonable 
expectation to have found a similar female predisposition to PLD in WSS in these 
studies, as PLD is known to be significantly associated with PCAG, but this was not the 
case. Alternatively, it is possible that additional risk factors that contribute to PCAG 
risk (but not to PLD) are more frequent in females than males. 
3.1.3.3 Associations between IOP and sex and age 
Possible associations between IOP and PLD, age and sex in the three breeds (BH, FCR 
and DDT) included in this study were also investigated. IOP is known to be influenced 
by a number of factors in dogs, including diurnal variations and age. To reduce the 
possible influence of diurnal variations in these studies, all tonometric measurements 
were performed between the hours of 10:00 and 16:00 GMT. An association of IOP 
with age has already been reported in the Samoyed where a significantly higher IOP 
was demonstrated in dogs less than 1 year old compared to older dogs and, in animals 
seven years or older, there was a pronounced decrease in IOP
49
. These studies failed to 
show any association between IOP and age in the BH or FCR. However, the DDT was 
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similar to the Samoyed in that a moderately strong negative correlation was observed 
between IOP and age (i.e. higher IOPs were observed in younger dogs). The reason for 
this finding is unknown although, in other species, has been proposed as physiological 
being correlated with ocular growth
194
. In humans, IOP has been shown to decrease 
with age in Japanese but an increasing IOP with age has been shown in Europeans and 
Americans with both genetic and environmental factors (e.g. blood pressure, 
cardiovascular disease and obesity) likely being influential
195-197
. 
Previous studies have shown no association between IOP and the degree of PLD in the 
FCR and English Springer Spaniel
29,32
. The studies described in this thesis demonstrated 
a similar lack of association in the FCR and BH. However, a significant association was 
found between IOP and degree of PLD in the DDT. The median IOP, counterintuitively, 
decreased gradually with increasing degree of PLD (i.e., grades 0, 1, 2, 3). Explanations 
for the different associations between breeds may lie in differences in the anatomy of 
the ICA between the different breeds which, in turn, may be influenced by genetic 
variations.  
3.1.3.4 Evidence of PLD progression 
A significant positive linear relationship was observed between PLD and age in all 
breeds studied apart from the BC. Age-related narrowing of the ICA has been a 
generally accepted phenomenon for some time, but only recently has PLD been 
formally recognised as progressive when Pearl et al. reported that 39 of 96 (40.6 %) 
FCR demonstrated PLD progression over time
29,35,49
. An association with age would not 
be expected for a congenital, non-progressive disorder, and thus the studies reported 
here both support the previous finding in the FCR and provide cross-sectional evidence 
of a similar progressive nature of PLD in other breeds. The reason for the lack of an 
association between PLD and age in the BC is unknown. It may be because either PLD 
is not progressive in this breed or, alternatively and more likely, the sample size was too 
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small to detect a correlation in this breed, which appears to have a relatively low PLD 
prevalence in the United Kingdom. 
In these studies, not only was cross-sectional evidence of an association between PLD 
and age demonstrated but it was also possible to demonstrate longitudinal evidence of 
PLD progression in individual WSS over time. Sixty-five WSS were previously 
examined under the BVA/KC/ISDS Eye Scheme by a single examiner and found to be 
unaffected for PLD (grade 0) and were subsequently available for reexamination. Of 
these, 35 (53.8 %) demonstrated PLD progression with 38.4 % becoming moderately or 
severely affected. This is similar to the 40.6 % progression rate reported in the FCR. In 
the FCR, multiple examiners were involved and inter-examiner agreement was not 
addressed. In contrast, in the study reported here only two examiners were involved and 
the second examination was performed by a different examiner thereby effectively 
masking the results of the previous examination. Other explanations for the apparent 
progression of PLD in WSS are possible. These include grader differences, as the first 
examiner was shown in a subsequent study to grade from leniently then the second 
examiner (section 3.2.3), and also the possibility of grader drift. 
As  PLD was originally thought to be a congenital abnormality
60
, it was previously 
thought that eradication of PLD, and thus PCAG, would be relatively straightforward, 
by gonioscopic examination of dogs before breeding and the subsequent elimination of 
affected individuals from the breeding population. The continued high prevalence of 
PLD in the majority of the breeds studied here suggests that this strategy has not been 
entirely effective. This is likely, in part at least, due to the progressive nature of PLD 
which goes unnoticed in those dogs only examined once in early life. Increasing the 
frequency of gonioscopic examinations of individual dogs during and beyond their 
breeding lives should increase the rate of identification of affected dogs and their 
offspring. Additionally, further reduction in the prevalence of PLD may be made 
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possible by the identification of genetic factors responsible for the diseases, and the 
subsequent development of DNA tests which breeders can utilize as a tool for selective 
breeding. However, identification of such factors is likely to be challenging because 
both PLD and PCAG are thought to be multigenic traits
78
. Furthermore, complete 
eradication of PCAG is unlikely to be possible by these means alone as risk factors 
other than PLD, such as progressive narrowing of the ICA and deeper, unidentified 
abnormalities within the ICA, may continue to exist. PLD itself may be an imperfect 
biomarker of abnormalities within the trabecular meshwork which cannot be assessed 
by standard gonioscopy. Further characterisation of these deeper outflow pathways by 
high resolution ultrasonography and ultrasound biomicroscopy is required in both 
normal dogs and those which go on to develop PCAG. It is likely that such examination 
techniques will prove more sensitive indicators of an individual dog’s risk of developing 
PCAG than gonioscopy. 
 Conclusion 3.1.4
These studies provide current prevalence data for PLD in seven breeds in which 
PLD/PCAG is known or is suspected to have an inherited aetiology. Cross-sectional 
and/or longitudinal evidence of PLD progression in six of these breeds is provided, 
which may account for the continued high prevalence of the condition despite routine 
gonioscopic testing before breeding. There were no consistent associations between 
PLD and IOP or PLD and sex in the breeds studied. 
 Gonioscopy in the dog: inter-examiner variability and the search for a 3.2
grading scheme 
 Introduction 3.2.1
When performing gonioscopy as part of the BVA/KC/ISDS Eye Scheme, the examiner 
is required to estimate the proportion (or percentage) of PLD that affects the entire 
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circumference of the ICA. Anecdotally, this estimation of the percentage of PLD is 
considered to be susceptible to subjectivity. This anecdotal suspicion has led to the 
application of ‘gonioscopy grading schemes’ in research as an attempt to reduce the 
influence of subjectivity on examination findings
31,35,47,48
.  In this study, level of inter-
examiner agreement when applying gonioscopy findings to two recently published 
gonioscopy grading schemes and simplifications of these schemes was performed
35,48
. 
This study was performed opportunistically and after the performance of the 
aforementioned studies in this chapter. 
The objectives of this study were to i) assess inter-examiner variability in estimating the 
percentage of PLD in canine eyes and ii) assess what level of inter-examiner agreement 
could be achieved by applying four different gonioscopy grading schemes to the 
assigned percentage scores. This study has since been published
198
. 
Table 3.6. Details and results of the four gonioscopy grading schemes tested in the 
study. 
Scheme 2 is a simplification of published scheme 1, and Scheme 4 is a simplification of 
published Scheme 3
35,48
. 
Ordinal grade Scheme 1
35
 Scheme 2 Scheme 3
48
 Scheme 4 
Percentage of ICA affected by PLD 
 
0 
1 
2 
3 
 
0 % 
5 – 15 % 
20 – 90 % 
˃ 90 %  
 
< 20 % 
20 – 90 % 
˃ 90 % 
N/A 
 
< 25 % 
25 – 50 % 
55 – 75 % 
˃ 75 % 
 
< 25 % 
25 – 75 % 
˃ 75 % 
N/A 
  
 Results 3.2.2
3.2.2.1 Scoring of percentage of PLD 
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The mean percentage (± SE) of PLD to affect an individual eye was 12.1 % (± 2.4) for 
Examiner 1 (James Oliver) and 8.7 % (± 1.7) for Examiner 2 (Beverley Cottrell). The 
percentage range of PLD was 0 – 95 for Examiner 1 and 0 – 80 for Examiner 2. The 
median and mode percentage of PLD was 0 % for both examiners and both data sets 
exhibited positive kurtosis and skewness (data not shown) reflecting the majority of 
ICAs that were judged to be entirely normal (0 % PLD) by both examiners. Kernel 
density plots for both examiners were visually assessed and showed similar skewed 
distributions (Figure 3.2). A scatterplot representing the relationship of the PLD scores 
assigned by the two examiners is shown in Figure 3.3. The Pearson’s product-moment 
correlation coefficient (R) was 0.91 indicating a strong positive relationship between the 
results of the two examiners.  
There was evidence for statistically significant non-random differences in percentage 
scores for PLD assigned to individual eyes between the two examiners. Examiner 1 
scored 34/98 eyes (34.7 %) higher than Examiner 2 when all eyes were included (P = 
0.05). This difference was most marked in the subset of eyes in which both examiners 
considered PLD to be present; Examiner 1 scored 22/30 eye (73.3 %) higher than 
Examiner 2 (P  =  0.0005) (Figure 3.4 and Figure 3.4). These data were also examined 
using a Bland-Altman plot (Figure 3.5). The plot highlights that the majority of the data 
represent low PLD percentage scores and, for these, inter-examiner agreement was 
strongest. The eight data points above the upper line represent the outliers for which 
inter-examiner agreement was lowest and further illustrates the systematic non-random 
bias with most data points appearing above the red line as the mean of the scores 
increases. 
Chapter 3 Prevalence of pectinate ligament dysplasia 
108 
 
 
Figure 3.2. Kernel density plots of percentage of PLD assigned to eyes for the two 
examiners. 
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Figure 3.3. Bubble scatterplot and linear regression of the relationship between 
percentage scores of PLD for individual eyes assigned by the two examiners. 
The Pearson’s product-moment correlation coefficient (R) was 0.91 indicating a strong 
positive relationship between the two sets of results. NB Not all 98 data points are seen 
owing to overlapping of many data points. Instead, proportionally sized bubbles are 
used to give indication of number of data points present. 
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Figure 3.4. Paired data of PLD scores for Examiners 1 and 2 in WSS.  
In general, Examiner 1 tended to score a higher percentage PLD than Examiner 2. Not 
all paired data points owing to overlapping, particularly at low PLD percentages. 
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Figure 3.5. Bland-Altman plot of paired data for Examiners 1 and 2.  
The averages of PLD percentages of Examiners 1 and 2 are on the X axis and the 
differences between PLD percentages between Examiners 1 and 2 are on the Y axis. 
The lines corresponding to the mean of the difference between scores (red line, +3.4) 
and 95% limits of agreement at ±1.96xSD (blue lines, +24.6 and -17.8) are marked to 
allow simple assessment of outlying observations. NB Not all 98 data points are seen 
owing to overlapping of many data points. 
3.2.2.2 Ordinal grade assignment 
A summary of the ordinal grade scores assigned by the two Examiners for all four 
schemes is provided in Table 3.7. Inter-examiner agreement of ordinal scores was first 
quantified for level of agreement beyond that expected by chance alone using kappa 
statistic for each of the schemes: 
Scheme 1: There were 60 (61.2 %) observed agreements and 38 (38.8 %) observed 
disagreements. The kappa statistic (± SE) was 0.35 (± 0.08) and the level agreement 
was considered ‘fair’. This scheme (which was used in the previously performed PLD 
prevalence studies) in its current form was therefore considered unacceptable. This 
somewhat disappointing level of agreement might be explained by the narrow 
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boundaries between grades 0 and 1 in this scheme and the subsequent inability for 
examiners to differentiate between such small percentage differences. To further assess 
this hypothesis, inter-examiner agreement within grades 0 and 1 in Scheme 1 was also 
analysed separately with eyes being graded as 2 or 3 by either or both examiners being 
excluded from the analysis. The two examiners both categorised 79 of the 98 eyes as 
either grades 0 or 1, which represented 49 (62.8 %) observed agreements and 30 (27.2 
%) observed disagreements. The resulting kappa statistic (± SE) of 0.12 (± 0.12), 
representing a ‘poor’ level of agreement above that expected by chance alone, provided 
evidence for this hypothesis. 
Scheme 2 (a simplification of Scheme 1): There were 89 (90.8 %) observed 
agreements and 9 (9.2 %) disagreements. The kappa statistic (± SE) was 0.68 (± 0.09) 
and the level agreement was again considered ‘good’. This scheme was considered 
acceptable.  
When this study was conducted, the BVA/KC/ISDS Eye Scheme considered dogs to be 
unaffected’ if both eyes exhibit < 20 % PLD and ‘affected’ if either or both eyes exhibit 
≥ 20% PLD. This, in essence, represents a further simplification of Scheme 2 in which 
grades 1 and 2 are merged. Application of this simple ‘two-tier’ grading scheme to the 
same data presented in the current study was subsequently performed and resulted in a 
kappa statistic of 0.83 (95 % CI = 0.61 to 0.99) which can be considered a ‘very good’ 
level of agreement beyond that which would be expected to occur by chance. 
Scheme 3: There were 87 (88.78 %) inter-examiner agreements and 11 (11.22 %) 
disagreements. The kappa statistic (± SE) was 0.50 (± 0.09) and the level agreement 
was considered ‘moderate’. Although the level of agreement was higher, this scheme in 
its current form was also considered unacceptable.  
Scheme 4 (a simplification of Scheme 3): There were 88 (89.8 %) observed 
agreements and 10 (10.2 %) disagreements. The kappa statistic (± SE) was 0.54 (± 0.09) 
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and the level agreement was again considered ‘moderate’. This scheme was considered 
unacceptable.  
Table 3.7. Ordinal grades assigned by each examiner for each of four grading 
schemes.  
 Scheme 1 Scheme 2 Scheme 3 Scheme 4 
Examiner 1 2 ☺ 1 2 ☺ 1 2 ☺ 1 2 ☺ 
O
rd
in
a
l 
G
ra
d
e 
0 56 53 40 79 84 78 85 87 84 85 87 84 
1 23 31 9 17 14 11 5 6 3 8 10 4 
2 17 14 11 2 0 0 3 4 0 5 1 0 
3 2 0 0 NA NA NA 5 1 0 NA NA NA 
κ value 
Agreement  
0.35 
Fair 
0.68 
Good 
0.50 
Moderate 
0.54 
Moderate 
☺ columns denote number of eyes where examiners were in agreement on ordinal grade provided. NA = not applicable. κ = kappa 
statistic. 
 Discussion 3.2.3
In this prospective study, the results of how two different ophthalmologists evaluated 
the same ICAs of 98 different canine eyes for degree of PLD were compared. The 
results for each examiner appeared similar on examination of descriptive statistics and 
kernel density plots. Furthermore, a strong positive relationship between the two 
examiners was found on a scatterplot with simple linear regression. These results were 
encouraging and showed that as one examiner scored an ICA with a higher percentage 
of PLD, so did the other. Although there was strong association between results, 
however, it did not necessarily follow that each examiner assigned similar percentage 
PLD scores to each ICA. The analysis of inter-observer agreement was meaningful 
since the percentage scoring of PLD is considered to be subjective and has led to the 
proposal of several different grading systems with the goal to reach improved 
consistency
31,35,47,48
. When paired results were analysed overall, a statistically 
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significant non-random difference was found between percentage scores assigned by the 
two examiners, and which was markedly different when restricted to eyes in which both 
examiners considered PLD was present. Thus, for the first time, evidence for inter-
examiner subjectivity when performing gonioscopy has been provided. Examiner 1 
consistently scored higher than Examiner 2, which is to be expected as inter-scorer 
difference is common when measurement involves subjective judgment of a 
characteristic. Scores are affected by bias with a tendency of scores to drift towards 
what is expected by the examiner. The tendency for Examiner 2 to be more ‘lenient’ 
may also explain why 100 % of the 65 dogs previously examined by Examiner 2 were 
graded 0. 
It is important to note, however, that this does not detract from the importance of 
performing gonioscopy as a means of detecting dogs with PLD per se. Before this study 
was published, the BVA/KC/ISDS Eye Scheme operated a simple ‘two-tier’ gonioscopy 
grading scheme. When the data derived from the current study were applied to this 
situation, a ‘very good’ level of agreement was attained45. 
More sophisticated grading of PLD than a simple ‘two-tier’ scheme is desirable for 
several reasons. Firstly, it would allow a more detailed level of monitoring of PLD 
progression in individual dogs over time than is currently afforded by the current 
‘affected’ vs ‘unaffected’ categorisation. This is important because, although PLD was 
originally thought to be a near congenital anomaly, there is now evidence of PLD 
progression over time in several breeds
35,45,46,48
. PLD grading could help veterinary 
ophthalmologists identify those dogs more likely to be at risk of PCAG as well as 
contribute to the understanding of the pathogenesis of the disease. It should be noted, 
however, that only dogs with severe PLD are considered to be at risk of PCAG and 
indeed the majority of dogs with PLD will not develop glaucoma. Secondly, a multi-
tiered grading scheme may help breeders to make informed decisions on appropriate 
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matings. This would be particularly pertinent to those breeds which are numerically 
small and have a high prevalence of PLD. In these breeds, it would be undesirable to 
eliminate all dogs with PLD as this would restrict the gene pool which may, in turn, lead 
to the selection of other undesirable inherited characteristics. However, although there is 
sufficient evidence that PLD is inherited, the precise mode of inheritance is unknown 
and no causative mutations for PLD have yet been identified
78
.   
In this study, inter-examiner agreement in PLD estimation was assessed using two 
recently published gonioscopy grading schemes along with simplifications of these 
scheme
35,48
. These published schemes were chosen because they were composed of four 
relatively broad grades and it was considered that two different examiners would be 
more likely to categorise eyes similarly than schemes with larger numbers of narrow 
grades. In Scheme 1, the boundaries between the different grades were unequally 
divided (Table 3.6). The proposed benefit of this scheme is that it allows the 
identification of PLD at both ends of the spectrum i.e. those eyes which had absolutely 
no evidence of PLD and those with > 90 % PLD and being considered at risk of 
PCAG
31,35. When Scheme 1 was applied to the percentage scores, however, only a ‘fair’ 
level of agreement was found between the two examiners. This study of inter-examiner 
agreement was performed following the studies of PLD prevalence which had employed 
Scheme 1 (the most recently published scheme at the time). In hindsight, it could be 
argued that because this Scheme showed the lowest level of inter-examiner agreement it 
was a suboptimal choice for the previous studies. Having, said this, the inclusion of a 
single examiner in these studies, should have reduced the influence of subjectivity and, 
at the very least, allowed for relative PLD grading.  
When grades 0 and 1 were merged, however, giving rise to the three-tiered Scheme 2 
agreement improved to ‘good’ which led us to conclude that this scheme provided an 
acceptable level of agreement between the two examiners. The large intermediate 
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bandwidth of this scheme, however, would only allow detection of dogs with very 
marked progression of PLD to involve > 90 % of the circumference of the ICA. 
Although the relationship between the degree of PLD and incidence of glaucoma is not 
precisely understood, the identification of dogs with PLD affecting > 90 % of the ICA is 
likely to be clinically important. In a previous study, dogs with PLD affecting an 
estimated 87.5 % of the ICA had a 60 % probability of developing glaucoma and those 
dogs with 100 % PLD all developed glaucoma
32
. 
At face value, Scheme 3 appeared the most desirable of the schemes because the grades 
were divided into four equally sized categories. If inter-examiner agreement could be 
shown to be good, then this scheme should better allow for detection of gradual 
progression of PLD in individual dogs over time and also be a useful tool for breeders in 
mating selection in particular for those breeds in which PLD is most prevalent. 
Unfortunately, however, only a ‘moderate’ level of agreement was achieved with this 
Scheme. Furthermore, and rather surprisingly, the level of agreement beyond chance 
only marginally improved and remained at ‘moderate’ when this scheme was simplified 
in Scheme 4 which had a much broader intermediate grade than the original scheme. 
These findings suggested that the two examiners were in agreement when scoring eyes 
at the unaffected end of spectrum but had difficulty in agreeing on eyes which were 
considered to be more severely affected by PLD.  
In this study, the two examiners were not asked to assess ICA width by gonioscopy as 
this was considered too subjective, as has been suggested by authors of previous 
gonioscopy studies
31,35,45,46
. Read et al. (1998) considered ICA width to be too variable 
between normal dogs, between eyes of individual dogs and even within the same eye 
and Fricker et al. (2015) commented that position of the goniolens and angle of 
photographic image capture to be important sources of variability
31,170
. Some authors, 
however, have included ICA width in their studies
29,30
. Although correlations have been 
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shown between ICA width and PLD and glaucoma
29,30
, inter-examiner variability in 
assessing ICA width and the validity of width grading schemes have not yet been 
assessed. Estimation of ICA width remains an important evaluation, however, and with 
increasing research into and availability of high resolution imaging, validated and 
objective methods of measuring ICA width will likely become available in the future. 
There are, of course, some study limitations which must be discussed. Firstly, the 98 
eyes examined in this study were not truly independent with two eyes being derived 
from each dog. PLD is known to have high heritability and clinical experience is that 
left and right eyes are similarly affected by degree of PLD
32
. It is therefore possible that, 
although each examiner was blinded to the results of the other examiner and to those of 
any previous examinations, he or she may have been influenced by his or her own 
examination findings of the first eye when examining the second. Both examiners, 
however, examined the eyes of each dog consistently and examination of both eyes was 
thus equally subject to such bias and, for the practical purposes of this study, this was 
considered an acceptable limitation. Secondly, it is possible that the differences and 
agreements found between the two examiners in this study might not be representative 
of the general panel membership of the BVA/KC/ISDS Eye Scheme. The two 
examiners involved in this study are, however, both active panellists of the Eye Scheme 
being both experienced in performing gonioscopy in the WSS and having published on 
the technique in this breed and, as such, were considered suitable examiners for the 
purpose of the study
45,60
. It would be interesting, however, to perform a similar study 
involving multiple, and perhaps less experienced, examiners to assess if inter-examiner 
results become even more variable. 
 Conclusion 3.2.4
In conclusion, inter-examiner variability in gonioscopic evaluation of PLD in dogs for 
the first time was investigated. Although, there was a strong positive correlation 
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between the results of the two examiners, there was a statistically significant, non-
random difference in the results when the examiners were asked to estimate PLD to the 
nearest 5 %, with Examiner 1 tending to score higher than Examiner 2. The level of 
inter-examiner agreement beyond chance alone for four different gonioscopy grading 
schemes was also investigated. A good level of agreement could only be achieved with 
a scheme of no more than three categories and with a large intermediate bandwidth 
which would limit the ability to monitor PLD progression. Furthermore, the level of 
agreement for all assessed grading schemes fell short of the ‘very good’ level of 
agreement offered by the currently employed two-tiered scheme. Thus, it appears that 
increasing the complexity of any grading scheme will likely come at the expense of 
inter-examiner agreement.  
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4 Pectinate ligament dysplasia and primary closed angle glaucoma in 
four dog breeds: genetic investigations 
 Pectinate ligament dysplasia and primary closed angle glaucoma in the 4.1
Welsh Springer Spaniel: a candidate gene approach 
 Introduction 4.1.1
PCAG was first reported in the WSS in 1998, when 28 cases of PCAG were reported
60
.  
Females were affected more frequently than males (2.1:1) and the average age of onset 
was 2 years 9 months. PCAG was found to be familial and an autosomal dominant 
mode of inheritance was suggested. To date, no genes have been reported to be 
associated with PCAG or PLD in this breed. This study sought to investigate possible 
associations between 11 candidate genes and PCAG and PLD in the WSS. 
 Materials and methods 4.1.2
4.1.2.1 Sample collection and DNA extraction 
DNA samples from 77 WSS were used in this study. These samples derived from dogs 
examined in 3.1.2.2.1 as part of the PLD prevalence study as well as those collected 
from clinical cases of PCAG examined at the AHT and received from collaborators. 
DNA, collected either as buccal mucosal swabs or blood collected in EDTA, was 
extracted as outlined in 2.2.1. The 77 samples used consisted of 28 dogs with PCAG 
(PCAG cases), 31 dogs with moderate or severe PLD (PLD cases) and 20 dogs which 
were unaffected or mildly affected (controls). For the purposes of this study, only PLD 
cases with PLD affecting 50 % or more of the ICA were included. The control dogs 
were at least five years of age at the time of examination to allow for possible PLD 
progression and PLD affected < 10 % of the ICA of each eye. 
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4.1.2.2 Candidate gene selection 
Eleven candidate genes were selected based on previously published associations with 
primary glaucoma in humans and/or dog (Table 4.1). 
4.1.2.3 Microsatellite identification and primer design 
The chromosomal coordinates in the canine reference assembly (CanFam3.1) of each 
candidate gene, or its canine orthologue, were first established in Ensembl 
(http://www.ensembl.org)
185,186
. Following this, a pair of microsatellites (all 
dinucleotide repeats) flanking the gene was identified using the UCSC genome browser 
(https://genome.ucsc.edu/) and a pair of primers flanking the microsatellite was then 
designed, as described in 2.2.5
174,175
. PCR and sequencing reaction components, thermal 
cycling parameters and primer details can be found in Appendices II, III and IV.  
Alleles and allele frequencies were compared between PCAG cases and controls and 
PLD cases and controls and were assessed for association with disease using the Chi 
square test of independence. Statistical significance was set at P = 0.05/number of 
candidate gene microsatellites tested (0.05/22 = 0.002). 
4.1.2.4 Further investigation of ADAMTS17 
Amplification and sequencing of ADAMTS17 exons was performed in two PCAG cases, 
two PLD cases and four unaffected controls. These samples were chosen on the basis of 
microsatellite genotyping results. All PCAG and PLD cases were homozygous for the 
disease-associated alleles and three of the four controls were not (Table 4.3). The fourth 
control (25200) was homozygous for the disease-associated alleles. 
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Table 4.1. PCAG candidate genes: genes associated with primary glaucoma in 
humans and dogs. 
Candidate 
gene 
Canine 
orthologue 
(where 
different) 
Genomic coordinates of gene 
(CanFam3.1) 
Species Phenotype(s) Reference 
ADAMTS10  chr20:53,089,604-53,107,084 Dog POAG 68-70 
ADAMTS17  chr3:40,613,857-40,939,685 Dog POAG 75,107 
CHX10  chr8:47,455,430-47,473,918 Human PACG 199 
COL1A2  chr14:19,883,733-19,920,718 Dog PCAG 170 
CYP1B1  chr17:30,269,745-30,278,554 Human Congenital 
glaucoma 
200 
eNOS NOS3 chr16:15,053,167-15,072,277 Human PACG 164 
HGF  chr18:21,329,616-21,410,296 Human PACG 158 
MFRP C1QTNF5 chr5:14,528,039-14,562,907 Human PACG 158 
MMP-9  chr24:33,273,918-33,281,411 Human PACG & POAG 157,201-203 
RABB22A  chr4:43,108,891-43,157,949 Dog PCAG 170 
SRBD1  chr10:47,742,907-47,939,042 Human 
& dog 
PCAG (dog) 
POAG (human) 
94,204 
POAG = primary open angle glaucoma, PCAG = primary closed angle glaucoma and PACG = primary angle closure glaucoma 
 Results 4.1.3
4.1.3.1 Microsatellite genotyping 
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Sixteen out of 22 of the microsatellites genotyped were polymorphic in the cohort of 
WSS and therefore informative for allele allocation studies. The microsatellite upstream 
of ADAMTS17 was significantly associated with both PCAG and PLD and the 
microsatellite downstream of ADAMTS17 was significantly associated with PCAG 
(Table 4.2). No other microsatellites were associated with PCAG or PLD. Individual 
genotyping results are presented in Appendix V. 
Table 4.2. Microsatellite allele genotyping association results. 
Microsatellite Study cases Study controls df χ2 value P-value 
ADAMTS10_M1 PCAG cases Controls 7 7.01 0.4278394 
ADAMTS10_M1 PLD cases Controls 7 2.82 0.9011394 
ADAMTS17_M1 PCAG cases Controls 3 19.95 0.0001738* 
ADAMTS17_M1 PLD cases Controls 1 12.02 0.0005263* 
ADAMTS17_M2 PCAG cases Controls 2 12.63 0.001809* 
ADAMTS17_M2 PCAG cases Controls 2 9.10 0.0105672 
C1QTNF5_M1 PLD cases Controls 1 0.64 0.4237108 
C1QTNF5_M1 PCAG cases Controls 1 0.00 1 
C1QTNF5_M2 PLD cases Controls 1 0.06 0.806496 
C1QTNF5_M2 PCAG cases Controls 1 0.01 0.9203444 
CHX10_M1 PCAG cases Controls 3 3.05 0.3839802 
CHX10_M1 PLD cases Controls 3 3.83 0.2804159 
COL1A2_M2 PCAG cases Controls 4 1.86 0.7614887 
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Microsatellite Study cases Study controls df χ2 value P-value 
COL1A2_M2 PLD cases Controls 4 5.19 0.2683519 
CYP1B1_M1 PCAG cases Controls 2 0.08 0.9607894 
CYP1B1_M1 PCAG cases Controls 2 0.69 0.7082204 
HGF_M1 PLD cases Controls 3 2.71 0.4385306 
HGF_M1 PCAG cases Controls 3 3.98 0.2636319 
MMP_M1 PLD cases Controls 3 3.69 0.2969428 
MMP_M1 PCAG cases Controls 3 2.34 0.5049013 
MMP_M2 PCAG cases Controls 1 3.07 0.0797495 
MMP_M2 PLD cases Controls 1 0.05 0.8230633 
NOS3_M1 PCAG cases Controls 2 0.64 0.726149 
NOS3_M1 PLD cases Controls 2 2.49 0.2879409 
NOS3_M2 PCAG cases Controls 1 1.46 0.2269301 
NOS3_M2 PCAG cases Controls 1 6.28 0.0122108 
RAB22A_M2 PLD cases Controls 1 0.66 0.4165599 
RAB22A_M2 PCAG cases Controls 1 0.78 0.3771411 
SRBD1_M1 PLD cases Controls 2 6.50 0.0387742 
SRBD1_M1 PCAG cases Controls 2 2.95 0.2287787 
SRBD1_M2 PCAG cases Controls 2 0.75 0.6872893 
SRBD1_M2 PLD cases Controls 2 1.63 0.4426393 
*denotes statistical significance (P < 0.002) 
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4.1.3.2 Further investigation of ADAMTS17 
Owing to the strong association between ADAMTS17 flanking microsatellites and 
PCAG and PLD, this candidate gene was investigated more closely for candidate 
variants. Following ADAMTS17 exon resequencing in eight WSS samples, a total of 11 
SNPs were identified but none fully segregated with either of the disease statuses 
(PCAG or PLD) (Table 4.3). Partial segregation for some SNPs was observed but these 
SNPs were either synonymous or intronic variants. Intronic variants were assessed using 
the Variant Effect Predictor (Ensembl) and were considered unlikely to be pathogenic. 
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Table 4.3. Candidate SNP genotyping results. 
AHT 
No. 
Phenotype ADAMTS17 
microsatellite 
genotype 
SNP position on chromosome 3 (CanFam3.1) and genotype in each sample 
M1 M2 
4
0
6
1
5
0
5
5
 
4
0
7
4
8
3
2
8
 
4
0
7
4
8
3
3
0
 
4
0
7
4
8
3
7
7
 
4
0
8
0
8
2
4
2
 
4
0
8
3
0
9
4
8
 
4
0
8
3
1
2
0
1
 
4
0
8
3
1
3
8
0
 
4
0
8
5
8
5
3
7
 
4
0
8
5
8
7
0
4
 
4
0
8
5
8
9
4
3
 
17170 PCAG case 154/154 180/180 T/T T/T T/T T/T G/G G/G C/C G/G T/T C/C A/A 
25165 PCAG case 154/154 180/180 T/T T/T T/T T/T G/G G/G C/C G/G T/T C/C A/A 
25056 PLD case 154/154 180/180 T/T T/T T/T T/T G/G G/G C/C G/G T/T C/C A/A 
25211 PLD case 154/154 180/180 T/T T/T T/T T/T G/G G/G C/C G/G T/T C/C A/A 
25036 Control 150/150 171/171 T/C T/T T/T T/T G/G G/G C/C G/G C/T C/C A/A 
25075 Control 150/154 171/180 T/C T/T T/T T/T G/G A/G C/T A/G C/T C/T A/G 
25185 Control 150/154 172/182 C/C T/T T/T T/T G/G A/G C/T A/G C/C C/T A/G 
25200 Control 154/154 180/180 T/T T/T T/T T/T G/G G/G C/C G/G T/T C/C A/A 
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 Discussion 4.1.4
This study investigated possible associations between 11 candidate genes and PCAG 
and PLD in the WSS. A microsatellite-based candidate gene association approach was 
chosen in this study for a few reasons. Firstly, this approach made advantage of 
previously performed studies conducted in humans and, to a lesser extent, in dogs which 
had already identified plausible candidate genes. Secondly, this approach is relatively 
affordable for modest sized laboratories compared to relatively expensive GWAS. 
Thirdly, a previous report of PCAG in the WSS suggested an autosomal dominant mode 
of inheritance (although admittedly evidence for this was very limited)
60
. If PCAG in 
the WSS is indeed a single gene disease, then a candidate gene approach should have 
the power to detect significant associations with disease with the number of samples 
available in this study (provided the correct candidate gene was investigated). A 
disadvantage of a candidate gene approach is that it introduces significant bias as it is 
based on a priori knowledge of a gene’s function or association with disease. Thus, 
success of such an approach, relies on the presence of phenotypically similar diseases 
which share similarities at the molecular level
82
. PACG in humans has been very well 
characterised phenotypically but the same cannot be said for the closest canine 
phenotype, PCAG. In the WSS, PCAG is associated with PLD but characterisation of 
the deeper outflow pathways has not been performed. 
This study showed significant associations between PCAG and PLD and microsatellites 
flanking ADAMTS17. ADAMTS17 mutations have previously been reported to be 
associated with the canine ocular phenotypes POAG and PLL, as well as multiple ocular 
phenotypes in humans, suggesting the gene to be very important in microfibril function 
and maintenance
107,122,125
. Unfortunately, ADAMTS17 exon resequencing of PCAG 
cases, PLD cases and control dogs failed to reveal any variants which fully segregated 
with disease. This was not surprising, however, as both PCAG and PLD are now, and 
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contrary to the early suggestion of autosomal dominant inheritance,  considered to be 
complex diseases likely involving multiple genetic risk factors that are unlikely to 
segregate well. Furthermore, these diseases might results from intronic (including 
splice-site), intergenic and structural variants which were not investigated in this study. 
However, at this point it was decided not to pursue the candidate gene approach for 
PCAG and PLD in the WSS. Instead, a GWAS (which does not suffer from a priori 
bias) was undertaken with the aim of identifying PCAG and PLD susceptibility loci 
(section 4.2). 
 Conclusion 4.1.5
A microsatellite-based candidate gene linkage analysis study was performed to 
investigate associations between PCAG and PLD and 11 candidate genes which had 
previously been associated with primary glaucoma in the human and/or dog. Significant 
association was found for ADAMTS17, however, ADAMTS17 exon resequencing failed 
to reveal variants which fully segregated with disease. 
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 Pectinate ligament dysplasia and primary closed angle glaucoma in the 4.2
Basset Hound, Flatcoated Retriever, Dandie Dinmont Terrier and Welsh 
Springer Spaniel: genome-wide association and next-generation sequencing 
strategies 
 Introduction 4.2.1
GWAS have become popular in the investigation of inherited canine traits and, recently, 
attention has turned towards PCAG. In the BH, a GWAS of 37 PCAG cases and 41 
controls revealed significant associations at two novel loci which contain the candidate 
genes COL1A2 and RAB22A but no candidate variants were reported
170
. In a subsequent 
paper, the same group reported a non-synonymous variant in NEB to segregate with 
PCAG in BH (CanFam2 chr19:55885214 A>G)
171
. In the DDT, a GWAS has been 
performed in a cohort of 23 PCAG cases and 23 controls, revealing an association with 
a novel 9.5 Mb locus on canine chromosome 8
106
. To date, however, no variants 
causative of canine PCAG have been reported. Here, a combination of GWAS and NGS 
was used to investigate the genetic mechanisms underlying PCAG and PLD in four 
breeds: BH, FCR, DDT and WSS. Results of the BH studies have been published
205
. 
 Results 4.2.2
GWAS were first conducted for each individual breed using five case-control set 
definitions (2.2.9). Table 4.4 summarises the results of the filtering steps undertaken for 
quality control of data and correction of population stratification using GEMMA for the 
four individual breeds. MDS and Q-Q plots were performed for each analysis and can 
be found in Appendix VI and haplotype and haplotype permutation analysis plots can 
be found in Appendix VII. The analytical descriptions and analysis plots below are all 
following analysis with GEMMA.
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Table 4.4. Summary of number of samples, results of application of quality control filtering steps and correction of population stratification 
for the individual breed GWAS performed.  
Breed Phenotype of 
cases 
Phenotype of 
controls 
No. cases No. controls SNPs with MAF 
<0.05 
SNPs with 
<0.97 call rate 
SNPs remaining 
for analysis 
λ before 
correction 
λ after 
correction 
BH PCAG Controls 24 37 71,687 11,749 96,259 1.96 1.04 
 PCAG + PLD Controls 81 37 71,633 10,166 97,282 1.34 1.00 
 PLD Controls 57 37 73,253 11,935 94,781 1.28 1.01 
 PCAG PLD 24 57 72,150 9,858 96,868 2.23 1.01 
 PCAG Controls + PLD 24 94 71,633 10,166 97,282 2.25 0.96 
FCR PCAG Controls 19 89 78,384 6,519 92,489 1.12 1.06 
 PCAG + PLD Controls 78 89 78,333 5,664 92,970 1.21 1.03 
 PLD Controls 59 89 78,243 5,806 92,995 1.14 1.05 
 PCAG PLD 19 59 78,507 5,362 93,002 0.93 0.90 
 PCAG Controls + PLD 19 148 78,333 5,664 92,970 1.07 1.02 
DDT PCAG Controls 32 51 85,752 5,300 85,854 1.70 1.01 
 PCAG + PLD Controls 53 51 85,824 5,013 85,945 1.70 1.04 
 PLD Controls 21 51 86,766 5,688 84,718 1.24 1.06 
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Breed Phenotype of 
cases 
Phenotype of 
controls 
No. cases No. controls SNPs with MAF 
<0.05 
SNPs with 
<0.97 call rate 
SNPs remaining 
for analysis 
λ before 
correction 
λ after 
correction 
 PCAG PLD 32 21 86,580 5,502 84,950 1.26 1.06 
 PCAG Controls + PLD 32 72 85,824 5,502 84,950 1.66 1.01 
WSS PCAG Controls 36 33 74,860 4,363 97,176 2.06 1.04 
 PCAG + PLD Controls 90 33 76,116 4,480 95,830 1.72 1.03 
 PLD Controls 54 33 76,330 4,622 95,582 1.54 0.99 
 PCAG PLD 36 54 75,018 4,295 97,028 1.86 1.04 
 PCAG  Controls + PLD 36 87 76,116 4,363 97,176 2.00 1.02 
No. = number, λ = lambda (genomic inflation factor) 
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4.2.2.1 BH 
In this breed, the NEB variant reported by Ahram et al.
171
 was first genotyped in a 
cohort of 158 BH by Sanger sequencing (10 PCAG cases, 52 PLD cases and 96 
controls). One hundred and fifty-seven BH (10 PCAG cases, 52 PLD cases and 95 
controls) were homozygous for the variant (G/G) and only one control was 
heterozygous (A/G). Eighty-three non-BH dogs were also genotyped for the variant. 
Fifty-nine of these were homozygous for the variant (G/G), 15 were heterozygous (A/G) 
and only 9 were homozygous for the reference allele (A/A). Thus, it appeared that the 
SNP at this location is a common polymorphism and may actually be more common in 
dogs than the reference allele. 
For the GWAS, data derived from 153 dogs, comprising 59 PCAG cases, 57 PLD cases 
and 37 controls, were available for analysis. Thirty-five of the PCAG cases were 
derived from dogs bred in the USA, all other samples were from European bred dogs. 
An MDS plot of USA and European dogs revealed a heterogeneous distribution with 
USA dogs clustering separately (Figure 4.1). USA dogs were therefore excluded from 
the initial GWAS but were used to follow-up signals of interest and any identified 
candidate variants. Thus, GWAS were performed using 118 dogs, comprising 24 PCAG 
cases, 57 PLD cases and 37 controls. 
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Figure 4.1. MDS plot of European and USA BH. 
 PCAG cases and controls 4.2.2.1.1
After filtering, 24 PCAG cases and 37 controls and 96,259 SNPs remained for analysis. 
No SNPs reached the threshold suggestive of genome-wide significance (Figure 4.2). 
 
Figure 4.2. Manhattan plot demonstrating association of SNP markers with PCAG 
in BH. 
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 PCAG and PLD cases and controls 4.2.2.1.2
After filtering, 81 PCAG and PLD cases and 37 controls and 97,282 SNPs remained for 
analysis. No SNPs reached the threshold suggestive of genome-wide significance 
(Figure 4.3). 
 
Figure 4.3. Manhattan plot demonstrating association of SNP markers with PCAG 
and PLD cases in BH. 
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 PLD cases and controls 4.2.2.1.3
After filtering, 57 PLD cases and 37 controls and 94,781 SNPs remained for analysis. 
No SNPs reached the threshold suggestive of genome-wide significance (Figure 4.4). 
 
Figure 4.4.  Manhattan plot demonstrating association of SNP markers with PLD 
in BH. 
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  PCAG cases and PLD cases 4.2.2.1.4
For this analysis, 24 PCAG cases and 57 PLD cases and 96,868 SNPs remained after 
filtering. One SNP (BICF2G630505097; CanFam3.1 chr24:17381226; -log10P = 6.42) 
reached the threshold suggestive of genome-wide significance (Figure 4.5). 
 
Figure 4.5. Manhattan plot demonstrating association of SNP markers with PCAG 
relative to PLD in BH. 
 PCAG cases and PLD cases and controls 4.2.2.1.5
After filtering, 24 PCAG cases and 94 PLD cases and controls and 97,282 SNPs 
remained. One SNP reached a stronger level of genome-wide statistical association in 
this analysis than in 4.2.2.1.4 (BICF2P544799; CanFam3.1 chr24:18739902; -log10P = 
6.84) (Figure 4.6). Conditional analysis was used to assess whether additional loci were 
associated with PCAG in this breed. To achieve this, the top SNP was introduced as a 
covariate in the mixed model which revealed an additional SNP at a distinct 
chromosomal location that reached genome-wide significance (BICF2P928441; 
CanFam3.1 chr37: 24747131; -log10P = 6.73) (Figure 4.7). Conditional analysis using 
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both associated SNPs as covariates in the model revealed no further SNPs to reach 
genome-wide significance (Figure 4.8). 
 
Figure 4.6. Manhattan plot demonstrating association of SNP markers with PCAG 
cases relative to PLD cases and controls in BH. 
 
Figure 4.7. Manhattan plot demonstrating association of SNP markers with PCAG 
relative to PLD cases and controls in BH using BICF2P544799 as a covariate. 
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Figure 4.8 Manhattan plot demonstrating association of SNP markers with PCAG 
relative to PLD cases and controls in BH using BICF2P544799 and BICF2P928441 
as covariates. 
The strength of association of these three SNPs with PCAG was further assessed in the 
individual SNP dataset using logistic regression with assistance from Dr Sally Ricketts. 
This was done for both the original GWAS cohort and also with the addition of the 
USA PCAG samples. All three SNPs were strongly associated with PCAG and the 
strength of association increased following addition of USA PCAG samples to the 
analysis (Table 4.5). As an exploratory analysis, a non-weighted risk score was 
constructed using counts of risk alleles BICF2G630505097 and BICF2P928441 (the 
most strongly associated SNPs on chromosome 24 and 37 SNPs following addition of 
USA PCAG samples). The risk score explained 54 % of the phenotype variation. 
 Definition of associated loci 4.2.2.1.6
Associated loci were defined based on pair wise linkage disequilibrium estimates of 
these top three SNPs. The results of the strongest associated SNPs on chromosome 24 
were combined to give a single locus by loading SNP data into Haploview and 
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assessing LD amongst SNPs. The following chromosomal loci were defined: 
CanFam3.1 chr24:17,381,226-18,739,902 and chr37:24,747,131-24,958,250.  
4.2.2.1.6.1 Identification and genotyping of candidate variants 
WGS data were available from three BH with PCAG (Table 2.4). However, only data 
from one BH PCAG case were used to interrogate the two loci identified from GWAS 
on the basis of genotypes of the top GWAS SNPs (BICF2P544799 and 
BICF2P928441). The case chosen (BaH_28502) was heterozygous for the alternative 
alleles (other BH PCAG cases for which WGS were held were homozygous for the 
reference alleles). Firstly, the identified associated loci were visually screened for 
structural variants using the WGS sequences from the BH PCAG case and those from 
six control dogs in IGV. Then the BH PCAG case was compared with WGS data from 
97 dogs of other breeds (controls) as described in section 2.2.12. The controls were dogs 
without PCAG and were of breeds not known to be predisposed to PLD or PCAG. The 
identified associated loci above were screened to identify variants for which the 
alternative allele segregated in the case but not in the controls. Identified variants were 
further screened in a consortium of 465 canid WGS (DBVD). Only variants that were 
private to the BH were further investigated. Three candidate variants were identified 
with this approach. Initial genotyping of one of these (chr37:24,861,167 A>G SNP) by 
Sanger sequencing in 126 BH (48 PCAG cases (European and USA), 49 PLD cases and 
29 controls) revealed that 125 BH were homozygous for the reference allele (A/A) and 
only one (the PCAG cases WGS sample) was a heterozygote (A/G). This variant was 
not further investigated. The remaining two variants (Table 4.6) were genotyped in the 
GWAS cohort to test level of association with PCAG. For both variants, association 
with PCAG was weaker than that of the top three SNPs (Table 4.6), and they were 
therefore not investigated any further. 
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Table 4.5 Association of GWAS top SNPs with PCAG in the BH relative to controls and PLD cases.  
Top SNP from 
GWAS 
USA PCAG cases 
included? 
No. PCAG cases No. PLD cases and 
controls 
OR Lower 95% 
CI 
Upper 95% 
CI 
P-value (log 
likelihood 
ratio test) 
Fisher’s exact 
P-value 
chr24:17381226 
BICF2G630505097 
No 24 94 13.73 5.06 37.26 4.2 x 10
-11
 1.4 x 10
-11
 
Yes 59 94 18.84 7.97 44.51 1.6 x 10
-21
 1.2 x 10
-21
 
chr24:18739902 
BICF2P544799 
No 24 94 28.35 8.50 94.58 1.6 x 10
-11
 1.1 x 10
-10
 
Yes 59 94 15.81 6.03 41.45 1.4 x 10
-12
 7.1 x 10
-12
 
chr37: 24747131 
BICF2P928441 
No 24 94 18.03 4.44 73.28 1.1 x 10
-6
 3.9 x 10
-6
 
Yes 59 94 14.76 4.19 51.96 3.6 x 10
-8
 1.7 x 10
-7
 
No. = number, OR = odds ratio, CI = confidence interval 
C
h
a
p
ter 4
 G
en
etic in
vestig
a
tio
n
s o
f p
rim
a
ry clo
sed
 a
n
g
le g
la
u
co
m
a
 
 
 
 
1
4
0
 
Table 4.6. Association of candidate variants with PCAG in the BH relative to PLD cases and controls  
CanFam3.1 
coordinate and 
associated gene 
Nature of variant 
and genotyping 
method 
USA PCAG 
cases included? 
No. PCAG 
cases 
No. PLD 
cases and 
controls 
OR Lower 
95% CI 
Upper 
95% CI 
P-value 
(log 
likelihood 
ratio test) 
Fisher’s 
exact P- 
value 
chr24:17727188 
ATRN 
A>G intronic SNP 
Sanger sequencing 
No 23 93 15.28 5.14 45.48 3.6 x 10
-10
 4.6 x 10
-10
 
Yes 57 93 11.77 4.90 28.26 6.5 x 10
-14
 1.9 x 10
-13
 
chr24:18222425 
PTPRA 
2bp intergenic 
insertion 
AFLP 
No 24 93 3.95 2.01 7.77 1.7 x 10
-5
 6.4 x 10
-5
 
Yes 59 93 3.24 2.01 5.21 1.9 x 10
-7
 1.2 x 10
-6
 
No. = number, OR = odds ratio, CI = confidence interval 
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4.2.2.1.6.2 Identification of candidate genes from RNA-Seq 
Whole transcriptome data derived from ICA tissues were used to compare differential 
gene expression between five BH PCAG cases and four non-BH controls in the loci 
determined from GWAS (Table 4.7). In the chromosome 24 locus, differential gene 
expression was present for five genes: SIGLEC1, C24H20orf194, SLC4A11, 
PROSAPIP1 and OXT. In the chromosome 37 locus, differential expression was present 
for three genes: CXCR2, CXCR1 and ARPC2. A survey of the functions and associated 
phenotypes of these genes revealed no evidence of reported association with glaucoma. 
All genes, however, appeared to be involved in inflammation and immunity (Table 4.8).
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Table 4.7. Differential gene expression results for the BH PCAG loci. 
Gene CanFam3.1 coordinate 
Test 
success  
FPKM 
Controls 
FPKM PCAG 
cases 
log2(fold 
change) 
Test 
statistic 
P-value Q-value Significant? 
Locus chr24:17,381,226-18,739,902 
LOC100855425 24:17377802-17459234 OK 3.66177 4.27275 0.222624 0.105002 0.90045 0.972499 no 
RNF24 24:17377802-17459234 OK 13.5062 15.8018 0.226461 0.549112 0.2461 0.564651 no 
PAX1 24:1743907-1752578 NO TEST 0.751058 0.206085 -1.86569 0 1 1 no 
PANK2 24:17463086-17489560 OK 19.9698 18.2754 -0.127921 -0.289163 0.55265 0.833548 no 
MAVS 24:17511842-17529197 OK 29.2054 32.6664 0.161573 0.390852 0.42265 0.743935 no 
AP5S1 24:17539786-17543605 OK 8.54101 8.52501 -0.00270593 -0.00393991 0.99425 0.998863 no 
CDC25B 24:17552205-17561823 OK 12.1744 14.8 0.28175 0.556191 0.2447 0.563837 no 
CENPB 24:17569396-17572311 OK 31.9742 38.916 0.283456 0.799702 0.1328 0.393219 no 
SPEF1 24:17572374-17578571 OK 1.5338 1.92433 0.327243 0.400218 0.3999 0.724145 no 
C24H20orf27 24:17586019-17600147 OK 22.4481 29.0792 0.373394 0.779776 0.1107 0.352522 no 
HSPA12B 24:17600534-17619889 OK 6.57984 9.70452 0.560605 1.14769 0.0296 0.142427 no 
SIGLEC1 24:17636164-17667080 OK 2.18752 12.5593 2.52139 4.87528 5.00E-05 0.0008345 yes 
ADAM33 24:17668462-17682217 OK 10.7869 8.23265 -0.389845 -0.829875 0.0807 0.285699 no 
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Gene CanFam3.1 coordinate 
Test 
success  
FPKM 
Controls 
FPKM PCAG 
cases 
log2(fold 
change) 
Test 
statistic 
P-value Q-value Significant? 
GFRA4 24:17686816-17690747 OK 3.16594 2.14218 -0.563553 -0.711984 0.2384 0.555935 no 
ATRN 24:17698237-17859816 OK 18.7085 14.7908 -0.338994 -0.812765 0.08165 0.288073 no 
C24H20orf194 24:17908366-18050002 OK 14.0202 9.25396 -0.599364 -1.46229 0.00165 0.0153647 yes 
SLC4A11 24:18057411-18068425 OK 28.8724 6.6876 -2.11013 -4.36281 5.00E-05 0.0008345 yes 
ITPA 24:18070979-18082187 OK 11.9247 16.3186 0.452557 0.814939 0.0945 0.316902 no 
DDRGK1 24:18085722-18098868 OK 17.4284 15.1717 -0.200057 -0.450069 0.33115 0.659854 no 
LOC102157332 24:18111855-18122295 NOTEST 0.531426 0.412288 -0.366218 0 1 1 no 
PROSAPIP1 24:18111855-18122295 OK 20.0459 12.6993 -0.658565 -1.63743 0.00105 0.0107012 yes 
FASTKD5 24:18124262-18166506 OK 13.9635 14.315 0.0358696 0.0772293 0.86905 0.965583 no 
CST11 24:181590-184213 NOTEST 0 0 0 0 1 1 no 
AVP 24:18183056-18184827 NOTEST 0.182349 0.0787568 -1.21123 0 1 1 no 
OXT 24:18193380-18194236 OK 18.6151 5.43912 -1.77503 -2.94744 0.0006 0.0068551 yes 
MRPS26 24:18215054-18217105 OK 24.9994 26.2617 0.0710653 0.176449 0.7648 0.934576 no 
LOC102151131 24:18217903-18222755 NOTEST 0.0563875 0.0232463 -1.27838 0 1 1 no 
LOC102154818 24:18224354-18395654 NOTEST 0.867838 0.884208 0.0269605 0 1 1 no 
PTPRA 24:18224354-18395654 OK 30.9735 28.6433 -0.112839 -0.288467 0.5554 0.835146 no 
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Gene CanFam3.1 coordinate 
Test 
success  
FPKM 
Controls 
FPKM PCAG 
cases 
log2(fold 
change) 
Test 
statistic 
P-value Q-value Significant? 
VPS16 24:18401450-18424606 OK 11.5555 11.6659 0.0137143 0.0286225 0.95285 0.989023 no 
PCED1A 24:18424775-18429698 OK 18.7163 16.9792 -0.140525 -0.340822 0.5442 0.828421 no 
LOC102155387 24:18442763-18443512 NOTEST 0.12029 0.206892 0.782359 0 1 1 no 
TMEM239 24:18443575-18445637 NOTEST 0.308423 0.133061 -1.21283 0 1 1 no 
C24H20orf141 24:18445693-18446873 NOTEST 0.202272 0.317907 0.652307 0 1 1 no 
CPXM1 24:18453867-18460350 OK 8.40695 13.7502 0.7098 1.29913 0.0077 0.0506978 no 
EBF4 24:18470596-18528305 OK 1.69066 1.6627 -0.0240522 -0.0278686 0.96215 0.991001 no 
IDH3B 24:18556489-18561401 OK 46.7683 38.3285 -0.287114 -0.659815 0.1486 0.420704 no 
NOP56 24:18561409-18566780 OK 28.0915 30.953 0.139945 0.325807 0.48615 0.78904 no 
TMC2 24:18577342-18642204 NOTEST 0.308586 0.147869 -1.06136 0 1 1 no 
ZNF343 24:18661008-18665685 NOTEST 0.245175 0.133892 -0.872746 0 1 1 no 
SNRPB 24:18674022-18683315 OK 62.0096 61.9386 -0.00165212 -0.004023 0.99365 0.998542 no 
TGM6 24:18700241-18721827 NOTEST 0.0171946 0 - 0 1 1 no 
TGM3 24:18753637-18793790 NOTEST 0.0342808 0.138228 2.01158 0 1 1 no 
Locus chr37:24,747,131-24,958,250 
RUFY4 37:24809358-24830254 OK 1.71109 1.18547 -0.52945 -0.51443 0.27475 0.599772 no 
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Gene CanFam3.1 coordinate 
Test 
success  
FPKM 
Controls 
FPKM PCAG 
cases 
log2(fold 
change) 
Test 
statistic 
P-value Q-value Significant? 
CXCR2 37:24831509-24846517 OK 3.35508 1.02764 -1.70702 -1.59836 0.00145 0.013826 yes 
CXCR1 37:24861913-24866062 OK 1.82409 0.616257 -1.56557 -1.58159 0.0041 0.030963 yes 
ARPC2 37:24914388-24936198 OK 84.4912 137.67 0.704343 1.97128 0.00035 0.004435 yes 
GPBAR1 37:24940929-24943399 OK 1.26415 2.05007 0.697505 0.919835 0.14675 0.417894 no 
AAMP 37:24943657-24948585 OK 40.9075 43.1513 0.077039 0.181187 0.70665 0.913414 no 
PNKD 37:24948682-25008542 OK 6.30845 7.78033 0.302547 0.202254 0.70135 0.911242 no 
OK = test successful, NOTEST = not enough alignments for testing 
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Table 4.8. Details of differentially expressed genes, their functions and associated disorders and phenotypes. 
Gene Gene full name Function Associated disorders/phenotypes 
SIGLEC1 Sialoadhesin Endocytic receptor mediating 
clathrin dependent endocytosis 
Glomerulonephritis 
Sclerosis 
X-linked intellectual disability 
C20orf194 Chromosome 20 open reading frame 194 May act as an effector for ARL3 HIV-1 
Hepatitis 
SLC4A11 Solute Carrier Family 4 Member 11 Transporter which plays an 
important role in sodium-mediated 
fluid transport in different organs 
Corneal dystrophy 
HIV-1 
Hepatitis 
PROSAPIP1 Proline Rich Synapse Associated Protein Interacting 
Protein 1 
May be involved in promoting the 
maturation of dendritic spines 
Hepatitis 
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Gene Gene full name Function Associated disorders/phenotypes 
OXT Oxytocin Contraction of smooth muscle of 
uterus and mammary gland 
Persistent genital arousal 
Endometritis 
Inhibited male orgasm 
Epignathus 
Chorioamnionitis 
Parturition 
Lactation 
CXCR1 Chemokine (CXC) Receptor 1 Neutrophil activation, neutrophil 
count 
HIV-1 
Pyelonephritis & urinary tract 
infections 
Idiopathic anterior uveitis 
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Gene Gene full name Function Associated disorders/phenotypes 
CXCR2 Chemokine (CXC) Receptor 2 Neutrophil activation, neutrophil 
count 
Congenital neutropenia 
Neutrophil migration 
Pyelonephritis 
Septicaemia 
Granulocytic anaplasmosis 
ARPC2 Actin Related Protein 2/3 Complex Subunit 2 Actin filament assembly. Platelet, 
reticulocyte and neutrophil count 
Platelet, reticulocyte and neutrophil 
count 
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4.2.2.2 FCR 
Genotyping data derived from 166 dogs, comprising 19 PCAG cases, 59 PLD cases and 
89 controls, were analysed.  
 PCAG cases and controls 4.2.2.2.1
After filtering, 19 cases and 89 controls and 92,489 SNPs remained for analysis. No 
SNP markers reached the threshold suggestive of genome-wide significance (Figure 
4.9). 
 
Figure 4.9. Manhattan plot demonstrating association of SNP markers with PCAG 
in FCR. 
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 PCAG and PLD cases and controls 4.2.2.2.2
After frequency and genotype pruning of individuals and SNPs, 78 cases and 89 
controls, and 92,970 SNPs remained for analysis. No SNPs reached the threshold 
suggestive of genome-wide significance (Figure 4.10). 
 
Figure 4.10. Manhattan plot demonstrating association of SNP markers with 
PCAG and PLD in FCR. 
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 PLD cases and controls 4.2.2.2.3
After filtering, 59 cases and 89 controls and 92,995 SNPs remained for analysis. No 
SNPs reached the threshold of suggestive genome-wide significance (Figure 4.11). 
 
Figure 4.11. Manhattan plot demonstrating association of SNP markers with PLD 
in FCR. 
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 PCAG cases and PLD cases 4.2.2.2.4
After filtering, 19 PCAG cases and 59 PLD cases and 93,002 SNPs remained for 
analysis. No SNPs reached the threshold suggestive of genome-wide significance 
(Figure 4.12). 
 
Figure 4.12. Manhattan plot demonstrating association of SNP markers with 
PCAG relative to PLD in FCR. 
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 PCAG cases and PLD cases and controls 4.2.2.2.5
After filtering, 19 PCAG cases and 148 PLD cases and controls and 92,970 SNPs 
remained for analysis. No SNPs reached the threshold suggestive of genome-wide 
significance (Figure 4.13). 
 
Figure 4.13. Manhattan plot demonstrating association of SNP markers with 
PCAG relative to PLD cases and controls in FCR. 
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4.2.2.3 DDT 
Genotyping data derived from 104 dogs comprising 32 PCAG cases, 21 PLD cases and 
51 controls, were analysed. 
 PCAG cases and controls 4.2.2.3.1
After filtering, 32 PCAG cases and 51 controls and 85,854 SNPs remained for analysis. 
No SNPs reached the threshold suggestive of genome-wide significance (Figure 4.14). 
 
Figure 4.14. Manhattan plot demonstrating association of SNP markers with 
PCAG in DDT. 
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 PCAG and PLD cases and controls 4.2.2.3.2
After filtering, 53 PCAG and PLD cases and 51 controls and 85,945 SNPs remained for 
analysis. No SNPs reached the threshold suggestive of genome-wide significance 
(Figure 4.15). 
 
Figure 4.15. Manhattan plot demonstrating association of SNP markers with 
PCAG and PLD in DDT. 
 
 
 
 
C
h
a
p
ter 4
 G
en
etic in
vestig
a
tio
n
s o
f p
rim
a
ry clo
sed
 a
n
g
le g
la
u
co
m
a
 
Chapter 4 Genetic investigations of primary closed angle glaucoma 
156 
 
 PLD cases and controls 4.2.2.3.3
After filtering, 21 PLD cases and 51 controls and 84,718 SNPs remained for analysis. 
No SNPs reached the threshold suggestive of genome-wide significance (Figure 4.16). 
 
Figure 4.16. Manhattan plot demonstrating association of SNP markers with PLD 
in DDT. 
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 PCAG cases and PLD cases 4.2.2.3.4
After filtering, 32 PCAG cases and 21 PLD cases and 84,950 SNPs remained for 
analysis. No SNPs reached the threshold suggestive of genome-wide significance 
(Figure 4.17). 
 
Figure 4.17. Manhattan plot demonstrating association of SNP markers with 
PCAG relative to PLD cases in DDT. 
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 PCAG cases and PLD cases and controls 4.2.2.3.5
After filtering, 32 PCAG cases and 72 PLD cases and controls 85,824 SNPs remained 
for analysis. No SNPs reached the threshold suggestive of genome-wide significance 
(Figure 4.18). 
 
Figure 4.18. Manhattan plot demonstrating association of SNP markers with 
PCAG relative to PLD cases and controls in DDT. 
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4.2.2.4 WSS 
Genotyping data derived from 123 dogs, comprising 36 PCAG cases, 54 PLD cases and 
33 controls, were analysed. 
 PCAG cases and controls 4.2.2.4.1
After filtering, 36 PCAG cases and 33 controls and 97,176 SNPs remained for analysis. 
No SNPs reached the threshold suggestive of genome-wide significance (Figure 4.19). 
 
Figure 4.19.  Manhattan plot demonstrating association of SNP markers with 
PCAG in WSS. 
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 PCAG and PLD cases and controls 4.2.2.4.2
After filtering, 90 PCAG and PLD cases and 33 controls and 95,830 SNPs remained for 
analysis. No SNPs reached the threshold suggestive of genome-wide significance 
(Figure 4.20). 
 
Figure 4.20. Manhattan plot demonstrating association of SNP markers with 
PCAG and PLD in WSS. 
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 PLD cases and controls 4.2.2.4.3
After filtering, 54 PLD cases and 33 controls and 95,582 SNPs remained for analysis. 
No SNPs reached the threshold suggestive of genome-wide significance (Figure 4.21). 
 
Figure 4.21.  Manhattan plot demonstrating association of SNP markers with PLD 
in WSS. 
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 PCAG cases and PLD cases 4.2.2.4.4
After filtering, 36 PCAG cases and 54 PLD cases and 97,028 SNPs remained for 
analysis. No SNPs reached the threshold suggestive of genome-wide significance 
(Figure 4.22). 
 
Figure 4.22. Manhattan plot demonstrating association of SNP markers with 
PCAG relative to PLD in WSS. 
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 PCAG cases and PLD cases and controls 4.2.2.4.5
After filtering, 36 PCAG cases and 87 PLD cases and controls and 95,830 SNPs 
remained for analysis. No SNPs reached the threshold suggestive of genome-wide 
significance (Figure 4.23). 
 
Figure 4.23. Manhattan plot demonstrating association of SNP markers with 
PCAG relative to PLD cases and controls in WSS.  
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4.2.2.5 BH, FCR, DDT and WSS Meta-analysis 
Meta-analysis was performed across all four breeds to identify any shared regions of 
association with PCAG, PLD or both. This was done with assistance from Dr Sally 
Ricketts. Genotyping data derived from 111 PCAG cases, 191 PLD cases and 210 
controls were analysed. Individual breed GWAS GEMMA analyses were utilised in 
these analyses. Q-Q plots were performed for all meta- analyses (Appendix II) but 
MDS plots were not generated as meta-analysis takes breed variation into account by 
combining the summary statistics from the single breed analyses. Meta-analysis was 
only performed for SNPs that were informative and passed quality control measures in 
all four breeds. A summary of meta-analysis GWAS and results is presented in Table 
4.9. 
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Table 4.9. Summary of meta-analysis GWAS results. 
Breeds  Phenotype  No. samples No. SNPs 
analysed 
λ SNPs reaching 
Bonferroni 
significance 
Pooled Values P-value P-value for 
heterogeneity 
(Q statistic) 
Cases Controls Cases Controls OR Lower 
95% CI 
Upper 
95% CI 
BH 
FCR 
DDT 
WSS 
PCAG 
cases 
Controls 111 210 37756 1.12 BICF2P161081  
BICF2P242291  
(R
2
 = 1.0) 
1.30 1.18 1.43 1.7 x 10
-7
 0.81 
PCAG 
cases 
PLD cases 
& controls 
111 401 37726 1.07 None NA NA NA NA NA 
PCAG & 
PLD cases 
Controls 302 210 37726 1.05 None NA NA NA NA NA 
PLD cases Controls 191 210 36116 1.04 None NA NA NA NA NA 
PCAG 
cases 
PLD cases 111 191 37467 1.02 None NA NA NA NA NA 
DDT 
WSS 
PCAG 
cases 
Controls 68 84 62982 1.04 BICF2G630271568 0.76 0.69 0.85 2.1 x 10
-7
 0.86 
No. = number of dogs, OR = odds ratio, CI = confidence interval 
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 PCAG cases and controls 4.2.2.5.1
After filtering, 111 PCAG cases and 210 controls and 37,756 SNPs remained (Table 
4.9). In this analysis, two SNPs reached genome-wide significant association with 
PCAG (BICF2P242291; CanFam3.1 chr28:14711023 and BICF2P161081; CanFam3.1 
chr28:14721865; both –log10P = 6.77) (Figure 4.24). These two SNPs were in perfect 
correlation with each other (R
2
 = 1.0) and the heterogeneity statistic (0.81) indicated 
low heterogeneity between breeds (i.e. there was no significant difference in 
heterogeneity effect of the risk alleles across breeds) (Table 4.9). The strength of 
association of these SNPs was strongest in the individual datasets for the DDT and WSS 
(Table 4.10). Conditional analysis on BICF2P242291 was performed to assess for the 
presence of additional associations. No further SNPs reached genome-wide 
significance.  
 
Figure 4.24. Manhattan plot of meta-analysis across all four breeds demonstrating 
association of SNP makers with PCAG. 
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Table 4.10. Association of meta-analysis top SNPs with PCAG by breed. 
 Level of association 
following GEMMA 
FCR DDT WSS BH 
SNP BICF2P242291 P-value 0.015 0.006 0.006 0.166 
Beta coefficient 0.302 0.298 0.256 0.165 
BICF2P161081 P-value 0.015 0.006 0.006 0.166 
Beta coefficient 0.302 0.298 0.256 0.165 
4.2.2.5.1.1 DDT and WSS PCAG cases and controls 
Based on the finding of the strongest association of SNPs with PCAG from meta-
analysis in the DDT and WSS, a pair wise meta-analysis of these two breeds was 
performed using 68 PCAG cases, 84 controls and 62,982 SNPs (Table 4.9). One SNP 
reached genome-wide significance (BICF2G630271568; CanFam3.1 chr28:18,871,699; 
–log10P = 6.67) (Figure 4.5). Following GEMMA correction of association data, 
association of this SNP with PCAG was stronger in both the DDT (P = 0.004) and WSS 
(P = 0.0003) than that of the top SNPs in the previous meta-analysis (P = 0.006 for both 
breeds). Introduction of this SNP as a covariate in the model did not reveal and further 
SNPs to be associated with PCAG. 
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Figure 4.25. Manhattan plot of meta-analysis of DDT and WSS breeds 
demonstrating association of SNP markers with PCAG. 
4.2.2.5.1.2 Identification of breed-specific associated loci  
Breed-specific associated loci were defined based on pair wise linkage disequilibrium 
estimates (R
2
 ≥ 0.5) of the strongest associated SNP in each individual breed using 
Haploview (BICF2P242291 for the FCR and BICF2G630271568 for the WSS and 
DDT). The following chromosomal loci were defined (CanFam3.1): chr28:14,697,561-
14,721,865 (FCR), chr28:18,835,904-19,259,305 (WSS) and chr28:18,871,699-
19,358,417 (DDT). 
4.2.2.5.1.3 Identification and genotyping of candidate variants 
Firstly, the identified loci were visually screened for structural variants using the WGS 
data from one breed-specific PCAG case (selected on the basis that the alternative allele 
segregates in the case) and from six controls dogs in IGV. Identified loci were then 
screened for candidate variants using NGS approaches as for the BH (section 4.2.2.1.6). 
For each breed and locus, WGS data from PCAG-affected dogs (one FCR, one DDT 
and three WSS) of the breeds in question were compared with those from 97 control 
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dogs of other breeds. The control dogs were unaffected by PCAG and were from breeds 
not known to be predisposed to PCAG. Variants for which the alternative allele 
segregated in the cases, but not in the controls were identified. These were then further 
assessed in a consortium of 465 canid whole genome sequences (DBVD). Only variants 
which segregated in the PCAG case and were absent in all other sequences were further 
investigated. Candidate variants were then genotyped in the relevant breed specific 
GWAS cohorts. The following candidate variants were identified:  a T>C intergenic 
SNP (chr28:14,624,548) in the FCR; a C>T intergenic SNP (chr28:19,274,452) in the 
DDT and; a 6 bp intergenic deletion (chr28:19,274,198-19,274,204) in the WSS. Only 
for the FCR candidate variant was association as strong as that of the top GWAS SNP 
(Table 4.11). 
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Table 4.11 Association of candidate variants with PCAG in the FCR, DDT and WSS. 
Breed Variant details 
(genomic 
coordinates are 
CanFam3.1) 
Genotyping 
method 
Correlation 
between 
GWAS top 
SNP and 
candidate 
variant 
Cases Controls No. 
cases 
No. 
controls 
OR Lower 
95% 
CI 
Upper 
95% 
CI 
P-value 
Log 
likelihood 
ratio test 
Fisher’s 
exact P-
value 
FCR chr28:14,721,865 
BICF2P161081 
(GWAS top SNP) 
GWAS data 1.0 
 
PCAG 
cases 
Controls 19 87 5.06 1.59 16.12 7.8 x 10
-3
 8.4 x 10
-3
 
chr28:14,624,548 
T>C intergenic SNP 
(candidate variant) 
Sanger 
sequencing 
PCAG 
cases 
Controls 19 87 5.06 1.59 16.12 7.8 x 10
-3
 8.4 x 10
-3
 
DDT 
 
chr28:18,871,699 
BICF2G630271568 
(GWAS top SNP) 
GWAS data 0.46 PCAG 
cases 
Controls 32 51 0.32 0.15 0.72 3.1 x 10
-3
 5.1 x 10
-3
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Breed Variant details 
(genomic 
coordinates are 
CanFam3.1) 
Genotyping 
method 
Correlation 
between 
GWAS top 
SNP and 
candidate 
variant 
Cases Controls No. 
cases 
No. 
controls 
OR Lower 
95% 
CI 
Upper 
95% 
CI 
P-value 
Log 
likelihood 
ratio test 
Fisher’s 
exact P-
value 
chr28:19,274,452 
C>T intergenic SNP 
(candidate variant) 
Sanger 
sequencing 
PCAG 
cases 
Controls 32 51 1.74 0.88 3.45 0.11 2.4 x 10
-4
 
WSS chr28:18,871,699 
BICF2G630271568 
(GWAS top SNP) 
GWAS data 0.76 PCAG 
cases 
Controls 35 33 7.41 2.77 19.81 7.9 x 10
-7
 4.8 x 10
-6
 
chr28:19,274,198 
intergenic 6bp 
deletion (candidate 
variant) 
AFLP PCAG 
cases 
Controls 35 33 3.25 1.43 7.38 2.4 x 10
-3
 2.9 x 10
-3
 
OR = odds ratio, CI = confidence interval 
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 PCAG and PLD cases and controls 4.2.2.5.2
After filtering, 302 PCAG and PLD cases, 210 controls and 37,726 SNPs remained. No 
SNPs reached genome-wide significance (Figure 4.26). 
 
Figure 4.26. Manhattan plot of meta-analysis across all four breeds demonstrating 
association of SNP markers with PCAG cases and PLD cases. 
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 PLD cases and controls 4.2.2.5.3
After filtering, 191 PLD cases, 210 controls and 36,116 SNPs remained for analysis. No 
SNPs reached genome-wide significance (Figure 4.27). 
 
Figure 4.27. Manhattan plot meta-analysis across all four breeds demonstrating 
association of SNP markers with PLD. 
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 PCAG cases and PLD cases 4.2.2.5.4
After filtering, 111 PCAG cases, 191 PLD cases and 37,467 SNPs remained. No SNPs 
reached genome-wide significance (Figure 4.28). 
 
Figure 4.28. Manhattan plot of meta-analysis across all four breeds demonstrating 
association of SNP markers with PCAG relative to PLD. 
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 PCAG cases and PLD cases and controls 4.2.2.5.5
After filtering, 111 PCAG cases, 401 PLD cases and controls and 37,726 SNPs 
remained for analysis. No SNPs reached genome-wide significance (Figure 4.29). 
 
Figure 4.29. Manhattan plot of meta-analysis across all four breeds demonstrating 
association of SNP markers with PCAG relative to PLD cases and controls. 
 Discussion 4.2.3
In this series of studies, GWAS were performed in dogs of four different breeds with 
normal eyes, with PLD or with PCAG. In the BH, initial GWAS revealed two SNP 
markers on CFA24 to be significantly associated with PCAG. Analysis of sliding 
window haplotypes and permutations of these haplotypes corroborated these findings 
(Figure A2 and Figure A). Conditional analysis using one of these SNP markers as a 
covariate revealed an additional SNP marker on CFA37 to be associated with PCAG in 
this breed. The GWAS findings were also supported by the fact that the strength of 
association of PCAG with these SNP markers increased when analysis was repeated 
with the addition SNP data from USA BH PCAG samples particularly for 
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BICF2G630505097 which was also the most strongly associated SNP in the original 
analysis. This SNP is located in an intergenic region (chr24:17,381,226) with RNF24 
(chr24:17,423,245-17,454,478) and PANK2 (chr24:17,463,603-17,489,677) being the 
nearest upstream genes. These are potentially interesting candidate genes for PCAG as a 
previous study of a glaucoma-related trait in humans, optic nerve head morphology, 
revealed a significant linkage signal at the RNF24/PANK2 locus
206
.  Further studies 
comparing optic nerve head morphology in dogs with normal eyes and those with PLD 
and/or PCAG are required however.  
It was interesting that significant association of SNP makers with PCAG was found in 
the PCAG cases and PLD cases analysis and not in the PCAG cases and controls 
analysis. PLD is considered a consistent risk factor for, and therefore likely to be on the 
causal pathway to, canine PCAG
29,31-33
. Therefore, it is considered there are shared 
genetic factors between PCAG and PLD cases and significant association with disease 
(PCAG and/or PLD) would more likely be discovered when analysing PCAG and PLD 
cases combined with controls owing to the greater number of cases, and thus power, of 
such analysis. Instead, these studies revealed two loci which are significantly more 
common in PCAG cases than in both PLD cases and controls. This is not a completely 
unexpected finding, however, as, although PLD is a risk factor for PCAG, only a 
minority of dogs with PLD are thought to develop PCAG. It is thus likely that the two 
chromosomal loci identified are involved in the ‘trigger’ of progression from PLD to 
PCAG. It is considered that PLD is required for but not sufficient for PCAG, thus 
whether a dog develops PCAG will depend on its genotype at both the PLD locus and 
PCAG locus (or loci). It is possible that a similar (although admittedly likely more 
complex) scenario of genotypes illustrated in Table 4.12 is present in the dog, where 
PCAG cases have both the PCAG and PLD risk alleles (homozygous or heterozygous 
depending on mode of inheritance), PLD cases have the PLD risk allele but not the 
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PCAG risk allele and controls may have a mixture of protective and risk alleles at both 
loci. In this situation, when SNP genotypes of PCAG cases and PLD cases are 
compared by GWAS, PCAG cases and PLD cases may be sufficiently different at the 
PCAG locus to detect a GWAS signal. When PCAG cases are compared with PLD 
cases and controls combined, there may only be a slight increase in GWAS signal 
intensity because controls have a mixture of risk and protective alleles at the PCAG 
locus. When PCAG cases or PLD cases and controls are compared, there may be 
insufficient power to detect a GWAS signal as the controls have a mixture of risk and 
protective alleles at both loci – presumably larger sample numbers would be required to 
detect a signal in this situation. This scenario may well explain the GWAS findings in 
the BH in which only PCAG loci, and not a PLD locus (or loci), were identified. The 
inability to detect GWAS signals in the other breeds could be explained by the presence 
of a greater number of PCAG loci in these breeds requiring greater sample numbers to 
provide sufficient power for locus detection. 
Table 4.12. Simple model of genotypes at PLD 
and PCAG loci. 
Phenotype 
PLD locus 
genotype 
PCAG locus 
genotype 
PCAG cases 
 
- 
 
- 
PLD cases - + 
Controls + or - + or - 
-  denotes risk allele (homozygous or heterozygous depending on mode of 
inheritance), + denotes reference allele 
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The GWAS in the BH did not provide any evidence of association of PCAG with loci 
previously implicated in this phenotype in this breed. A previous study employing a 
GWAS of PCAG in USA BH reported two regions in association with PCAG following 
multiple hypothesis testing correction of raw P values by permutation
170
. These 
susceptibility loci were situated on CFA14 (chr14:19,911,001-20,161,358) and CFA24 
(chr24:43,091,222-43,595,979) and contained the collagen gene COL1A2 and oncogene 
RAB22A respectively. Five additional SNPs on five additional chromosomes were 
similarly associated with PCAG using the same permutation adjusted significance 
threshold but were not investigated because they were located in non-coding regions. 
The same investigators reported another study whereby they employed two-point and 
multipoint linkage analyses of genome-wide SNP data to identify a locus on CFA19 
associated with PCAG in USA BH (including some dogs used in their previous 
GWAS). Using exome-sequencing analysis, a possibly damaging, non-synonymous 
variant in the Nebulin gene (NEB) was found to segregate with PCAG
171
. The data of 
this thesis do not corroborate the findings of these reports. The differences in 
susceptibility loci reported in USA BH may relate to their rarity in European BH. The 
difference in findings may also be partly explained by differing methodology employed. 
In the USA GWAS, population stratification was corrected using a MDS analysis and 
threshold for significance was set by permutation testing using 1,000 permutations. In 
the GWAS reported here, population stratification was corrected using the mixed model 
GEMMA and threshold for genome-wide significance was set using Bonferroni 
correction. Bonferroni is considered particularly stringent in the dog owing to the large 
LD in this species which provided reassurance of the reliability of the findings
207
. 
Finally, these data suggest that the reported NEB variant is a benign polymorphism.  
Single breed GWAS in the other three breeds (FCR, DDT and WSS) did not reveal any 
significant association of SNP markers with either PCAG or PLD. The reason for this 
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likely relates to paucity of samples in light of the suspected complex nature of canine 
PCAG and PLD – PCAG in the BH may have a simpler genetic background than in the 
other three breeds. It is likely that multiple genetic, and possibly also environmental, 
factors are involved in canine PCAG and PLD
78
. The number of samples required for 
GWAS to be informative in locus identification depends on the inheritance pattern of 
the investigated trait. For complex traits in dogs, it has been predicted that a fivefold 
risk allele can be detected with 100 cases and 100 controls but a twofold risk allele 
would require approximately 500 cases and 500 controls to be identified
85
. Minimal 
numbers predicted to detect a fivefold disease risk allele were only achieved with meta-
analysis of combined summarised GWAS data from the four breeds. In the meta-
analysis, a significant association with PCAG was found on CFA28. The BH did not 
appear to contribute to the meta-analysis signal which complements the finding of the 
individual breed GWAS. It appears that BH PCAG associated loci are likely to be 
different to the other three breeds. The WSS and DDT breeds contributed the greatest to 
this signal with the top SNP in these two breeds being BICF2G630271568 
(chr28:18,871,699) which maps to SORCS1. SORCS1 is associated with amyloid 
deposition and has primarily been associated with Alzheimer’s disease in humans208-210. 
Glaucoma in human has also been associated with amyloidosis and, thus, SORCS1 may 
represent a promising candidate gene for canine PCAG
207,211,212
. 
A previous GWAS of PCAG in the DDT using 23 cases and 23 controls revealed a 
novel 9.5 Mb locus on CFA8 although level of association did not reach the Bonferroni 
threshold level of significance
106
. In this thesis, a larger sample cohort was used and no 
association of CFA8 SNP markers with PCAG in the DDT was found. Again, this could 
relate to the complex nature of PCAG and the presence of multiple causative genetic 
factors distributed at differing frequencies among populations. It is also interesting to 
note, that these GWAS did not support an association between PCAG or PLD with 
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ADAMTS17 in the WSS or any other breed. As it is known that this gene is well-
captured by the CanineHD BeadChip, these results suggest that the association with 
ADAMTS17 reported in 4.1.3.1 is unlikely to be true
107,122
. 
Following identification of susceptibility loci for PCAG, a NGS approach was used to 
identify variants associated with disease. The AHT has used this approach successfully 
before to identify variants responsible for single gene disorders
107,213,214
. WGS of 
PCAG-affected dogs (one from each of BH, FCR and DDT and three WSS) were used 
to perform breed-specific analyses using large numbers of WGS from control dogs to 
identify variants which segregated with disease in the loci defined by previous GWAS 
and subsequent analysis. All variants found using this approach were in non-coding 
regions and, as such, not immediately provocative as pathogenic. Having said this, 
intergenic and deep intronic variants are being increasingly recognised as having 
important gene regulatory functions in disease than previously thought
215,216
. Thus, 
perhaps the lack of discovery of an association of exonic variants with PCAG, which is 
thought to be complex, is unsurprising. However, all identified (non-coding) candidate 
variants, other than that identified in the FCR, were less strongly associated with PCAG 
than the relevant top SNP, making them unlikely to be pathogenic variants. Although it 
was disappointing not to find candidate variants for PCAG using this approach, it was 
not entirely unexpected. Similar to the dog, adult-onset forms of primary glaucoma in 
humans are inherited as complex traits
111
. Although GWAS have successfully identified 
genomic loci for PACG in humans using large case-control sets (thousands of 
individuals), as reported in this thesis in much smaller sets of canine samples, 
pathogenic variants remain elusive
169,217
.  
In parallel to the WGS-based PCAG approach, RNA-Seq data were used to attempt to 
elucidate candidate genes involved in PCAG in the BH. Similar to the candidate variant 
analysis, a targeted approach based on the loci identified as a result of GWAS was used. 
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Eight genes were found to be differentially expressed although, on the face of it, none of 
these appear to be obvious candidates for canine PCAG. Instead, all genes identified 
have functions related to inflammation and immunity. This finding was not completely 
unexpected. Jian et al. identified over 500 genes with statistically significant changes in 
expression level in the glaucomatous canine retina
218
. Genes with elevated expression 
were found to be largely associated with inflammation, such as antigen presentation, 
protein degradation, and innate immunity. Thus, it appears that the results reported here 
corroborate these findings and may contribute to an enhanced understanding of the 
molecular events that occur in canine eye with advanced primary closed angle 
glaucoma. Unfortunately, however, because intraocular inflammation is such a common 
finding in any canine eye with end-stage glaucoma (be it primary or secondary), 
traditional gene expression studies may be less helpful in helping understand the 
primary genetic aetiology of the disease having more power to detect ‘effect’ rather than 
‘cause’. 
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5 Primary open angle glaucoma: molecular investigation using a 
candidate gene approach in three dog breeds 
 Introduction 5.1
POAG is characterised by the presence of typical clinical signs of glaucoma, such as 
elevated IOP in the presence of an open ICA during the early stages of disease
72
. The 
only dog breed in which POAG has been extensively clinically characterised is the 
Beagle in which a laboratory colony was established and studied. In this breed, 
elevation of IOP is apparent before 12 months of age with other signs of glaucoma 
becoming apparent before 36 months of age
72
. In the clinical setting, however, dogs 
with POAG present much later than this and usually demonstrate advanced chronic 
clinical signs of glaucoma at the time of diagnosis. This late presentation is most likely 
explained by the chronic and insidious nature of the disease with affected dogs retaining 
some vision until very late in the disease process and without demonstrating signs of 
pain obvious to the owner. 
During the course of gonioscopy screening sessions in BH (Chapter 3), two dogs with 
POAG were discovered – a form of glaucoma not previously reported in the breed. The 
AHT laboratory had also received DNA samples from a third BH and three BFdB dogs 
diagnosed with POAG and 21 SP dogs diagnosed with POAG and/or PLL, including 10 
cases examined by myself. As discussed in section 1.2, differential diagnosis between 
PLL and POAG in the SP can be problematic and it is likely that there is only one 
breed-related condition in the SP, namely POAG which, in line with POAG in other 
breeds, leads to secondary buphthalmos and lens instability. To avoid confusion, and in 
line with the other two breeds, the phenotype in this breed will also be referred to as 
POAG hereafter, although it is acknowledged that a detailed clinical description of the 
phenotype in this breed is lacking. 
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In dogs, POAG is a relatively rare condition, although its high prevalence in specific 
breeds suggests an inherited aetiology. POAG has previously been reported in the 
Beagle and Norwegian Elkhound in which it is inherited as an autosomal recessive 
condition caused by two breed-specific mutations in ADAMTS10
68-70
. Further research 
in the Beagle has shown that the ADAMTS10 mutation responsible for POAG is also 
associated with an inherently weaker and biochemically distinct posterior sclera before 
clinical evidence of optic nerve damage becomes apparent
124
. POAG in the Petit Basset 
Griffon Vendeen has recently been reported to be associated with a novel mutation in a 
closely related gene, ADAMTS17, and another mutation in this gene has been published 
as the cause of PLL in multiple breeds
74,122,123
.  
The specific objective of these studies was to interrogate ADAMTS17 as a candidate 
gene for POAG in the BH, BFdB and SP. The ultimate aim of the studies was to 
develop and offer DNA tests for these breeds to reduce the prevalence of this painful 
and blinding disease. The data presented here have since been published
75,219
 . 
 Materials and methods 5.2
 Sample collection and DNA extraction 5.2.1
POAG was diagnosed by certified veterinary ophthalmologists in 3 BH (2 males, 1 
female), 3 BFdB (1 male, 2 females) and 21 SP (11 females, 10 males) dogs. Thirteen of 
these dogs were examined by myself (2 BH and 10 SP). The mean age (± SD) of the 
POAG affected dogs was 49.3 ± 5.4 months (BH), 68.3 ± 12.7 months (BFdB) and 84.9 
± 8.9 months (SP).  Inclusion criteria for dogs with POAG were; absence of an 
identifiable cause of secondary glaucoma, open ICA on gonioscopy in the clinically 
affected and/or contralateral eye (chronic corneal changes in the affected eye may 
preclude gonioscopy), elevated IOP (> 25 mmHg), buphthalmos and lens subluxation. 
A further 223 BH, 24 BFdB and 42 SP dogs underwent complete ophthalmic 
examination by myself and were all found to be free from all clinical signs of POAG as 
C
h
a
p
ter 4
 G
en
etic in
vestig
a
tio
n
s o
f p
rim
a
ry clo
sed
 a
n
g
le g
la
u
co
m
a
 
Chapter 5 Genetic investigations of primary open angle glaucoma 
184 
 
described above. These dogs were at least 72 months of age at the time of examination 
and, in the absence of any signs of POAG, were considered suitable controls for 
subsequent genotyping experiments. The 223 clinically unaffected BH had a mean age 
of 52.0 ± 2.61 months, and 85 (38 %) were male and 138 (62 %) were female. The 24 
clinically unaffected BFdB had a mean age of 124.38 ± 78.1 months, and 12 (50 %) 
were male and 12 (50 %) were female.  The 42 clinically unaffected SP had a mean age 
of 93.5 ± 3.7 months, and 16 were male (38 %) and 26 (62 %) were female. DNA was 
extracted from buccal mucosal swabs from each dog as described in section 2.2.1.  
 ADAMTS10 and ADAMTS17 candidate variant genotyping 5.2.2
All POAG-affected BH, BFdB and SP dogs were genotyped for the two previously 
published ADAMTS10 POAG-associated variants (Beagle and Norwegian Elkhound), 
the ADAMTS17 POAG variant (Petit Basset Griffon Vendeen) and the ADAMTS17 PLL 
variant (multiple terrier breeds) (details in Table 5.1) using primers and thermal cycling 
parameters as previously described
68,70,74
.  Genotyping was performed in parallel for the 
BH and BFdB, but separately at a later date in the SP. As a result, in the SP, genotyping 
for the newly discovered BH and BFdB ADAMTS17 POAG variants was also 
performed
75
. The SP project was initiated by colleagues, namely Sophie Rustidge and 
Louise Pettitt, who first identified the mutation in 10 affected dogs, after which the 
project was taken over by myself. Genotyping was performed using Sanger sequencing 
methodology as described in section 2.2. 
 ADAMTS17 resequencing and sequencing data analysis 5.2.3
Primer pairs were designed to amplify the coding sequence and flanking splice sites for 
all 23 canine ADAMTS17 exons using gene sequences derived from the Ensembl 
genome browser (ENSCAFG00000010709) (Appendix IV). This was performed in 3 
affected and 3 unaffected BH, 3 affected and 3 unaffected BFdB and 10 affected and 5 
unaffected SP. Genomic DNA was amplified using PCR with reaction components and 
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thermal cycling parameters as outlined in Appendices II and III. Illumina sequencing 
libraries were generated from the ADAMTS17 exon as described in section 2.2.10. Read 
alignments (BAM files) were visualised and manually browsed for variants using IGV. 
The potential pathogenicity of non-synonymous variants was tested with the SIFT 
bioinformatics tool (http://sift.jcvi.org/)
220
. To demonstrate level of conservation 
relating to discovered variants, ADAMTS17 protein sequences were derived from the 
Ensembl genome browser (http://www.ensembl.org) and aligned using the Clustal 
Omega multiple sequence alignment tool (http://www.ebi.ac.uk/Tools/msa/clustalo/). 
 Genotyping of ADAMTS17 candidate causal variants 5.2.4
Candidate causal variants were genotyped using one or more methods depending on the 
nature of the variant: AFLP, Sanger sequencing or allelic discrimination. Primers were 
designed to amplify the candidate causal variants using gene sequences derived from the 
UCSC genome browser (https://genome.ucsc.edu/). PCR and thermal cycling reactions 
varied for each breed and are presented in Appendix III. The BH and SP deletion 
variants were genotyped by AFLP and the BFdB SNP variant by Sanger sequencing, as 
described in section 2.2.12. Additional genotyping of the BFdB SNP variant was 
performed by allelic discrimination, using primers and probes provided in Appendix 
IV, and as described in section 2.2.12
221
. Based on the entire genotyping data set for 
each breed, POAG association statistics for candidate variants were calculated using 
PLINK
178
. Mutant allele frequencies and the expected frequency of affected dogs 
(assuming the alleles were in Hardy-Weinberg equilibrium within the population) were 
determined for the BH and SP. 
 cDNA synthesis and sequencing 5.2.5
One POAG-affected BH and one POAG-affected SP underwent unilateral enucleation 
on welfare grounds. An additional dog (12 year old Golden Retriever) was euthanized 
for reasons unrelated to this study. Prior to euthanasia of this dog, a complete 
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ophthalmological examination (including gonioscopy and tonometry) was performed to 
rule out the presence of any clinical signs of POAG (or other inherited ocular disease), 
allowing the subsequently harvested ocular tissue to serve as (non-breed matched) 
control tissue. Ocular tissue was harvested and stored in RNAlater (Ambion) at -80 
o
C. 
RNA was subsequently extracted from the tissues of the ICA and cDNA synthesised 
from the RNA as described in section 2.3.2.2. Primer pairs spanning each of the two 
breed-specific ADAMTS17 mutations were designed using cDNA sequences derived 
from the Ensembl genome browser and Primer 3 (Appendix  IV)
174,175,185,186
. 
Amplification of target regions of cDNA by PCR, PCR product purification and Sanger 
sequencing were performed as described in section 2.2. Sanger sequencing was 
performed for all four assays in the control dog’s tissue (Golden Retriever) but only for 
the breed-relevant assays in the POAG-affected dogs’ tissues. For the BH assays, Q 
solution was used in the PCR reaction (GC rich regions). This was replaced with MQ in 
the SP assays. 
 Quantitative reverse transcriptase PCR 5.2.6
cDNA synthesised in 5.2.5 was used for relative qRT-PCR to investigate ADAMTS17 
transcript expression in three technical replicates each of normal ocular tissue (Golden 
Retriever), POAG-affected SP ocular tissue and POAG-affected BH ocular tissue as 
described in 2.3.2.2. ADAMTS17 transcript expression was compared between normal 
tissue and affected tissue for the SP and BH separately. Assays were designed for the 
target ADAMTS17 gene and for a ubiquitously expressed housekeeping gene (TBP) 
gene for comparison. Details of the designed assay are presented in Appendix IV.  
 Results 5.3
 ADAMTS10 and ADAMTS17 variant genotyping 5.3.1
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All POAG-affected BH, BFdB and SP dogs were homozygous for the wild type alleles 
at the chromosomal locations of all four previously published POAG/PLL-associated 
variants. 
 ADAMTS17 resequencing 5.3.2
5.3.2.1 BH 
Visual scanning of the sequence reads, aligned with CanFam3.1, from three clinically 
affected and three unaffected BH revealed only one variant that segregated with disease. 
This variant was a homozygous 19 bp deletion in exon 2 of ADAMTS17 (CanFam3.1 
chr3:40,614,853-40,614,872) and was confirmed by Sanger sequencing (Figure 5.1). 
This variant results in the loss of 19 coding nucleotides (c.193_211del), which in turn is 
predicted to shift the amino acid reading frame resulting in 87 aberrant amino acids 
before the introduction of a premature termination codon (p.Lys69GlyfsTer88).  
Fifty clinically unaffected BH over the age of 72 months (controls) were genotyped for 
this allele by AFLP; all were homozygous for the wild type allele. Genotyping of 173 
additional BH recruited for a different study and also known to be free of clinical signs 
of POAG, revealed 137 were homozygous for the wild type allele and 36 were 
heterozygous for the mutation. The frequency of the deletion in this subset of 223 BH 
was therefore 0.081 and the predicted frequency of affected dogs in the population 
estimated to be 0.007. One hundred and fifty-two dogs of unrelated breeds were all 
homozygous for the wild type allele. Following identification of this mutation, the 
owners of all affected dogs were contacted and pedigrees were obtained and reviewed. 
Analysis of these revealed two of the affected dogs to be full siblings although the third 
affected dog shared no common ancestors in its five generation pedigree. Taking into 
account the presence of the two full siblings, the association statistic between the 
deletion and POAG based on the entire genotyping dataset (two POAG affected and 220 
unaffected) was P = 1.26 x 10
-10
. 
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Figure 5.1. Next-generation and Sanger sequencing data depicting the site of 19bp 
deletion in a BH with POAG. 
a) IGV view of the 19 bp deletion in a BH affected with POAG. The location of this 
homozygous deletion is chr3:40,614,853-40,614,872 (CanFam3.1). b) 
Electropherograms depicting the site of the deletion. The red box delineates the affected 
sequence in wild type, carrier and POAG-affected dogs.  
5.3.2.2 BFdB 
Visual scanning of the sequence reads, aligned with CanFam3.1, from three clinically 
affected and three clinically unaffected BFdB dogs revealed only one variant that 
segregated with disease - a homozygous G>A substitution in exon 11 of ADAMTS17 
(c.1552G>A; p.Gly519Ser) (CanFam3.1 chr3:40,808,345, Figure 5.2).  
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Figure 5.2. Next generation and Sanger sequencing results depicting the site of the 
SNP associated with POAG in BFdB. 
a) Visualisation of the SNP in IGV. The localisation of this homozygous SNP is 
chr3:40,808,345 (CanFam 3.1). b) Electropherogram depicting the site of the SNP. The 
red box depicts the exact site of the mutation (CanFam3.1 chr3:40,808,345). At this 
location, the wild type is GG, the carrier is AG and the POAG case is AA. 
All three affected BFdB dogs were homozygous for this non-synonymous SNP, which 
causes a glycine to serine (p.Gly519Ser) amino acid change in the disintegrin-like 
domain of ADAMTS17 and is predicted to be deleterious by SIFT
222
. Sequencing of 24 
clinically unaffected BFdB dogs revealed five to be heterozygous for the mutation and 
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19 were homozygous for the wild type allele. The association statistic of the variant 
with POAG based on the entire genotyping dataset (three POAG affected and 24 
unaffected) was P = 2.80 x 10
-7
. Genotyping of 85 dogs of unrelated breeds and 90 dogs 
of related breeds (BH, Standard Wire Haired Dachshund, Petit Basset Griffon Vendeen, 
Grande Basset Griffon Vendeen) for this variant with an allelic discrimination assay 
revealed them all to be homozygous for the wild type allele (Figure 5.3 and Figure 
5.4). 
 
Figure 5.3. Allelic discrimination plot in BFdB dogs 
Red squares indicate 10 BFdB dogs which are all homozygous for the wild type allele, 
blue squares indicate three BFdB dogs homozygous for the POAG variant and green 
squares indicate five heterozygous BFdB dogs. Black squares are non-template controls. 
The variant allele is detected by the relative intensity of VIC and the wildtype allele by 
the relative intensity of FAM. Rn = the normalised intensity of the reporter dye (FAM), 
ΔRn = Rn (post-PCR read) – Rn (pre-PCR read). 
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Figure 5.4. Allelic discrimination plot in affected, carriers and normal dogs 
Red squares indicate dog of breeds related to BFdB which are all homozygous for the 
wild type allele, blue squares indicate two BFdB control dogs homozygous for the 
POAG mutation and green squares indicate two heterozygous BFdB control dogs. Black 
squares are non-template controls. The variant allele is detected by the relative intensity 
of VIC and the wildtype allele by the relative intensity of FAM. Rn = the normalised 
intensity of the reporter dye (FAM), ΔRn = Rn (post-PCR read) – Rn (pre-PCR read). 
5.3.2.3 SP 
Visual scanning of the sequence reads, aligned with CanFam3.1, revealed only one 
variant that segregated with disease in all 10 POAG-affected and 5 unaffected SP dogs. 
This variant was a homozygous 6 bp deletion in exon 22 of ADAMTS17 (CanFam3.1 
chr3:40,935,387-40,935,393) and was confirmed by Sanger sequencing (Figure 5.5).  
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Figure 5.5. Next generation and Sanger sequencing results depicting the site of the 
6bp deletion in the SP with POAG. 
a) Visualisation of the 6 bp deletion in an affected dog in IGV. The location of this 
homozygous deletion is chr3:40,935,387-40,935,393 (CanFam3.1). b) 
Electropherograms depicting the site of the deletion. The red box delineates affected 
sequence in wild type and POAG-affected dogs. 
The variant represents an inframe deletion (c.3070_3075del) and is predicted to result in 
the loss of two valine residues in the resultant polypetide, while the rest of the amino 
acid sequence remains unchanged (p.Val1024_Val1025del) (Figure 5.6). 
 
Figure 5.6. DNA and corresponding protein sequences in a normal SP (top) and 
one affected with POAG (bottom) 
The 6 bases which are deleted are indicated by shading and the red arrow indicates the 
site of the deletion in the affected dog. The deletion is predicted to result in the loss of 
two valine residues in the resultant polypeptide. 
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A further 11 POAG-affected dogs were genotyped and were also found to be 
homozygous for the deletion. Forty-two clinically unaffected dogs over the age of 72 
months (controls) were genotyped for this allele; all were either homozygous or 
heterozygous for the wild type. The association statistic between the deletion and 
POAG based on the entire genotyping data set was P = 3.79 x10
-14
. Ninety five dogs of 
other breeds were all homozygous for the wild type allele. Since the discovery of this 
variant, genotyping of 100 further SP dogs without phenotype information has been 
performed which has enabled allele frequency within the breed to be calculated. Of 
these 100 dogs, 43 were homozygous for the wild type allele, 39 were heterozygous and 
18 were homozygous for the mutant allele.  This corresponds to a mutant allele 
frequency of 0.42. 
 cDNA sequencing results 5.3.3
cDNA sequencing was successfully achieved for all four primer pairs (two each for the 
6 bp deletion in SP and the 19 bp deletion in BH) in the control dog’s tissue and the 
relevant breed POAG-affected tissue. Visualisation of alignments in Staden confirmed 
the 6 bp deletion in the SP tissue, the 19 bp deletion in the BH and their absence in 
control tissue. This confirmed that both deletions were in coding genomic DNA and 
were transcribed into mRNA. 
 ADAMTS17 expression analysis in the SP and BH 5.3.4
In the SP, mean ΔCT was 3.76 for the case and 1.68 for the control providing a ΔΔCT of 
2.08. This corresponded to a 4.24 fold reduction in ADAMTS17 expression in the case 
compared to the control (P = 0.00063) (Figure 5.7). 
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Figure 5.7. Histogram demonstrating a four-fold reduction in expression of 
ADAMTS17 transcript in ocular tissue from a SP POAG case compared to a 
Golden Retriever control. Error bars represent standard deviation. 
In the BH, mean ΔCT was 1.95 for the case and 1.68 for the control providing a ΔΔCT of 
2.08. This corresponded to a non-significant 1.21 fold reduction in ADAMTS17 
expression in the case compared to the control (P = 0.3). 
 Discussion 5.4
The objective of these studies was to investigate ADAMTS17 as a candidate gene for 
POAG in three different dog breeds – the BH, BFdB and SP. ADAMTS17 was 
considered a strong candidate gene for study for several reasons. Firstly, a different 
mutation in ADAMTS17 has recently been reported to cause POAG in another dog breed 
by the AHT – the Petit Basset Griffon Vendeen74. Secondly, a different ADAMTS17 
mutation is known to cause another canine ocular phenotype, PLL, which is 
characterised by structural abnormalities and weakness of the lens zonular fibres with 
ultimate dislocation of the lens from the patellar fossa
122,123
. The ciliary body is not only 
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the site of origin of the lens zonular fibres and involved in their ongoing maintenance, 
but it also contributes to IOP. The ciliary body is both responsible for AH production 
and also forms the ciliary cleft via which AH is drained from the eye into the systemic 
circulation. It is also already known that ADAMTS17 is expressed within the ciliary 
body
122
. Thus, with consideration, it would not be surprising for different mutations 
within this gene to be associated with multiple intraocular phenotypes relating to 
abnormal function of the same anatomical region of the eye
122
.  Thirdly, ADAMTS17 
mutations cause Weill-Marchesani and Weill-Marchesani-like syndromes in 
humans
125,126
. These syndromes are rare connective tissue disorders which are 
characterised by various intraocular phenotypes including ectopia lentis, spherophakia, 
myopia and glaucoma along with joint stiffness and brachydactyly (Table 5.1). Clinical 
and genetic studies of these diseases suggest that ADAMTS17 also plays a role in lens 
zonule and connective tissue formation in humans
125,126
. Finally, mutations in closely 
related genes, ADAMTS10 and ADAMTSL4, are known to be involved in primary 
glaucoma and other ocular connective tissue disorders in both human and dog
68-
70,124,125,132,144
. 
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Table 5.1. Canine and human ADAMTS17 mutations and their phenotypes 
Species (breed 
or ethnicity) 
Ocular phenotype Systemic phenotype Exon / 
intron 
Mutation Nature of 
mutation 
State of 
zygosity 
Reference 
Previously identified 
Human (Saudi 
Arabian) 
Lenticular myopia, 
ectopia lentis, 
spherophakia, 
glaucoma 
Short stature Exon 18 c.2458_2459insG 
p.Glu820GlyfsTer23 
Frameshift Homozygous 
125
 
Human (Saudi 
Arabian) 
Lenticular myopia, 
ectopia lentis, 
spherophakia 
Short stature, 
brachydactyly, joint 
stiffness 
Intron 12 c.1721+1G>A Splice site Homozygous 
125
 
Human (Saudi 
Arabian) 
Lenticular myopia, 
ectopia lentis, 
spherophakia, 
Short stature Exon 4 c.760C>T 
p.Gln254* 
Nonsense Homozygous 
125
 
Human (Saudi 
Arabian) 
Spherophakia Short stature Exon 4 c.652delG 
p.Asp218ThrfsTer41 
Frameshift Homozygous 
127
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Species (breed 
or ethnicity) 
Ocular phenotype Systemic phenotype Exon / 
intron 
Mutation Nature of 
mutation 
State of 
zygosity 
Reference 
Human 
(Tunisian) 
Microspherophakia, 
myopia 
Short stature, 
congenital ichthyosis 
Exon 1-3 106.96 kb deletion Deletion Homozygous 
128
 
Human (Indian) Microspherophakia Short stature, 
brachydactyly 
Intron 5 c.873+1G>T Splice site Homozygous 
126
 
Dog (multiple 
breeds) 
PLL None Intron 10 c.1473G>A Splice site Homozygous 
122
 
Dog (PBGV) POAG None Intron 12 Large scale 
rearrangement 
Inversion Homozygous 
107
 
Identified in present study 
Dog (BH) POAG None Exon 2 c.193_211del 
p.Lys69GlyfsTer88 
Deletion Homozygous 
75
 
Dog (BFdB) POAG None Exon 11 c.1552G>A 
p.Gly519Ser 
Missense Homozygous 
75
 
Dog (SP) POAG 
 
None Exon 22 c.3070_3075del 
p.Val1024_Val1025del 
Deletion Homozygous 
219
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Although previous studies have implicated the importance of ADAMTS17 protein in 
mammalian intraocular physiology, its exact functions are unknown. ADAMTS17 (a 
disintegrin and metalloproteinase with thrombospondin type 1 motifs) is a member of a 
family of 19 known mammalian zinc-dependent metalloproteinases. Like other matrix 
metalloproteinases (MMPs), ADAMTSs have a role in ECM degradation and turnover 
as well as in proteolysis of cell surface and soluble proteins
223-225
. All ADAMTSs are 
secreted, extracellular enzymes that have a compound domain organisation comprising, 
from the amino terminus: a signal peptide followed by a pro-domain; a catalytic 
domain; and an ancillary domain that contains one or more thrombospondin type 1 
repeats (Figure 5.8)
223,226
. The pro-domain, amongst other functions, maintains latency 
and directs proper folding of the enzyme. The catalytic domain is comprised of 
metalloproteinase and disintegrin-like modules and confers the protease activity of the 
protein. The ancillary domain determines substrate specificity, localisation of the 
protease and its interaction partners
126,223,226
.  ADAMTS-like genes (ADAMTSL) encode 
proteins that resemble the ancillary domains of ADAMTS but lack their catalytic 
domains and it is thought that these proteins may modulate the activities of the 
ADAMTSs
225,226
. 
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Figure 5.8. ADAMTS17 protein structure denoting amino acid positions of the BH, 
BFdB and SP POAG mutations 
ADAMTS17 is composed of a signal peptide (SiP), prodomain (PRO), catalytic domain 
(CAT) (composed of the metalloproteinase (MP) and disintegrin-like domains (DL)) 
and an ancillary domain (ANC). The BH deletion corresponds to amino acid position 
(P) 65 which is located in PRO. The BFdB mutation corresponds to amino acid position 
519 which is located in DL. The SP deletion corresponds to amino acid position 1024 
which is located in ANC. Adapted from Kelwick et al.
223
. 
Although, the exact functions of ADAMTSs and ADAMTSLs are unknown, there is 
strong support of a functional association between ADAMTS proteins and fibrillin 
microfibrils. Mutations in ADAMTS10, ADAMTS17 and ADAMTSL4 result in 
phenotypes that resemble those caused by mutations in fibrillin-1 (FBN1)
125,132,227-229
. It 
is thus suggested that ADAMTS and ADAMTSL proteins are involved either in 
microfibril assembly, stability and anchorage or the formation of function-specific 
supramolecular networks having microfibrils as their foundation
134
. How this functional 
relationship might be involved in POAG is unclear. The ECM of the trabecular 
meshwork is thought to be important in regulating IOP
21
. In response to elevated IOP, 
specific proteases including MMPs are thought to be released by trabecular meshwork 
cells and are activated to degrade selected ECM molecules, leading to decreased 
resistance to AH outflow
230,231
. Furthermore, ADAMTS4 mRNA levels increase in 
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response to increased IOP and recombinant ADAMTS4 increase outflow facility in 
human and porcine anterior segments
144
. Thus, loss of function mutations in genes 
which encode the proteins involved in ECM degradation are likely to be associated with 
elevated IOP and glaucoma. 
 
Investigation of ADAMTS17 as a candidate gene for POAG in the three breeds studied 
led to the discovery of three novel breed-specific POAG-associated mutations.  
 BH 5.4.1
In the BH, a homozygous 19 bp deletion in exon 2 was present in all POAG-affected 
dogs. The deletion is predicted to alter the reading frame of the gene, leading to 87 
aberrant amino acids before introducing a premature stop codon at the 5’ end of exon 3 
(Figure 5.9), a predicted truncation of 86.1 % of the protein if the RNA is stable and not 
subjected to nonsense mediated decay. The observation from the ADAMTS17 transcript 
expression analysis that expression of the mutant transcript is not significantly different 
from the normal transcript suggests that nonsense-mediated decay does not occur. The 
truncated region of the protein includes the entire catalytic domain, which is expected to 
lead to complete loss of protein function. Unfortunately, it was not possible to directly 
demonstrate the presence of truncated protein (for example by Western blot) as 
sufficient ocular tissue was only available for RNA (and not protein) extraction. 
Further supportive evidence for the deletion as the causative mutation of POAG in the 
BH was derived from genotyping. The genotyping cohort included 223 BH which had 
undergone complete ophthalmic examination and were found to be free from clinical 
signs of POAG at the time. Fifty of these were significantly older than the POAG cases 
and were thought to be at very low risk of developing POAG in the future. These dogs 
served as controls and none were found to be homozygous for the identified mutation. 
Genotyping of the entire cohort allowed calculation of carrier frequency within the 
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breed within the United Kingdom. These dogs were all resident in and distributed 
widely around the United Kingdom and DNA had been collected from them for a 
parallel study. They can therefore be considered a random cohort with respect to the 
current study and relatively representative of the BH population in the United Kingdom. 
The frequency of the mutant allele (0.081) and expected frequency of dogs affected with 
POAG (0.007) are fairly high.  
 
Figure 5.9. DNA and corresponding protein sequences in a normal BH and one 
with POAG. 
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The position of the deletion is indicated with a black arrow and the 19 deleted bases are 
indicated by shading in the DNA sequence of the normal (wild type) dog. The deletion 
generates a frame shift leading to 87 aberrant amino acids (underlined) before the 
introduction of a premature stop codon, indicated by shading in the POAG-affected dog. 
 BFdB 5.4.2
In the BFdB, the p.Gly519Ser  variant identified to be associated with POAG 
corresponds to the disintegrin-like domain of ADAMTS17 which is essential for the 
catalytic function of the protein (Figure 5.8)
223
. This glycine is a highly conserved 
residue within the disintegrin-like domain across the entire ADAMTS family and also 
across species (Figure 5.10 and Figure 5.11), providing strong evidence that this SNP 
is causal for POAG in this breed. Furthermore, 85 dogs of unrelated breeds and 90 dogs 
of related breeds were all homozygous for the wild type allele indicating that this 
variant is not a common polymorphism within the wider canine population. Owing to 
the lack of a sufficiently large cohort of randomly selected dogs, it was not possible to 
estimate the mutant allele frequency within the BFdB population. 
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Figure 5.10. A selected region of the amino acid sequence of the disintegrin-like 
domain in the entire ADAMTS family in dogs 
The region is centred on the glycine residue (in red) which is highly conserved and is 
the site of the missense mutation in the BFdB. 
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Figure 5.11. A selected region of the amino acid sequence of the disintegrin-like 
domain of ADAMTS17 in 31 species 
The region is centred on the glycine residue (in red) which is highly conserved and is 
the site of the missense mutation in the BFdB. 
 SP 5.4.3
In the SP, a 6 bp deletion in exon 22 of ADAMTS17 was significantly associated with 
POAG.  This represents an inframe deletion and is predicted to result in the loss of two 
valine residues in the ancillary domain of the resultant protein. These two valine 
residues are highly conserved across species (Figure 5.12) and mutations affecting this 
domain have already been shown to be strongly associated with ectopia lentis and other 
ocular phenotypes in humans
125,223,232
. Further evidence in support of this mutation as 
causative of POAG in the SP is derived from the significant four-fold reduction in 
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ADAMTS17 mRNA expression in affected ocular tissue and from the fact that the 
mutation was not found in 95 dogs of other breeds.  
 
Figure 5.12. A selected region of the amino acid sequence of the ancillary domain 
of ADAMTS17 in 44 species. 
The two valine residues (delineated in red) predicted to be removed by the 6 bp deletion 
in the POAG-affected SP are highly conserved.  
 DNA Testing for POAG 5.4.4
The ultimate aim of these studies was to develop DNA tests for POAG for those breeds 
in which disease-associated variants were discovered, and make these tests available to 
breeders. Level of interest in DNA testing varied between breeds but was sufficient for 
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the BH and SP to justify development and provision of these diagnostic tools. The DNA 
tests should have multiple benefits:  
 DNA tests will allow for identification of genetically affected young dogs which 
have not yet developed POAG. This will allow for longitudinal clinical 
monitoring of these dogs for early signs of clinical disease which will allow 
improved phenotypic characterisation of the disease and facilitate understanding 
of POAG pathogenesis.  
 Monitoring of genetically affected dogs for early signs of disease will also allow 
earlier medical and/or surgical intervention which may improve the prognosis 
for vision although, as yet, the most appropriate treatment remains unknown.  
 DNA tests will also enable breeders to eliminate this painful and blinding 
disease from their breeds over time, whilst allowing them to judiciously breed 
with carriers which may have desirable inherited characteristics which it would 
be advantageous to retain. 
 The ability to safely breed with carriers will also avoid the detrimental loss of 
genetic diversity in these breeds. 
 Conclusion 5.5
Three separate mutations in ADAMTS17 are reported that are all strongly associated 
with the same ocular phenotype, POAG, in three different dog breeds. In all three 
breeds, and in line with all other previously reported canine ADAMTS17 mutation-
associated phenotypes, POAG appears to be an autosomal recessive condition. This 
study provides further evidence of the importance of ADAMTS17 in intraocular 
physiology and increases the total number of reported canine ADAMTS17 mutations to 
five (Table 5.1). Further work, however, is required to understand how ADAMTS17 is 
involved in POAG pathogenesis. 
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6 General discussion and future perspectives 
This study was conceived with three main aims: 
1. To provide robust and current PLD prevalence data for seven dog breeds known 
to be affected by PLD and PCAG.  
2. To investigate the genetic basis of PLD and PCAG in four dog breeds. 
3. To investigate the genetic basis of POAG in three dog breeds. 
Although the results of these studies have already been discussed in the relevant 
chapters, some further discussion of the most significant findings and future 
possibilities for research is warranted. 
 Prevalence of PLD 6.1
The prevalence of PLD in seven breeds known to be affected by PLD and PCAG has 
been published in three separate publications
45,46,192
. These data will aid breed clubs and 
veterinary health schemes in future surveillance of this abnormality and be informative 
of the benefit of screening for PLD prior to breeding. Previous PLD prevalence data had 
only been published for the FCR some 20 years ago and the current data suggest that the 
widespread use of gonioscopy testing in this breed has been very successful in reducing 
PLD (and possibly PCAG) prevalence in this breed
32
. The PLD data have also 
influenced the stance of the BVA/KC/ISDS Eye Scheme, with regard to 
recommendations regarding the necessity to perform gonioscopy in certain breeds, the 
frequency of gonioscopy eye testing and how PLD could be better graded than the 
existing system.  
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Perhaps, the most interesting finding of the investigations into PLD prevalence relates 
to evidence for PLD progression. In six of the seven breeds studied, there was 
significant association of PLD with age and it was also possible to show that PLD is 
progressive in > 50 % of individual dogs of a single breed. These findings corroborated 
those of Pearl et al. who reported PLD progression in 40 % of individual FCR
35
. The 
mechanisms by which an abnormality, previously considered to be congenital and static, 
can undergo significant progressive change in certain dogs are unknown but will be of 
important research interest for the future and will likely explain why only a minority of 
dogs with PLD go on to develop PCAG. If the underlying genetic variants which 
differentiate dogs with static PLD from those which develop PCAG can be determined, 
this would allow for accurate identification of at risk individuals and their elimination 
from the breeding population whilst, at the same time, allowing dogs with PLD but 
without the genetic risk factors for PCAG, to be used for breeding and therefore 
maintain genetic diversity. The genetic investigations of PCAG and PLD in the BH 
revealed two loci to be associated with PCAG but not PLD. These loci may harbour the 
genetic factors that separate static and progressive PLD although a separate GWAS to 
compare these two phenotypes (static and progressive PLD) would be required to 
demonstrate this. 
To further understand the mechanisms underlying PLD progression, a better 
characterisation of the phenotype of PLD and the deeper changes that occur within the 
ciliary cleft is needed. Gonioscopy only permits visual evaluation of the ICA and, if 
PLD is extensive, not even the anterior ciliary cleft can be examined. Although PLD is 
considered a risk factor for PCAG, it is likely that other anatomical and physiological 
components of the AH outflow pathways are at least involved or may be causative of 
PCAG itself. Serial characterisation of the AH outflow pathways of large numbers of 
individual dogs by digital photography, high resolution ultrasound biomicroscopy 
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and/or ocular computed tomography should shed light on the chronological changes in 
those eyes which demonstrate PLD progression and develop PCAG. Furthermore, it is 
not yet known if congenital PLD differs from adult progressive PLD. To investigate 
this, histological studies of numerous dogs of different ages would need to be 
performed, however, such studies are unlikely to be performed as they would be 
impractical, expensive and unethical. 
A possible mechanism which may explain progressive changes in the AH outflow 
pathways may relate to abnormalities in maintenance and turnover of the ECM. As 
discussed in 1.1.2.1, the ECM is critical in providing resistance to AH outflow and IOP 
regulation and, thus, any changes in its formation, processing or molecular interactions 
may play important roles in the pathogenesis of glaucoma. The research presented in 
this thesis, and the work of others, have shown highly significant associations of 
ADAMTS10 and ADAMTS17 with canine POAG. These genes encode enzymes 
involved in ECM degradation and turnover and loss of function mutations in these 
genes is thought to play a role in IOP elevation and glaucoma development. These 
canine POAG genes, and related genes, would make logical candidates for canine 
PCAG and, indeed, the microsatellite-association work provided some limited evidence 
of association of ADAMTS17 with this phenotype. 
 Genetic investigations of PLD and PCAG 6.2
 Limitations of GWAS 6.2.1
PCAG is considered complex, likely involving multiple genetic, and possibly 
environmental, factors. GWAS were used to identify chromosomal loci associated with 
PCAG and PLD and the findings are likely to prove to be significant breakthroughs for 
PCAG, paving the way for other techniques to explore these regions for candidate 
causal variants and genes. GWAS have been used extensively over the last decade to 
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improve the understanding of the genetic basis of many complex traits by revealing 
associated susceptibility loci. This has provided invaluable insights into the allelic 
architecture of many multifactorial traits. In humans, GWAS typically involves 
thousands of subjects whereas, in the dog, much more modest samples numbers are 
used because many fewer canine samples are required to detect significant association 
compared to human studies, owing to the extensive LD, and also owing to financial 
constraints and difficulty in case and control collection
85
. A study by Bianchi et al. 
demonstrated how GWAS can be used with relatively modest sample numbers to detect 
associations with complex canine disease
207
. They investigated canine hypothyroidism – 
a complex clinical disease thought to be caused by a combination of genetic and 
environmental factors. They first performed GWAS in three individual breeds: 
Hungarian Vizslas (n = 74), Rhodesian Ridgebacks (n = 95) and Gordon Setters (n = 
165). Association with disease was found within the same locus for each breed 
although, admittedly, Bonferroni significance was only reached for the largest (Gordon 
Setter) study. Subsequent meta-analysis of summary data from these three studies was 
used extremely effectively to increase the power of the individual GWAS and confirm 
the associated shared locus which reached Bonferroni significance. Some interesting 
comparisons can be made between this and the GWAS studies reported in this thesis. 
The GWAS reported herein also resulted in some significant and promising findings 
using very modest numbers. In the BH, two loci were found to be associated with 
PCAG relative to PLD using a total of only 81 samples (24 PCAG cases and 57 PLD 
cases) and level of association was increased when combining controls with the PLD 
cases (a total of 118 samples). It was not possible to show significant association with 
PCAG in the other individual breed analyses using similar sample numbers. This likely 
relates to an increased complexity of PCAG in these breeds with the small sample sizes 
used being too modest to provide sufficient statistical power for detecting small genetic 
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effects. This is particularly true if the risk variant is a rare allele with a small OR
233
. In 
human studies, when the causal SNP is rare (MAF < 10 %), a sample size of 3,000 may 
still be underpowered to detect small genetic effects
234
. For complex traits in canine 
GWAS, approximately 100 cases and 100 controls are required to detect a five-fold risk 
allele and 300 cases and 300 controls to detect a two-fold risk allele
85,103
. Although 
these studies suggest that the GWAS reported here were underpowered for the most 
part, sample numbers compare favourably to other canine GWAS for complex disease 
(including those for PCAG) that have also used modest sample numbers and have 
reported significant findings
106,170,235,236
. Evidence for the negative impact small sample 
size had on the GWAS reported here, comes from the meta-analysis in the DDT and 
WSS. No association with PCAG was found in the GWAS of PCAG cases and controls 
in either breed in the individual breed analyses using 83 DDT and 69 WSS. However, 
when summary data from these analyses were meta-analysed (152 samples), significant 
association with disease was discovered revealing a shared locus for PCAG in the DDT 
and WSS. Thus, similar to that of Bianchi et al., the meta-analysis approach reported 
here improved power to detect association of disease risk.  Further samples will be 
genotyped in the future, in the hope that significant associations can also be shown for 
individual breed GWAS in the FCR, WSS and DDT. 
Current GWAS may also have insufficient power to detect true association of SNP 
variants with disease by virtue of design. In humans, because > 10 million common 
genetic variants are likely to exist in the human genome, and only around 500,000 
variants are genotyped in individuals in GWAS, only a fraction of all genetic variants is 
being studied
237
. In the GWAS presented, the SNP array used contained 172,115 SNPs 
which have a mean spacing of 13 kb which, although would be sufficient for studies in 
single gene diseases, would have much less power to detect associations with diseases 
caused by multiple genetic variants in particular where sample sizes are small and there 
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is variable or poor tagging of causal variants
85,103
. Hayward et al. showed, by using 
simulation studies, that reducing the mean SNP marker spacing in canine GWAS to 2 
kb resulted in a significant increase in power for detecting moderate effect loci and, 
thus, the availability of denser canine arrays will improve the power of GWAS to detect 
associations with complex disease
238
. The most recent Illumina CanineHD BeadChip 
contains over 220,000 SNP markers to improve density across breeds, fill in gaps and 
replace poorly tagged coding variants. Furthermore, ThermoFisher Scientific has 
recently launched a canine genotyping array containing over 670,000 variants equally 
distributed across the chromosomes. Future work is needed, however, to assess what 
level of increased power is actually afforded with the use of these new arrays. 
Another important potential limitation of GWAS is the possibility of false positive 
associations of tested SNPs with disease.  In human GWAS, nearly 500,000 SNPs are 
commonly scored and, even if there is no true association of any of these SNPs with 
disease, it is still common for some of the statistical tests performed to offer P-values of 
the order of 10
-6
, and the inference of false positive association with disease.  False 
positive calls may be less of a problem in canine GWAS, in which many fewer SNPs 
tend to be studied (in the region of 90,000 SNPs were used in the GWAS reported in 
this thesis). Also, to reduce the possibility of false positives in the GWAS, Bonferroni 
correction was used which is considered a particularly stringent means of correction for 
canine GWAS and perhaps, if anything, is more likely to result in false negative 
calls
207,239
. Confirmation of true association of SNPs with disease risk, however, is best 
achieved by replication studies but this is often not possible, particularly in dogs, owing 
to the lack of adequate numbers of samples in a given population.  
 Imputation 6.2.2
Given the modest sample numbers combined with the stringent method of correction 
used in the reported GWAS, false negative calls are very likely to have been 
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experienced. Imputation has been used in human studies to reduce the possibility of 
false negative calls. Imputation has now become an essential tool in the analysis of 
human GWAS and allows geneticists to accurately evaluate the evidence for association 
at genetic markers that are not directly genotyped
237
. Genotype imputation has been 
used widely in the analysis of GWAS to boost power, fine-map associations and 
facilitate the combination of results across studies using meta-analysis
240
. Imputation 
exploits the correlated structure of genomic variation to impute (predict) genotypes at 
missing sites and to then test for association with both observed and unobserved 
imputed SNPs
241
. Imputation may, therefore, allow GWAS to reveal associations with 
disease at loci which would otherwise go undetected. This is because, in GWAS, the 
association of SNPs with disease risk will be weakened by any departure from perfect 
LD between the observed (tested) SNP and the unobserved risk-enhancing SNP. 
Imputation can ‘close the gap’ between observed unassociated SNPs and unobserved 
associated SNPs by incorporating haplotype information of observed SNPs along with 
LD structure of the full HapMap
242
. In humans, imputation can be highly accurate (> 98 
%) in regions of the genome but reduces particularly in ‘recombination hotspots’241. 
Imputation can also be used to generate SNP data for GWAS from low-coverage WGS. 
Cai et al. reported how they imputed genotypes across 11,670 human samples, using 1.7 
X WGS data, allowing them to perform a successful GWAS of major depressive 
disorder as part of the CONVERGE project
243
. To the author’s knowledge, imputation 
has not yet been used in the genetic investigation of canine complex disease. This most 
likely relates to the lack of availability of a canine haplotype map. The situation may 
change in the future, however, as more and more dogs are genotyped and these data are 
subsequently shared. The accuracy of imputation, however, may be variable as it will 
depend on the availability of sufficient genotyping data for the specific population of 
interest (e.g. a particular breed). 
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 Copy number variant screening 6.2.3
Genome-wide copy number variant (CNV) screening presents another method to 
investigate the genetic basis of complex disease and, thus far, has only experienced 
limited use in the dog. CNV is a type of genomic structural variation in which sections 
of the genome are repeated or deleted and the number of repeats/deletes in the genome 
varies between individuals. CNVs may represent up to 10 % of the human genome and 
their effects range from benign to directly pathogenic. Pathogenic consequences of 
CNVs include altered gene regulation and structure and unmasking of recessive alleles, 
and their importance has been shown in several human complex diseases such as 
Crohn’s disease, rheumatoid arthritis and psoriasis244-246. The importance of CNVs in 
canine phenotypes has also been demonstrated with a duplication event encompassing 
three genes causing the dorsal hair ridge in Ridgeback dogs and an upstream gene 
duplication causing skin wrinkling in Chinese Shar-Pei
247,248
. Genome-wide CNV scans 
can be performed by various methods but one is whole-genome SNP-genotyping arrays 
which potentially allow CNV detection in conjunction with GWAS making it an 
attractive tool. Molin et al. presented the first CNV investigation based on the 
CanineHD 170 K genotyping array used in this thesis and identified 29 novel CNV 
regions
249
. The development of a growing catalogue of canine CNV regions will act as a 
rich resource for future investigation of canine complex disease. 
 Identification of candidate genes and causal variants 6.2.4
A main challenge of GWAS in investigating complex disease is to pinpoint causative 
genes as the majority of GWAS hits are in non-coding or intergenic regions because 
complex disease is often caused by disturbance to biological networks, not by isolated 
genes or proteins. Regulatory SNPs can influence gene expression through a number of 
mechanisms that include the three dimensional organisation of the genome, RNA 
splicing, transcription factor binding, DNA methylation, and long non-coding 
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RNAs
250,251
. Investigation of SNPs with complex trait disease in dogs with potential 
regulatory function through expressed quantitative trait loci (eQTL) studies or other 
methods is currently lacking. Recently, attention has turned towards use of genome-
wide gene association analyses (GWGAS) to help detect the most relevant, likely causal 
genes. MAGMA is a tool for gene analysis and generalised gene-set analysis of GWAS 
data and can be used to analyse both raw genotype data as well as summary SNP P-
values from a previous GWAS or meta-analysis
252
. Along with performing imputation 
methods in their GWAS, Hammerschlag et al. also performed a GWGAS using 
MAGMA in their investigations of persistent insomnia
253
. They used 19,427 protein 
coding genes and annotated all the SNPs of the association analysis to these genes 
resulting in 18,355 genes being covered by at least one SNP. The advantage of GWGAS 
is that it has the potential to identify genes in which multiple genetic variants may mask 
effects that are not significantly strong enough to be picked up by GWAS. Conversely, 
however, and because GWGAS takes all SNPs within the gene into account, it is 
possible that a gene that is truly associated with disease is not identified by GWGAS 
because the genes may harbour many more tested SNPs that do not show an association. 
To investigate causal variants for PCAG in the loci determined by the GWAS reported 
in this thesis, a NGS WGS approach using one or three cases (depending on the breed) 
and > 500 controls was employed. Such an approach has previously proven successful 
in identifying causal variants in single gene canine disorders
254-256
. It is perhaps not 
surprising, that a similar approach to investigate complex disease using so few cases 
was unsuccessful. Future studies using WGS approaches to elucidate candidate PCAG 
causal variants should take several factors into account. Firstly, a much larger sample 
cohort is likely to be needed to detect causal variants for PCAG than for single gene 
disorders. Secondly, efficiency of a WGS approach will be improved by selecting 
samples on the basis of a homozygous genotype for the GWAS top SNP. Unfortunately, 
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owing to timing logistics, GWAS were performed following the acquisition of WGS 
data which reduced the number of useful WGS for analysis and these were all 
heterozygotes. Since the completion of the PhD, however, our GWAS findings in the 
BH have been published which has aided in application for further funding
205
. WGS 
will now be performed in 15 BH comprising 9 with PCAG which are homozygous for 
one or both of the two top GWAS SNPs and 6 with PLD which are homozygous for the 
alternative alleles. Finally, because the use of a large number of WGS is likely to be 
cost prohibitive for most modestly sized canine research laboratories, future availability 
of imputation could potentially be used to reduce costs.  
Further investigation of canine PCAG should probably integrate several of the above 
discussed methodologies. Integrative approaches that combine multiple forms of data 
can more accurately capture pathway associations and so provide a comprehensive 
understanding of the molecular mechanisms that cause complex diseases
257
.  
 Genetic investigation of POAG 6.3
In this thesis, highly significant associations of three different ADAMTS17 mutations 
with canine POAG are reported. ADAMTS17 is a strong candidate gene for POAG as 
the role of metalloproteinases in AH outflow resistance and IOP has long been 
suggested, being hypothesised to relate to changes in the amount or composition of the 
ECM of the outflow pathways
21,144,258
. Furthermore, several studies have identified the 
matrix metalloproteinase gene MMP-9 as a candidate gene for POAG and PACG in 
humans
259-262
. 
Functional evidence for the causality of the ADAMTS17 mutations reported in this 
thesis, however, was lacking mainly due to lack of tissue availability. Although, it was 
possible to demonstrate reduced ADAMTS17 expression for one of the POAG mutations 
(the 6 bp deletion in the SP), this was only performed using technical replicates of a 
single case and control. Additional experiments could be undertaken to assess the 
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effects the three different mutations have on ADAMTS17 protein, including whether or 
not the protein is expressed in truncated forms or whether they are differentially 
expressed in the AH outflow pathways of biological replicates of each breed. 
Furthermore, immunohistochemistry could be used to pinpoint the precise cellular 
location of protein expression and whether the mutation causes mislocalisation. 
RNA and protein experiments could also be expanded to include genes and proteins 
known to be involved in the same biological pathways or, indeed, to identify novel 
genes/proteins in the same pathways. 
To further help understand possible effects of the mutations on protein function, it 
would be interesting to understand what effect the different mutations have on 
ADAMTS17 structure. Structural modelling can be used to predict possible disruption 
caused by different variants and different programs are available to facilitate this
263
. 
Kuchtey et al. reported a Gly661Arg variant to be associated with POAG in the Beagle 
and used homology modelling to locate the position of the residue
68
. This was 
suggestive that the Gly661 residue was located within a tight turn, buried within the 
interface between the cysteine rich and thrombospondin repeat domains. The long polar 
side chain of arginine substituted at this position was predicted to disrupt the normal 
protein fold. 
Disruption of folding may reduce the stability of the protein which, in turn, is likely to 
have important functional consequences. Protein half-life measurement can be used to 
demonstrate, in vitro, the effect variants have on protein stability. Kuchtey et al. used 
commercially available mutagenesis and transcription/translation kits to demonstrate 
that the Gly661Arg form of ADAMTS10 is less stable, with a protein half-life of 
approximately 40 % of normal ADAMTS10. It would be interesting to perform similar 
experiments with the ADAMTS17 variants reported in this thesis. 
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In both humans and dogs, the TM undergoes ultrastructural changes with advancing age 
which are more pronounced in POAG patients
142,264
. These changes include thickening 
of the sheaths that surround elastin fibres and are composed of ECM, including fibrillin. 
How the canine ADAMTS10 and ADAMTS17 mutations might be involved in these 
ultrastructural changes is entirely speculative but it is interesting to note that, for both 
enzymes, fibrillin 1, has been proposed as a substrate
122,136
. 
 Thesis conclusion 6.4
To conclude, this thesis project has led to the provision of robust and current PLD 
prevalence data for seven dog breeds along with evidence of PLD progression which 
have formed the basis of three separate publications. Investigations of the genetic basis 
of PLD and PCAG led to the discovery of two novel PCAG loci in the BH and a shared 
PCAG locus in the DDT and WSS. These loci will be the focus of deeper investigation 
for causal variants in the future. The discovery and publication of three breed-specific 
POAG-associated mutations has not only further highlighted the importance of 
ADAMTS17 in intraocular physiology and AH outflow, but, through the provision of 
commercially available DNA test, has also had a significant and beneficial impact on 
canine welfare. 
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I. Buffers and solutions 
 Nucleon Reagent A: 6.304 g Tris Hydrochloride, 438.12 g Sucrose, 4.066 g 
MgCl2, 40 mL Triton X-100, Make up to 4 L with MQ, Adjust to pH 8.0 with 
40 % NaOH.  
 Nucleon Reagent B: 63 g Tris Hydrochloride, 22.3 g EDTA, 8.8 g NaCl, 800 
mL MQ, Adjust to pH 8.0 with 2M NaOH, Adjust to 1 litre with MQ and then 
add 10 g Sodium Dodecyl Sulphate (SDS).  
 1X TE Buffer (10mM Tris-HCL, 0.1mM EDTA): 10 mL 1 M Tris-
hydrochloride, 2 mL 500 mM EDTA, Add MQ to 1 L, Adjust to pH 8.0.  
 STOP: 10 mL Glycerol, 4 mL 500 mM EDTA, 1 mL 1M Tris, 1 mL 
Bromophenol blue. Diluted 1:5 with 1X TAE Buffer.  
 50X TAE Buffer: 242 g Tris base, 57.1 mL Glacial acetic acid, 37.2 g EDTA, 
Add double-distilled water to 1 L, Adjust to pH 8.0.  
 2-Log DNA ladder: 120 μL STOP, 240 μL 1X TAE Buffer, 40 μL 500 μg/mL 2-
Log DNA ladder.  
 SBDD Buffer: 160 mL 1M Tris base, 3 mL 1 M MgCl2, 50 mL 
Tetramethylenesulphone, 290 mL MQ.  
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II. PCR and sequencing reaction components 
Table A1. Microsatellite genotyping by AFLP. 
Component Volume/reaction (µL) Final concentration 
Genomic DNA (20ng/µL) 2.00  
dNTPs (1.5mM) 1.60 200µM 
Tailed Forward Primer (20µM) 0.10 0.17µM 
Reverse Primer (20µM) 0.25 0.42µM 
FAM-labelled tailed primer (10µM) 0.60 0.5µM 
HotStartTaq (5U/µL) 0.25 0.10U/µL 
Buffer (10X) 1.20 1X 
MilliQ 6.00  
Total 12.00  
Table A2. ADAMTS17 exon resequencing. 
Component Volume/reaction (µL) Final concentration 
Genomic DNA (20ng/µL) 2.00  
dNTPs (1.5mM) 1.60 200µM 
Forward Primer (20µM) 0.50 0.83µM 
Reverse Primer (20µM) 0.50 0.83µM 
HotStartTaq (5U/µL) 0.12 0.05U/µL 
Buffer (10X) 1.20 1X 
MilliQ 6.08  
Total 12.00  
*The Qiagen Q solution additive (1X) was used for GC rich amplicons (exons 1 & 2). 
Table A3. BH POAG variant genotyping. 
Component Volume/reaction (µL) Final concentration 
Genomic DNA (20ng/µL) 2.00  
dNTPs (1.5mM) 1.60 200µM 
Forward Primer (20µM) 0.24 0.4µM 
Reverse Primer (20µM) 0.24 0.4µM 
HotStartTaq (5U/µL) 0.48 0.04U/µL 
Buffer (10X) 1.20 1X 
MilliQ 6.24  
Total 12.00  
  
Appendix II PCR and sequencing reaction components 
237 
 
Table A4. BFdB and SP variant genotyping. 
Component Volume/reaction (µL) Final concentration 
Genomic DNA (20ng/µL) 2.00  
dNTPs (1.5mM) 1.60 200µM 
Forward Primer (20µM) 0.5 0.83µM 
Reverse Primer (20µM) 0.5 0.83µM 
HotStartTaq (5U/µL) 0.12 0.05U/µL 
Buffer (10X) 1.20 1X 
MilliQ 6.08  
Total 12.00  
Table A5. BFdB POAG variant assay. 
Component Volume/reaction (µL) Final concentration 
Genomic DNA (20ng/µL) 2.00  
Kapa Probe Fast qPCR (2X) 4.00 200µM 
Primer/probe assay (40X) 0.2 0.83µM 
MilliQ 1.80  
Total 8.00  
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III. Thermal cycling parameters 
Table A6. Microsatellite genotyping. 
Step Temperature Time 
Initiation 94 oC 4 m 
Denaturation 94  oC 30 s 
30 s       X 30 
1 m Annealing 55 
oC 
Elongation 72 oC 
Denaturation 94 oC 30 s 
30 s       X 8 
1 m Annealing 50 
oC 
Elongation 72 oC 
Final elongation 72 oC 30 m 
Final hold 12 oC ∞ 
Table A7. ADAMTS17 exon resequencing. 
Step Temperature Time 
Initiation 95 oC 10 m 
Denaturation 95  oC 30 s 
30 s       X 35 
1 m Annealing 56 
oC 
Elongation 72 oC 
Final elongation 72 oC 10 m 
Final hold 12 oC ∞ 
Table A8. BH POAG candidate variant genotyping. 
Step Temperature Time 
Initiation 95 oC 5 m 
Denaturation 95  oC 30 s 
30 s       X 35 
30 s Annealing 60 
oC 
Elongation 72 oC 
Final elongation 72 oC 30 m 
Final hold 12 oC ∞ 
Table A9. BFdB POAG candidate variant genotyping. 
Step Temperature Time 
Initiation 95 oC 5 m 
Denaturation 95  oC 30 s 
30 s       X 35 
30 s Annealing 57 
oC 
Elongation 72 oC 
Final elongation 72 oC 5 m 
Final hold 12 oC ∞ 
 
Table A10. SP POAG candidate variant genotyping. 
Step Temperature Time 
Initiation 95 oC 5 m 
Denaturation 95  oC 30 s 
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Annealing 60 oC 30 s       X 35 
30 s 
Elongation 72 oC 
Final elongation 72 oC 5 m 
Final hold 12 oC ∞ 
Table A11. Allelic discrimination assay. 
Step Temperature Time 
Denaturation 95 oC 3 s 
15s 
 
X 40 
Annealing 60 oC 
Final hold 12 oC ∞ 
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IV. Primers 
Table A12. Primers for microsatellites flanking candidate genes. 
Candidate gene microsatellite name Microsatellite* Start genomic coordinate (CanFam3.1) Tail-Forward primer sequence (5’-3’)+ Reverse primer sequence (5’-3’) Product size (bp) Tm (oC) 
ADAMTS10_M1 (GT)22 Chr20:53,027,087 GGTGGTGTTTCAGACCAGTTG GGGAGACACTAGAGAAAGAGGAAC 186 57 
ADAMTS10_M2 (GA)14 Chr20:53,132,686 CAGATGAGCTGTCCTCCTTCC GTGAAACCAGTCACCATCTCC 113 57 
ADAMTS17_M1 (CA)19 Chr3:40,636,343 GGCTACCTTGCATCAGTAGCTT GAGGTCAGTGAAAGATGCAGTG 136 57 
ADAMTS17_M2 (GT)19 Chr3:40,920,305 TCCAGAGGACACAGTGGAACT TAGCAATGGGAACGTCTGTTT 159 57 
C1QTNF5_M1 (CA)15 Chr5:14,349,500 ACTCATCCATTCCCAGGTAGC GTTAAGGATCCTGTGTGTCAAGG 100 57 
C1QTNF5_M2 (CA)13 Chr5:14,630,315 ATGTGGCACCATTTGTGAGC GGGCACTACTCTACCTGGTTCC 180 57 
CHX10_M1 (GT)16 Chr8:46,605,605 ATGTCAGCAGAGCAGGTATGG ATTCCTGAGCACTGCAAACC 169 57 
CHX10_M2 (CA)16 Chr8:47,514,640 GAGGATATGAGGTCAAGGATGG AGGTTCCCATCAACAATTTCC 144 57 
COL1A2_M1 (CA)17 Chr14:19,849,088 TCTCTCCAACACCTGAACCAC TAATTGTTGGTGGAACCGAGA 137 57 
COL1A2_M2 (CA)19 Chr14:20,593,102 AACCACAGGTGTGCTTAAAGG GTTCCCTGCCATGTTTATGC 134 57 
CYP1B1_M1 (CA)20 Chr17:30,265,057 TAGGGTGGGAGGAAGAGGATA GTAAGTGCCCTGGTGTGGTAA 179 57 
CYP1B1_M2 (GT)19 Chr17:30,339,848 TGGACCATCTTGCTTTGTACC GGTCATTTGCCTTGATGTGAC 186 57 
HGF_M1 (GT)15 Chr18:21,311,362 GCGGTTTAGAGCCACCTTTAG TCATTCTGGATGAATAGGCTTG 193 57 
HGF_M2 (CA)19 Chr18:21,382,566 TGGTTGGTAAATTAATAGGCAACA AAACCAACATGTTTCCCTTCC 176 57 
MMP_M1 (CA)17 Chr24:33,120,996 CTGCACTTGCATTACCTCTGG TTAAGAGCTCAGGCTTTGCTG 192 57 
MMP_M2 (CA)18 Chr24:33,312,853 AGGGCACTCAGGAAGACAGG CACAGGGAGTCTGCTTCTCC 174 57 
NOS3_M1 (CA)18 Chr16:14,901,925 AAGCCTTGTGGCTTAGTGGAT AACACCTCCTCCTTCCGTAGA 184 57 
NOS3_M2 (CA)17 Chr16:15,224,341 TATGCATGTGTGCCCTCAGT GGGCAAAGGCAAGGATATAAA 180 57 
RAB22A_M1 (CA)16 Chr4:43,040,954 GTCTCCCTTCCCAATGAGG GGACAAATGAGTAGCCCTTGG 177 57 
RAB22A_M2 (CA)17 Chr4:43,173,556 AAGAAGAGAGCTGGGCAGATT GAGGGAGCCTGGTCTTATTGT 153 57 
SRBD1_M1 (GA)12 Chr10:47,753,474 GAGGCTGCTTGGAGTCTTAGG TGATGGAAGTGACTTTGGTAGC 143 57 
SRBD1_M2 (CA)20 Chr10:47,866,917 CTTAGGGATACAGAAACACATGG TATTGGAAAGGAGGCATAAGG 173 57 
M1 = microsatellite upstream of gene, M2 = microsatellite downstream of gene, *The number is the number of times the dinucleotide in brackets is repeated, +Tail= 5’-TGACCGGCAGCAAAATTG-3’
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Table A13. PCR primers for PCAG candidate variant genotyping. 
Target name/ genomic 
coordinate (CanFam3.1) 
Forward primer sequence 
Reverse primer sequence 
Amplicon size 
(bp) 
Annealing temp 
(oC) 
NEB 
chr19:52,857,772 
ACCAGTAAGGTGAGTGCTTTCC 
AGGCTATGATCTCAGAACTGATGC 
103 57 
CXCR 
chr37:24,861,167 
TCCTTACCCTATCGAGTGGTTG 
GAGAGAGGCAGAGGAAGAAGG 
278 57 
ATRN 
chr24:17,727,188 
TTTCTCTCCCTCCAAGACTGG 
TTCCCATAGTGAGCCATTAGGT 
218 57 
PTPRA 
chr24:18,222,425 
TGGCTCAGTTGGTAAAGCATC 
GTCCTGGGTTGCCTCCTTAC 
377 57 
FCR 
chr:28:14,624,548 
CTGCCCAAGAATCACAATTTC 
CCTATCCTCTTACTCATCTTTCTGAC 
300 57 
DDT 
chr28:19,274,452 
GCCTGGAGAAACAGATTGCT 
TAAGGCCACATTGAGATTTGC 
390 57 
WSS 
Chr28:19,274,198 
GTGGTTTACGTGGCAACATTT 
TTGGCCAAGAGATGAGCTG 
291 57 
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Table A14. PCR Primers for ADAMTS17 exon resequencing. 
Target Forward primer sequence 
Reverse primer sequence 
Amplicon size 
(bp) 
Annealing temp 
(oC) 
Exon 1 TGATTTACCACGTTGGGTTTG 
AGCTGGAACTGGATCCGAAG 
273 56 
Exon 2 (5’) GCTGACGCGTCTCCTCTCTCCC 
CCGCCTCCTCCACCTCGAA 
285 56 
Exon 2 (3’) CCCCGGACCCCGAAAGC 
GCGACTAAGCGACGGGCAGA 
334 56 
Exon 3 ACATGAGGACCAGGCCAGA 
AGGGCTGCTACACATGAAATG 
474 56 
Exon 4 TTCGATGTGCCTCAGCTCTAC 
GACCCAGGCACTGAAACTACA 
591 56 
Exon 5 CCAACATCTTCCTCTGTTCCA 
GGAGAGCAGACAAGACTGACAA 
300 56 
Exon 6 CATGACCTGATCAACCACTGA 
TTACTGATGAGGATGCCAAGG 
558 56 
Exon 7 ATTGCTATGTGCAGGATGACC 
GCAACAGGAAAGGCAGAGTTT 
293 56 
Exon 8 GGTGAATCCCAAAGCATTACA 
GTAATCTCTCCCGTTCCCTGA 
488 56 
Exon 9 GTAGCCAAGTACAGGGCATCA 
CCTGGGAGAAATGAAGTAGGG 
567 56 
Exon 10 TCCAATGCCTGAGTCATCTTC 
AACTGCCTGTGAGGGTGTATG 
434 56 
Exon 11 TGAATTCCAAGTCCAAACCAG 
CCAGTGGAGCTTTAGGCACTAT 
315 56 
Exon 12 TGCAGTGATCTGGTGAGTGAG 
GCTTTGTTGAAGCTGAGATGC 
426 56 
Exon 13 GGAGGTTGCTTTGGAAACTCT 
ACTCTCCCAGAGTTGGGTCAT 
490 56 
Exon 14 GAACATGTGCTGGGTTTCTGT 
GTGGGCTTTATGCTCAGTCAC 
490 56 
Exon 15 CCTAGGCACCAACACTTGCT 
GCCTTTCAGCAAGCATAACAC 
450 58 
Exon 16 CTCAGAGTCAGACCAGCCTGT 
GCTTCCTTCCCTCTGTCATCT 
468 56 
Exon 17 CTGTGAGCCAGTCTTCCATTC 
ACCAGAACCCAGGTGATCTCT 
432 56 
Exon 18 TCTGAGGAACCCAAGAGTGAA 
GTTCCTGTGGAGAGACAGGTG 
449 56 
Exon 19 GCCATGTCTTACACACCCTCA 
GCAAGCAGAAGTCACTTAGCAA 
468 56 
Exon 20 TGAGTACATTTCCCTCCCTCA 
GGCAAGGACTGTGATACTTGG 
458 56 
Exon 21 TCAGACTCTAGATGCCCAGGA 
CTCTAGGGAGCATTGGGTTTC 
490 56 
Exon 22 AGCCTCCTTGTCCTGCATTAT 
AATCCCATCTCTGCAACCTCT 
489 56 
Exon 23 CGAGTGAGGGCAGCTTAGAGT 
TCAGGTTCACGCTCAAGTTCT 
469 56 
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Table A15. Primers for amplification of POAG candidate causal 
variants in ADAMTS17. 
Target Forward primer sequence 
Reverse primer sequence 
Amplicon size 
bp 
Annealing temp 
(oC) 
Exon 2 19bp 
deletion (BH) 
6FAM-ACGTGGAGGTGGTGGTGCTG 
CGAAGCTGCAGGTACAGGTC 
190 60 
Exon 11 SNP 
(BFdB) 
ATCCAGATTCACAACCCTCCT 
GGAGATAGAAGTGTTCCTCTTGC 
409 57 
Exon 22 6bp 
deletion (SP) 
AGCCTCCTTGTCCTGCATTAT 
TCTTGTCATTGCAGACCTCCT 
287 60 
Table A16. Allelic discrimination primers and probes used to genotype the 
BFdB POAG variant. 
Assay name Forward primer sequence 
Reverse primer sequence 
Reporter 1 sequence (5’VIC) Reporter 2 sequence (5’6-FAM) 
BFdBPOAG CTGCAAGACCAAGCTGGA 
ACTATTGAGTACAGTGCAGACCA 
CCTGGACGGCACCGAGT CCCTGGACAGCACCGAGT 
Table A17. Primers for sequencing the SP and BH ADAMTS17 mutations in 
cDNA. For each mutation, two pairs of primers were designed (SPPOAG 1 & 
2 and BHPOAG 1 & 2). 
Assay name Target (exon / deletion) Forward primer 
Reverse primer 
Amplicon 
size bp 
Annealing 
temp (oC) 
SPPOAG1 Exon 22 / 6bp deletion CGAGGACTATTCAGGCTGCTA 
TCTTGTCATTGCAGACCTCCT 
194 60 
SPPOAG2 Exon 22 / 6bp deletion GAGGTGTGCGAGGACTATTCA 
ATGTCCTGGCAGAGGTTCTTT 
317 60 
BHPOAG1 Exon 2 / 19bp deletion GACGTGGAGGTGGTGCTG 
GCGAAGCTGCAGGTACAGG 
192 61 
BHPOAG2 Exon 2 / 19bp deletion TGCTGCTGCTGCTGGTTT 
CCCGAGTAGAAGCACAGCTC 
346 61 
Table A18. ADAMTS17 qRT-PCR assay. 
Assay name Forward primer sequence Reverse primer sequence Probe (5’FAM) 
ADAMTS17 GGTCTCAATTTGGCCTTTACC CTTTACCCACTCTCCTGACATG ATCCTGTGCTGGC 
TBP AGCGAGGAAATATGCCAGAG TTCAAGATTCAGAACATGGTGGG TTCAAGATTCAGAA
CATGGTGGG 
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V. Raw data collected for Chapter 4 (CD ROM) 
Table A19. Data on breed, sex, age at examination, IOP (where taken), PLD 
percentage and equivalent ordinal grade. 
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VI. Genome-wide association Q-Q and MDS plots. 
 
Figure A1. BH: PCAG cases and controls. 
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Figure A2. BH: PCAG and PLD cases and controls. 
 
Figure A3. BH: PLD cases and controls. 
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Figure A4. BH: PCAG cases and PLD cases.  
 
Figure A5. BH: PCAG cases and PLD cases and controls. 
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Figure A6. FCR: PCAG cases and controls. 
 
Figure A7. FCR: PCAG and PLD cases and controls. 
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Figure A8. FCR: PLD cases and controls. 
 
Figure A9. FCR: PCAG cases and PLD cases. 
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Figure A10. FCR: PCAG cases and PLD cases and controls. 
 
Figure A11. DDT: PCAG cases and controls. 
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Figure A12. DDT: PCAG and PLD cases and controls. 
 
Figure A13. DDT: PLD cases and controls. 
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Figure A14. DDT: PCAG cases and PLD cases. 
 
Figure A15. DDT: PCAG cases and PLD cases and controls. 
Appendix VI Genome-wide association Q-Q and MDS plots 
253 
 
 
Figure A16. WSS: PCAG cases and controls. 
 
Figure A17. WSS: PCAG and PLD cases and controls. 
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Figure A18. WSS: PLD cases and controls. 
 
Figure A19. WSS: PCAG cases and PLD cases. 
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Figure A20. WSS: PCAG cases and PLD cases and controls. 
 
Figure A21. Q-Q plots of meta-analyses of BH, FCR, DDT & WSS. 
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Figure A22. Q-Q plot of meta-analysis of DDT & WSS: PCAG cases and controls.
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VII. GWAS haplotype and haplotype permutation association plots 
 
Figure A23. Haplotype association analysis. BH: PCAG cases and controls. 
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Figure A24. Haplotype permutation association analysis. BH: PCAG cases and 
controls. 
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Figure A25. Haplotype association analysis. BH: PCAG and PLD cases and 
controls. 
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Figure A26. Haplotype permutation association analysis. BH: PCAG and PLD 
cases and controls. 
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Figure A27. Haplotype association analysis. BH: PLD cases and controls. 
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Figure A28. Haplotype permutation association analysis. BH: PLD cases and 
controls. 
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Figure A29. Haplotype association analysis. BH: PCAG cases and PLD cases. 
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Figure A30. Haplotype permutation association analysis. BH: PCAG cases and 
PLD cases. 
 
Appendix VII GWAS haplotype and haplotype permutation association plots 
265 
 
 
Figure A31. Haplotype association analysis. FCR: PCAG cases and controls. 
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Figure A32. Haplotype permutation association analysis. FCR: PCAG cases and 
controls. 
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Figure A33. Haplotype association analysis. FCR: PCAG and PLD cases and 
controls. 
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Figure A34. Haplotype permutation association analysis.  FCR: PCAG cases and 
PLD cases vs controls. 
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Figure A35. Haplotype association analysis. FCR: PLD cases and controls. 
 
Appendix VII GWAS haplotype and haplotype permutation association plots 
270 
 
 
Figure A36. Haplotype permutation association analysis. FCR: PLD cases and 
controls. 
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Figure A37. Haplotype association analysis.  FCR: PCAG cases and PLD cases. 
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Figure A38. Haplotype permutation association analysis. FCR: PCAG cases and 
PLD cases. 
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Figure A39. Haplotype association analysis. DDT: PCAG cases and controls. 
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Figure A40. Haplotype permutation association analysis. DDT: PCAG cases and 
controls. 
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Figure A41. Haplotype association analysis. DDT: PCAG and PLD cases and 
controls. 
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Figure A42. Haplotype permutation association analysis. DDT: PCAG and PLD 
cases and controls. 
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Figure A43. Haplotype association analysis. DDT: PLD cases and controls. 
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Figure A44. Haplotype permutation association analysis. DDT: PLD cases and 
controls. 
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Figure A45. Haplotype association analysis. DDT: PCAG cases and PLD cases. 
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Figure A46. Haplotype permutation association analysis. DDT: PCAG cases and 
PLD cases. 
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Figure A47. Haplotype association analysis. WSS: PCAG cases and controls. 
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Figure A48. Haplotype permutation association analysis. WSS: PCAG cases and 
controls. 
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Figure A49. Haplotype association analysis. WSS: PCAG and PLD cases and 
controls. 
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Figure A50. Haplotype permutation association analysis. WSS: PCAG and PLD 
cases and controls. 
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Figure A51. Haplotype association analysis. WSS: PLD cases and controls. 
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Figure A52. Haplotype permutation association analysis. WSS: PLD cases and 
controls. 
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Figure A53. Haplotype association analysis. WSS: PCAG cases and PLD cases. 
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Figure A54. Haplotype permutation association analysis. WSS: PCAG cases and 
PLD cases. 
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VIII. Raw genotyping results (CD ROM) 
Table A20. Microsatellite genotyping. 
Table A22. Microsatellite genotyping. 
Table A23. BH PCAG candidate variant genotyping results.  
Table A24. FCR PCAG candidate variant genotyping results. 
Table A25. DDT PCAG candidate variant genotyping results. 
Table A26. WSS PCAG candidate variant genotyping results.
 
